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A. INTRODUCTION 
  
1. Harnessing Chemistry and Biology from Natural Product Structures 
The mountains, the seas and even the microscopic hideouts remain as 
brewing pots for current pharmaceuticals and future drug candidates. Whether 
directly isolated from nature or chemically-transformed in the laboratory, these 
compounds are at the helm of being the source molecules for directed, 
knowledge-based medicinal chemistry. If secondary metabolites serve as 
biological guardians for plant and marine organism to ward off pathogens or insect 
predators, in humans, natural products are used to cure some of the deadly 
diseases. A variety of past and current bioactive compounds from plants can 
easily illustrate the point e.g. artemisinin, taxol, vinblastine, quinine, camptothecin 
and the salicylic acid-derived, aspirin. Many, if not, have been significant 
challenges to the synthetic chemist to prepare in the laboratory.1 
 
 
Figure 1. Representative biologically active natural products. 
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The science of synthesis is a field that is vital to all areas of chemistry. It 
embraces the unique ability of chemists to create new reactions and to design 
molecules or molecular systems with a required (or predicted) set of properties. 
Explorations aimed at the synthesis of natural products has its origin in structure 
elucidation, which in decades prior to the dawn of modern physical and 
spectroscopic methods was accomplished by degradation and partial synthesis of 
chemical fragments or, in some cases, by the relay and/or total synthesis of the 
natural product itself. However, in spite of the modern techniques available to the 
natural products chemist, the complete stereochemical assignment of a novel 
metabolite on the basis of spectroscopic methods is still a challenging aspect. In 
such cases, organic synthesis continues to play a significant role in structure 
determination. Growing interest in natural products synthesis has also been 
propelled by the fact that many classes of important pharmaceutical agents 
isolated from natural products - lactam antibiotics, macrolide antibiotics, and 
steroid hormones are three illustrative classes of natural products that have given 
rise to important medicinal agents.2 Fascination with the role that secondary 
metabolites play in regulating cellular and other biological processes continues to 
provide the stimulus for natural products synthesis, as well as research on the 
creation of small-molecule libraries and ultimately drug candidates based on 
natural product prototypes. In many cases, the amount of natural products 
available from natural sources is so limited that total synthesis is needed in order 
to provide material for further pharmacological evaluation. 
As time progressed in the 20th century, the chemical community has 
witnessed the explosion of landmark and cutting edge advances in synthetic 
methods and strategies that have pushed the construction of biologically important 
complex molecular targets to be synthesized in the laboratory with minimal 
challenge.3-5 With organic synthesis boasting a rich history and perpetual 
recognition, a practicing chemist on this field has within his grasp the possibility of 
being able to create nearly any target with enough time and effort. An important 
remaining puzzle is to achieve syntheses with heightened levels of efficiency. To 
tackle this concern, the formal conceptualization of “economies” in synthetic 
designs involving the ideas of atom-,6 step-7 and redox-economy8 were spurred to 
streamline laborious synthetic sequences. 
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Parallel to this success thus came the resurgence of new technologies 
available for the discovery of chemical leads to counter the increasing demands 
for drugs against emerging and neglected diseases. Functional genomics studies 
has led to the unearthing of a record breaking number of potential therapeutic 
protein targets; combinatorial chemistry has stretched out the size of compound 
collections; and high-throughput screening (HTS) has enabled the screening of 
million-compound libraries. However, despite these breakthroughs, the number of 
hits entering development has remained more or less slow while pharmaceutical 
research productivity has continued to drop.9 Evidently, there is a need for new 
strategies for the production of new chemical leads with a better rate of success in 
clinical development. 
Fragment-based drug discovery is recognized recently as one of the stirring 
methods for lead generation. Fragments are small, low molecular weight 
molecules that usually form part of a natural product or biologically active 
compound. They are combined or optimized to generate lead compounds. Thus, 
during the past two years, fragment-based chemistry has caused a revolution in 
drug discovery by establishing a new route to lead compounds which have 
progressed into clinical trials.10 
 
2. Organic Synthesis with Renewable Resources  
The world is approaching a time where scarcity of petrochemical resources 
used to provide energy and chemical materials needed by the society is taking its 
toll. To address this dilemma, abundant biomass resources have been thought as 
promising alternatives for the sustainable supply of valuable, functionalized 
starting materials to the chemical industry (e.g. alcohols, aldehydes, ketones, and 
carboxylic acids) for manufacturing drugs and polymeric materials. In this 
perspective, the presence of highly oxidized functional groups in carbohydrates - 
the main compounds in biomass - poses an advantage over difficulties 
encountered to convert such functionality to organic fuels.11  
Current chemical investigations have been focused on the production of 
platform chemicals to design consistently structured compounds as useful and 
versatile chemical building blocks. Such platform chemicals have been reported to 
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be biologically and chemically fashioned from sugar. The building-block chemicals 
can be realized by subsequent transformation into a variety of highly important bio-
based chemicals and materials. Building-block chemicals are defined as 
polyfunctionalized compounds that reveal a potential to be converted into new 
types of useful molecules. A well-reported method for the degradation of 
hyperfunctionality in carbohydrates is an acid-catalyzed process for the selective 
removal of functional groups and formation of defined building blocks.12  
Furoic acid and furfuryl alcohol are among the monofunctionalized furan 
derivatives produced from furfural, a product of sugar dehydration.13 Over the past 
years, significant contributions arising from the Reiser group have defined the use 
of these chemical building blocks in organic synthesis. A number of 
stereocontrolled synthetic approaches have been laid down towards various 
natural products and their building blocks,14-20 as well as syntheses aimed at 
unnatural amino acids and peptides which are useful probes for secondary 
structure explorations and pharmacologic investigations.21-24 Thus, a development 
of novel strategy for trans-annulated -lactone synthesis opened doors towards the 
first enantioselective total synthesis of the anti-cancer sesquiterpenoid 
arglabinTM,14 and accordingly, is a testament and shining achievement on the 
potential of furan derivatives in complex molecule synthesis.  
 
Figure 2. Several organic compounds derived from furan derivatives according to Reiser 
et al. 
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B. MAIN PART - SYNTHETIC     STUDIES      TOWARDS          
                       LACTONE-CONTAINING FURANOCEMBRANOIDS FROM  
                       FURANS 
 
1. Isolation and identification of highly oxidized furanolactone cembrane 
diterpenoids from the octocoral genus Pseudopterogorgia 
Gorgonian octocorals (phylum Cnidaria, order Gorgonacea) living in the 
Caribbean waters are inexhaustible machinery of chemically and biologically 
fascinating secondary metabolites.1,2 Terpenoid natural products especially 
abound in number, and these include the sesquiterpenes, diterpenes, bis-
diterpenes, steroids and carotenoids. 1,2 
The genus Pseudopterogorgia comprised of over 20 species are located in 
the West Indies region from Bermuda to the Bahamas, the Florida Keys, the 
Greater and Lesser Antilles, and the northern coast of South America to Brazil 
(Figure 1). They are best known as “sea plumes” based on their large, highly 
plumose and physically soft forms.3 Species of this genus are well-known for the 
production of diterpenoids with complex molecular architecture that exhibit a wide 
array of biological activities including antibacterial, anti-inflammatory, antimalarial, 
and cytotoxic properties.4 
 
Figure 1. The Caribbean sea (photo credits from T. Laughlin, www.Shipdetective.com). 
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Pioneering studies on the marine natural product chemistry of 
Pseudopterogorgia kallos (Bielschowsky, 1918) (Figure 2) showed that it is a rich 
source of pseudopterane diterpenoids.5 However, during 2003–2008 subsequent 
chemical inspection has demonstrated that this gorgonian species also contains 
several minor bioactive diterpenes that are based on highly distinct novel carbon 
frameworks.6 Another noteworthy species that also mines structurally fascinating 
furan-based carbocyclic structures is Pseudopterogorgia bipinnata (Verrill, 1864) 
(Figure 2). This octocoral is well-known to contain cembranes, gersolanes and 
pseudopteranes which are also thoroughly investigated for their pharmacologic 
effects.7 
  
Figure 2. The Gorgonian octocorals – Pseudopterogorgia kallos (left) and 
Pseudopterogorgia bipinnata (right) (photo credits from from Robert Fenner and Dr. Juan 
Armando Sanchez). 
 
1.1 Bielschowskysin (1) from Pseudopterogorgia kallos6c 
As a result of continuing explorations of the Rodriguez group (University of 
Puerto Rico) on marine invertebrate natural products chemistry of species from the 
West Indian region, they studied the extracts of P. kallos collected near the Old 
Providence Island located in the Southwestern Caribbean Sea in 2003. From this 
specimen, they were able to isolate and elucidate the highly oxygenated 
hexacyclic diterpene, bielschowskysin (1) (Figure 3). The structure is highlighted 
by a tricyclo[9.3.0.02,10]tetradecane ring system which was extensively 
established through spectroscopic evidences and single-crystal X-ray diffraction 
analysis. A distinguishing attribute of 1 is a cis-fused [5,5] oxa-bicycle as well as a 
 9 
 
      MAIN PART Macabeo  2011 
dihydrofuran unit that is sometimes camouflaged as a 1,4 diketone moiety. 
Bielschowskysin is perhaps one of the most structurally daunting members of the 
furanocembranoid series due to its highly strained cage-like structure featuring a 
quaternary stereocenter in the tetrasubstituted cyclobutane which is also fused to 
a substituted oxocane ring. This skeletal carbocylic platform is unprecedented in 
the field of natural products. The X-ray crystal structure which defined only the 
relative configuration of 10 chiral centers were assigned as 
1S*,2S*,3S*,6S*,7S*,8S*, 10S*,11S*,12R*,13R*. 
 
Figure 3. Structure of bielschowskysin (1). 
Terpenoid 1 was found to exhibit antiplasmodial activity (IC50 = 10 g/mL) 
when tested against Plasmodium falciparum. Being able to prevent the growth of 
P. falciparum, 1 was also tested for anticancer screen using the NCI‟s in vitro cell-
based assays. Thus, 1 was observed to display strong and specific in vitro 
cytotoxicity against the EKVX non-small cell lung cancer (GI50 < 0.01 M) and 
CAKI-1 renal cancer (GI50  = 0.51 M). 
1.2 Verrilin (2) from Pseudopterogorgia bipinnata8 
In accord to the interest of the Rodriguez group to discover new 
antituberculosis agent, they were able to isolate and identify verrillin (2) (Figure 4) 
from a Colombian collection of P. bipinnata. Verrillin is a hexacyclic diterpene 
associated in structure to some bipinnatins, but possesses a novel carbon 
skeleton. Since the bipinnatins and 2 were purified within the same source, the 
latter is assumed to be generated from a significantly different biosynthetic 
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pathway that affords a novel cyclization pattern. Results of the structure 
elucidation paved the way towards the establishment of the relative 
stereochemistry of 2 with the tetrahydropyran ring and the eight-membered cyclic 
ketal having the chair and distorted crown conformation, respectively. In such 
conformation, verrillin (2) assumes an additional molecular stability via 
intramolecular hydrogen bonding between the C8 hydroxyl proton and the 
tetrahydropyran oxygen. Thus, the overall relative stereochemistry of 2 was 
assigned as 1S*,2S*, 3S*,6S*,7S*,8R*,10S*,11S*,12R*,13R*,15S*. 
 
Figure 4. The structure of verrillin (2). 
Verrillin (2) is characterized as a new class of regular diterpenes. The name 
verrillane was proposed for its structurally unique carbon framework. Although not 
yet proven, the carbobicyclic ring system appears to be produced by subsequent 
transannular cyclization of a suitable cembranoid precursor. The purification of 
both skeletal classes from the same specimen of P. bipinnata provides indirect 
support that the verrillane ring system could be synthesized in vivo by subsequent 
cyclization of the cembrane skeleton via  a C7-C11 bond formation. In an in vitro 
colorimetric assay against Mycobacterium tuberculosis H37Rv at 6.25 g/mL, 
diterpenoid 2 was found to be insignificantly proliferative. 
1.3 Bipinnatin K from Pseudopterogorgia kallos9 
A further chemical study of the terpenoid metabolites from the crude organic 
extract of the gorgonian octocoral P. kallos in 2008 has led to the isolation of 
bipinnatin K (3) (Figure 5) in addition to other six related furanocembranoid 
compounds. It is feasible that 3 might be an isolation artifact, and its presence in 
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the crude gorgonian extract implies that the true natural product present in this 
animal bears a highly reactive furanyl epoxide array (as in 9) that is susceptible to 
SN2-type methanolysis at C7. Such a transient epoxide would also be the most 
plausible biogenetic precursor to the rearranged furanocembrane bielschowskysin 
(1). Compound 3 was also evaluated to exhibit inhibitory action against an 
acetylcholine-binding protein (AChBP) from Aplysia californica. 
 
Figure 5. Structure of bipinnatin K (3). 
2. Proposed Biogenetic Pathways for Oxidized Furanolactone Cembranoid 
Metabolites 
The furanocembranoids and their derivatives are structurally variegated 
natural products that not only display a wide variety of oxidation patterns but also 
display a highly diverse carbon skeleton.9,10  
Their biosynthesis (Scheme 1) starts with a type A cyclization of 
geranylgeranyl diphosphate (4) to furnish the 14-membered macrocycle and yield 
a carbocation (5). At this point, the biosynthetic routes may vary depending on 
how the intermediary carbocation is trapped. In the case of the 
furanocembranoids, a simple loss of a proton from the isopropyl side chain affords 
the natural product neo-cembrene (6). From neo-cembrene 6, a series of 
regioselective oxidations with concurrent cyclization of the furan ring, as well as a 
7,8 double bond isomerization and an ensuing hydroxylation at C2 would afford 
bipinnatin J (7). Not much is known about the participating enzymes. Presumably 
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cytochrome P450 monooxygenases are involved in the oxidative reactions. The 
oxidative opening of the furan ring, which is frequently observed in 
furanocembranoids and their derivatives, is another area of interest.10  
 
  
Scheme 1. Biogenetic pathways to bipinnatin J (7) from geranylgeranyl pyrophosphate 
(4). 
 
Biosynthetic speculations accounted for the formation of bielschowskysin (1), 
verrillin (2) and other related polycyclic furanocembranoid derivatives may involve 
enzymatic oxidations, and transannular (cyclo)additions (Scheme 2). It is can be 
presumed that these natural products ultimately originated from simple 
furanocembranoids such as rubifolide or bipinnatin J (7). The exo-alkylidene 
dihydrofuran intermediates 8, 9 and 10 are all likely intermediates in the 
biosynthesis of 1, 2 and 3, respectively. These intermediates could be spawned by 
epoxidation of the 7,8 double bond, followed by „„doubly vinylogous‟‟ hydrolysis,or 
by hydration of an ene-dione stemming from the oxidative opening of the furan 
moiety. It is important to mention that the biosynthetic pathways conferred in 
Scheme 2 are merely speculative. The exact steps under which most the 
proposed steps occur remain unidentified. The carbon-skeleton of bielschowskysin 
1 is thought to be obtained via a transannular [2+2]-cycloaddition of 11, which 
again comes from the opening of the benzylic epoxide by the furan ring. The 
proposed route to verrillin 2 involves the synthesis of the higher oxidized precursor 
12. Again epoxidation of the benzylic double bond induces the cascade, but this 
time a transannular 1,4-addition with acetal formation leads to verrillin 2. The route 
to 3 may initially involve a regioselective epoxidation of 7,8 in 10 followed by a 
regioselective methoxide attack on the resulting oxirane.10 
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Scheme 2. Oxidative biogenetic proposals for 1-3. 
3. Aim of this study 
 
Despite the large body of oxidized and highly functionalized 
furanocembranoids reported in the literature, relatively little synthetic work has 
been carried out until recently. A handful of research groups reported several 
synthetic explorations towards furanocembranoids that culminated in semi- and 
total syntheses. With attention given to compounds 1-3, their total synthesis up to 
the present time has remained elusive. For the purpose of establishing their 
absolute configuration and further evaluation of their biological activity, studies 
aimed at their enantiocontrolled synthesis are wanting. Therefore, this study was 
designed to provide synthetic strategies towards 1-3, especially for 
bielschowskysin (1). 
This chapter is divided into two parts. The first part as outlined in Figure 6 is 
focused on three approaches aimed towards the enantiocontrolled construction of 
the northeastern segment of furanolactone cembranoid diterpenes 1-3 via 
intermediate 13 which is presumed to be a viable synthon for macrocyclic retron 
14. A common synthon for the first two approaches was a furan ester-derived 
cyclopropane carbaldehdehyde 15 which, after the addition of either nucleophiles 
16 or 17, and retro-aldol-lactonization sequences, leads to -substituted furan 
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lactone of type 13. The third approach features a Michael addition of 
furansiloxynitrile 18 to dimethylmaleate 19 which, after subsequent 
transformations involving enantioselective -keto ester reduction and lactonization 
provided also trans-lactone 13.  
 
 
Figure 6. General retrosynthetic analysis of 1-3. 
 
The second part of the study was an attempt to explore a facile, simplified 
approach towards the total synthesis of bielschowskysin (1) as illustrated in Figure 
7 starting (again) from furan derivatives such as furfuryl alcohol 20 and furan 
ester-derived cyclopropane 15. The furfuryl alcohol 20 was proposed to undergo 
manipulations leading to olefinic ester 21 which is then subjected to 
photocycloaddition, methylenation and allylic oxidation to provide the western 
cyclobutane sector 22. For the other side, Hosumi-Sakurai allylation of 15 followed 
by lactonization, homologation and allylic oxidation as key transformations was 
expected to deliver lactol carbaldehyde 23 for the eastern sector. 
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Figure 7. Retrosynthesis of bielschowskysin (1). 
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4. Stereoselective approaches towards the northeastern sectors of 1-3 
 
4.1 Diastereocontrolled vinylogous Mukaiyama aldol addition of 
heterosiloxydienes to trifunctionalized cyclopropane 15 
Adjacently linked five-membered heterocycles and -butyrolactone motifs are 
privileged substructures in a number of complex marine and plant natural 
products. These moieties are well-prominent in various furanocembranoid 
diterpenes (e.g. 1-3)6c,8,9 isolated from Pseudopterogorgia species, cytotoxic 
Annonaceous acetogenins (24 and 25)11 and alkaloids from the genera 
Securinega (e.g. 26),12 Stemmona (e.g. 27)13 and Pandanus (e.g. 28 and 29)14. 
The segments highlighted in the structures in Figure 8 feature bis-tetrahydrofuran 
motifs or, oxocane or azacane rings attached to a 4,5-disubstituted butyrolactol or 
butyrolactone. 
 
Figure 8. Representative natural products with bis-heterocycle framework. 
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Previous investigations in the Reiser group demonstrated that addition of 
various siloxyenol ethers and allylsilanes to cyclopropyl aldehyde 15 from 
enantiopure cyclopropanated heterocyclic esters afford anti-addition adducts of the 
type 30 under high Felkin-Ahn 1,2 and 1,3-stereocontrol (Scheme 3).15  
 
 
Scheme 3. Addition of silane and siloxy nucleophiles to cyclopropane 15.  
 
In accord to our interest in providing a suitable strategy to construct the 
northeastern segment(s) (ex. 31) of furanolactone cembranoid natural products 1-
3 from cyclopropane carboxaldehyde 15, we first envisioned a vinylogous 
Mukaiyama aldol reaction (VMAR) with heterosiloxydiene 32 as a key step to build 
the trans-butanolide -butenolide moiety 33 (where X = O) (Figure 9). A butenolide 
could be pictured as a masked furan which can be afforded through DIBALH 
reduction at -78 oC16 (ex. conversion of 33 to 34). With a furan moiety, oxidative 
transformations17 and carbon homologation reactions are possible en route 35 or 
36.  
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Figure 9. Retrosynthesis starting from a VMAR approach. 
 
The general scheme for the synthesis of the -heterocyclic trans-lactone 33 is 
shown in Scheme 4. The sequence starts with VMAR of siloxydiene 32 and 
cyclopropane 15 which affords cyclopropane platform 37, followed by an 
established lactone synthesis featuring a one-pot retro-aldol and lactonization 
reactions.15b To allow studies for the substrate scope of this methodology, various 
furanones including pyrrolidene and thiophenone-derived heterosiloxydienes were 
used for this purpose. 
 
Scheme 4. General synthetic scheme for lactone 33. 
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4.1.1 Synthesis of butenolide derivatives and N-Boc pyrrolidene 
  The synthesis of several 2-heterocyclic precursors 38 (Figure 10) were 
carried out as described in the literature by  
 
Figure 10. Siloxydiene precursors 38a-38g for VMAR. 
 
a) oxidative transformation from the corresponding aromatic heterocycle.18 
 
 
Scheme 5. Conditions. a) HCO2H, 30% H2O2, N,N-dimethylethanolamine, reflux, 6 
h, 23%; b) PbO2, BaCO3, 30% H2O2, H2O, 4 h, reflux; c) Boc2O, 
DMAP, MeCN, SiO2,45 min,  rt, 28% in two steps. 
 
b) regioselective carbonyl reduction.19 
 
Scheme 6. Condition: a) NaBH4, THF, 1 h, 0 
oC, 40%. 
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c) Suzuki-Miyaura arylation of ,-dibromobutenolide.20  
 
Scheme 7. Conditions. a) 5 mol% Pd(PPh3)2Cl2, TEBAC, CsF, H2O-PhMe (1:1), 18 h, 
reflux, 64% (38d); 74% (38e). 
 
The rest of the oxoheterocyclics were purchased commercially. The 
siloxydiene nucleophiles were prepared by deprotonation of oxoheterocycles 38a-
38g with triethylamine (TEA) followed by addition of either trialkylsilyl chloride (for 
38a) or trialkylsilyl triflate (TMSOTf or TBSOTf) (Scheme 8).20 
 
 
Scheme 8. Heterosiloxydiene synthesis. Conditions: a) TMSCl or R3SiOTf, TEA, DCM,  
                   0 oC.  
4.1.2 Synthesis of the cyclopropylcarbaldehyde 
The gram-scale synthesis of the highly functionalized cyclopropane 15 from 
furan 2-carboxymethyl ester 39 has been previously described in the 
literature.15b,21 The variety of chemical transformations possible with this scaffold 
has shuttled the birth of several synthetic applications towards natural product14-18 
and peptide synthesis.22 Both cyclopropane enantiomers are easily afforded with 
high enantiomeric purity after iterative recrystallizations (>99% ee) of the resulting 
product from a two-step procedure. 
The stereochemical fate of 15 derived- trans lactone is a consequence of 
reactions relying on asymmetric cyclopropanation with bis(oxazoline)-ligand (BOX) 
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and Felkin-Ahn addition of nucleophiles.21 Since a 4S, 5S stereochemistry is 
desired (1S,2S in biogenetic numbering; see Figure 8 for reference), the R,R-
isopropyl BOX-ligand derived from D-valine was used in the cyclopropanation 
procedure applied to 40 to afford (+)-41 (Scheme 9).  
 
 
Scheme 9. Cyclopropanation and ozonolysis: a) (i) ethyl diazoacetate (1.05 equiv), 
Cu(OTf)2 (0.66 mol%), (+)-
iPrBOX ligand (0.92 mol%), PhNHNH2 (0.82 mol%), 
DCM, 0 °C, 5 days; (ii) recrystallization (CH2Cl2, pentane), >99% ee, 45%; b) 
(i) O3, DCM, -78 °C; (ii) DMS (2.50 equiv.), 16 h, -78 °C - rt, 89%. 
  
The asymmetric induction observed for oxobicyclic (+)-41 can be explained 
from the mechanistic proposals of Pfaltz23 and Andersson24 for the stereoselective 
cyclopropanation of alkenes. The reactive copper complex 42 (Figure 11) is 
thought to be approached by furan 40 at the less hindered region in such a way 
that steric repulsions with the isopropyl group are minimized which consequently 
drives a [2+1] addition of the carbene ethyl ester to the presumably more electron 
rich alkene moiety.  
 
 
Figure 11. Mechanistic model for asymmetric cyclopropanation. 
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Finally, reductive ozonalysis of (+)-41 provided cyclopropylcarbaldehyde (+)-
15 in 90% yield (Scheme 9). A white to very slightly yellowish solid product was 
afforded after treatment of the yellow syrup with diethyl ether. This two-step 
procedure can be scaled up to 50-100 g and the final product is stable for months 
when stored under nitrogen at -20 °C. 
 
4.1.3 Vinylogous Mukaiyama aldol reaction (VMAR) of heterosiloxydienes to 
cyclopropane carboxaldehyde 15 
 
Within the realm of carbon-carbon bond-forming reactions, the vinylogous 
Mukaiyama aldol reaction of heterocyclic silyloxy dienes to aldehydes and ketones 
which involves chirality transmittal from a chiral (racemic or nonracemic) carbonyl 
a1-acceptor has been regarded as one of the powerful approaches to gain entry to 
highly functionalized -hydroxylated carbonyl architectures. In addition to 
regioselectivity issues, the generation of two adjacent stereocenters at the -
butenolide and at the C-OH positions also poses a challenging task (Scheme 
10).25 Several studies have been generated from the Casiraghi and Rassu 
laboratories that exploited, during the past decade, the addition of furan-, pyrrole-, 
and thiophene-based 2-silyloxy dienes with a variety of chiral pool-derived 
aldehyde synthons.26 
 
Scheme 10. Vinylogous Mukaiyama aldol reaction (VMAR). 
Our investigation thus started by reacting trimethylsiloxyfuran (38a, entry 1) 
with cyclopropane (+)-15 in the presence of BF3OEt2 following the original 
protocol described for the addition of silane derivatives.25 Boron trifluoride is an 
excellent Lewis acid which can effect very good yields and 1,4 stereoinduction.15b 
Based on the NMR spectra of intermediate cyclopropyl butenolide carbinol 37a-
37g, an almost complete conversion was achieved. Addition of other siloxydiene 
nucleophiles rendered no problems.  
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4.1.4 Synthesis of beta-substituted -(2-oxoheterocyclic)butyrolactones 
 
Aside from being small, strained organic fascination, cyclopropane 
derivatives have been utilized as versatile building blocks in a number of organic 
synthetic studies. Proper activation of the strained three-membered ring is a 
requirement, and generally, electron-donating or -accepting moieties are involved 
in their reactions to make polar reactions more favorable. Cleavage or 
enlargement of rings may then occur under relatively mild conditions. 
Nevertheless, synthetically useful aspects of these transformations most 
frequently involve precursor cyclopropanes containing functional groups that often 
ease out the rearrangement and allow further chemistries of the products 
obtained. Cyclopropane derivatives adorned with donor and acceptor groups are 
particularly amenable for synthetic operations, since electronic effects of these 
substituents assure activation of the cyclopropanes and a high versatility of the 
products after ring cleavage. Vicinally donor-acceptor-substituted cyclopropanes 
(43) serve as 1,3-dipolar synthon in many synthetically valuable transformations. 
Since the two charges of synthon 44 are in 1,3-relationship, many reactions 
utilizing 43 may be regarded as reactions involving a formal umpolung of reactivity 
and, therefore, often afford products not easily accessible by alternative methods. 
Most of the acceptor groups applied in a majority of studies reported in the 
literature are carbonyl groups, and therefore, most of the donor-acceptor 
cyclopropanes (D-A cyclopropanes) can be described by general structure 45 
(Scheme 11). The simplest ring cleavage products of type 46 are very useful 
intermediates due to the 1,4-distance of the two carbonyl groups.27  
 
Scheme 11. Donor-acceptor cyclopropane structure and chemistry. 
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It was previously reported that unpurified allylated cyclopropyl 
carboxaldehydes such as 15, can be smoothly transformed into functionalized -
lactones. Barium hydroxide-assisted cyclopropane ring cleavage and lactonization 
yields a trans-lactone -aldehyde. Alternatively, Otera’s tin(IV) catalyst-facilitated 
ring opening followed by acetalization with 1,2-ethanediol or methanol could also 
provide protected aldehydes in good yields.15,21,28 
Several lactonization conditions were evaluated to prepare the desired 
oxoheterocyclic lactones (Scheme 12).  Treatment of 37a with Ba(OH)2.8H2O and 
TEA, produced substantial decomposition as evidenced by a number of spots on 
TLC. When an Otera tin catalyst 47 (see Scheme 13 for preparation) was used, 
the methanol or ethylene glycol protected aldehyde 33 was yielded. A slightly 
lower yield was obtained for the methyl acetal 33a.1 compared to the 1,2-
dioxolane derivative 33a.2 (entry 3) with good diastereoselectivity. Hence, 
ethylene glycol was decided as the protecting alcohol. To check the effect of 
changing the silyl component in reaction diastereoselectivity, the TMS group was 
switched to a bulky TBS. An improvement in the selectivity was observed for 33a.2 
(dr 99:1 entry 4).  
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Scheme 12. Lactonization of 37a under a variety of conditions. a) Ba(OH)2.8H2O, MeOH, 
0 oC, 2 h; b) TEA, DCM, 0 oC, 2 h; c) 5 mol % cat. 47, MeOH, reflux, 12 h, 
38%; d) 5 mol % cat. 47, ethylene glycol, PhMe, reflux, 12 h, 40%. 
 
 
 
 
 
 
 
 
 
Scheme 13. Synthesis of Otera tin catalyst 47. a) Benzene, reflux, 12 h, 90%. 
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Table 1. Ketoheterocycle-Lactone 33 synthesis from sequential VMAR and retro-aldol – 
lactonization cascades 
 
 
Entry Heterosiloxydiene 
32 
Lactonization 
Reagent 
Lactone 33 Structure Isolated 
Yield (%) 
drd,e 
1 
 
A - - - 
2 
 
B 
 
 
38 83:17 
3 
 
C 
 
 
40 86:14 
4 
 
C 
 
 
40 99:1 
5 
 
C 
 
 
44 87:13 
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Table 1 continuation............ 
6 
 
C 
 
 
 
65 >99 
 
 
7 
 
 
 
C 
 
 
 
 
42 
 
 
91:9 
 
 
8 
 
 
 
C 
 
 
 
 
50 
 
 
90:10 
9 
 
 
A,C 
 
 
 
43c 
 
91:9 
10 
 
A or C - - 91:9
f 
aA: Ba(OH)2.8H2O; B: catalyst 47 (5 mol %), MeOH, reflux, 12 h; C: catalyst 47 (5 mol %), 
ethylene glycol, PhMe, reflux, 12 h. bC5’ stereochemistry is arbitrary. cPerformed after 
conjugate reduction with Pd/C, NaOAc, THF; Yield after three steps. dRatio of 4S,5S,5’S 
and 4S,5S,5’R diastereomers. eDetermined by 1H NMR integral analysis. fDetermined 
from the 1H NMR spectrum of crude cylopropane thiophenone carbinol 37f. 
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Having established the reaction sequence (TBS and ethylene glycol as enol 
and aldehyde protecting groups, respectively), several substituted siloxylated furan 
nucleophiles including a Boc-protected pyrrole and thiophene were further 
investigated for the substrate scope experiments (Table 1, entry 5-10). Good to 
moderate yields (38-65%) were obtained for 33a-33f with good to excellent 
diastereoselectivity (dr 84-99). In general, moderate to good yields were obtained. 
Due to the instability of cyclopropane pyrrolidenone 37f under method C 
conditions, a sequence involving conjugate reduction (H2, Pd/C) and barium 
hydroxide/MeOH lactonization (entry 9) was carried out to give pyrrolidenone 
lactone -carbaldehyde in moderate yield (Scheme 14). Thiophenone 
cyclopropane 37h was not stable in any of the lactonization reagents employed 
(entry 10). Purification of the major product (9%) obtained using condition C was 
identified to be an elimination compound 48 (Scheme 15).  
 
 
Scheme 14. Synthesis of Lactone 33f. Conditions: a) i. BF3-OEt2, DCM, -78 
oC, 16 h 
(93%); ii. H2 (1 atm), NaOAc, THF, 24 h, quantitative; b) Ba(OH)2.8H2O, 
MeOH, 0 oC, 2 h, 43%. 
 
 
 
 
Scheme 15. VMAR and attempted lactonization of 37g. Condition: a) i. BF3OEt2, DCM, 
78 oC, 16 h (95%); b) catalyst 10 (5 mol %), ethylene glycol, PhMe, reflux,  
                     12 h, 9%. 
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Large scale preparation of lactone 33c yielded two other minor products. LC-
MS examination showed molecular ions (M+ = m/z 300; M+ = m/z 210) which can 
be directly corroborated to intermediates 49 and 50 (Scheme 16). This only 
suggests that retro-aldol product 51 enters into two different pathways prior to the 
formation of the end product 33c – one being the acetalization-lactonization 
sequence and the other being the lactonization-acetalization sequence where the 
latter is more favored due to the separation of considerable amounts of semi-pure 
intermediate 50 (about 4%).  
 
 
Scheme 16. Plausible Otera tin-catalyzed lactonization pathway en route lactone 33. 
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4.1.5 Establishment of stereochemistry of the oxoheterocyclic 
butyrolactones 
 
 
In relation to previously reported stereoinductions under BF3-catalyzed 
Mukaiyama addition of siloxyenol ethers to 15, the expected trans-4,5-
disubstitution in the butyrolactone moiety was also observed. This finding was 
ascertained by the absence of a spatial correlation between H4 and H5 and the 
presence of a long distance correlation between the acetal proton and H5 in the 
NOESY spectrum (Figure 12).  
 
 
Figure 12. NOESY correlations in lactone 33c. 
 
The C5’ butenolide configuration was established based on single X-ray 
crystal structure of 33c (Figure 13) and chiro-optical ellipticity evidences. The 
absolute configuration at C5 of butenolides can be readily and unequivocally 
established from the CD spectrum. It can be directly correlated to the sign of the n-
* and -* Cotton effect (Figure 14). The validity of the helicity rule has been 
observed for simple 2(5H)-furanones substituted at C5 and to products of various 
VMAR-related studies.29 
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Figure 13. Single X-ray crystal structure of 33c. 
 
 
  
  
 
n- * (235 - 250 nm) 
 
 < 0 
 
 > 0 
-* (200 – 215 nm)  > 0  < 0 
   
Figure 14. Correlation of butenolide hellicity with molar ellipticity values and absorption 
wavelengths. 
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As reflected in the CD spectrum of 33a-e in MeOH (Figure 15), the 
butenolide lactones display negative and positive Cotton shifts for the -* and n-
* transitions, respectively, which is readily ascribable for derivatives with C5’S 
stereochemistry exhibiting M helicity. Noteworthy, the 2,3-diaryl butenolides 
produced bathochromic shifted bands associated to -*. The shift is presumably 
caused by the increased conjugation between the aryl rings and the ,-
unsaturated system.  
 
 
 
Figure15. CD spectra of lactones 33a-33e. 
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The H5-H5’ vicinal coupling (3J5,5’) was also studied for this purpose. The 
coupling constant information is also a credible guide for assigning the 5,5’-
syn/anti relative disposition of the two heteroatom substituents, with syn 
compounds exhibiting larger  J values compared to their anti counterparts. In this 
respect, the saturated bis-butyrolactone 52 formed through conjugate reduction by 
treating lactone 33a.1 with NaBH4/NiCl2 reagent system displayed a 6 Hz 
3J5,5’ 
coupling value, indicating a syn relationship between H5 and H5’ (Scheme 15). 
 
Scheme 15. Conjugate reduction of lactone 33a.1. Conditions: a) NaBH4, NiCl2, THF, 0 
oC, 1 h, 84%. 
 
4.1.6 Proposed mechanism of heterosiloxydiene addition  
It has been well-established that addition pathways described for siloxyenol 
ethers, trimethylsilyl cyanide (TMSCN) and allylsilanes (cyclic and acyclic variants) 
to 1,2,3-trifunctionalized cyclopropane carbaldehydes abide very well with the 
Felkin Ahn paradigm.15 Under this mechanism, it was suggested that the reactive 
conformer of 15 is s-cis and that by high Felkin Ahn stereocontrol, allows the 
addition of sterically demanding nucleophiles at the Re face where unfavorable 
interactions are avoided (Figure 16).15b,31 
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Figure 16. Mode of nucleophilic additions to cyclopropane carbaldehydes. 
Under Lewis acid-mediated VMAR of heterosiloxydienes with chiral prochiral 
aldehydes, two new stereocenters are formed which results into four 
diastereomeric condensation products. The ratio of the aldol products provides a 
measure of the preference for the respective transition structure. It was proposed 
that under this catalytic condition, either a ‘Diels-Alder-like’ transition-state model 
TS1 or an open-chain transition TS2 could be operative, accounting for the 
formation of syn or anti compounds (Figure 17). The aldehyde diastereofacial 
preference will mainly depend upon Lewis acid-carbonyl complexation, whereas 
discrimination of the siloxydiene -face will be dictated by the 
synclinical/antiperiplanar preference for the corresponding transition structures 
and favorable/unfavorable orbital overlap between the diene reagent and the 
incoming aldehyde -system. 
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Figure 17. Transition states for VMAR of heterosiloxydienes with aldehydes. 
With these stereochemical observations, noteworthy the trans arrangement 
of substituents in the -butyrolactone moiety, it is clear that addition pathways 
leading to the cyclopropyl carbinol butenolides is identical with those of the cyclic 
allylsilanes in accordance to the Felkin-Ahn philosophy. The high syn 
stereopreference was accounted from the synperiplanar orchestrated orbital 
overlap between the heterodiene and the aldehyde  system which may also 
feature a ‘Diels-Alder like’ transition state (Scheme 16). It was reported in a 
previous study that addition of prochiral cyclohexenol silyl ether to 15, gave a 1:1 
mixture of diastereomers.15b In this study, a successful 1,4-stereoinduction was 
achieved affording up to >99 diastereoselectivity. Clearly, steric effects play a 
significant role in the observed stereoselectivity. This can be explained from the 
substitution pattern effects at C2 and C3 of the oxoheterocyclic nucleophiles. With 
hydrogens or the presence of a methyl group at C-4, a high selectivity is observed. 
The decrease in selectivity observed with methyl or aryl moieties at C3 can be 
attributed to unfavorable interactions of the substituents with the methyl oxallyl 
group in cis relationship with the aldehyde.  
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Scheme 16. Plausible model for transition state addition of siloxydienes 32 to 
cyclopropanealdehyde 15. 
4.1.7 Synthesis of the model exo-enol furan lactone unit of bielschowskysin 
A more elaborate retrosynthetic analysis of bielschowskysin starting from 
butenolide lactone 33c is illustrated in Figure 18. A key 2+2 photocycloaddition 
reaction was first envisaged from retron 53. The synthesis of a model segment that 
is reminiscent for 53 (ex. acrylate exo-enol lactone 54) would be a very significant 
task. The introduction of the exo-enol functionality was thought to be possible via 
2,5-furan oxidation and acid-catalyzed selective elimination at C6 and C7 in retron 
55. The C12/C13 connection can be established by intramolecular Baylis-Hilmann 
reaction from retron 56. Homologation and elaborative functionalizations (en route 
to butenolide construction) of C9 and C14 from lactone 33c should generate 
acrylate lactone 57. The methacryl arm was proposed to be introduced via a Pd-
catalyzed coupling of methacrylate ester with the furan moiety. 
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Figure 18. Retrosynthetic analysis of bielschowskysin from lactone 33c. 
 
Beginning with butenolide-lactone 33c, the task was set to perform a global 
reduction with DIBALH to deliver lactol-furan 58 in a moderate yield (63%) 
(Scheme 17). Reoxidation of 58 under Ley’s condition furnished furan lactone 59 
quantitatively. In this form, the installation of the C17 exo-methylene moiety is 
possible. 
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Scheme 17. Conditions. a) DIBALH, DCM, -78 oC (63%); b) TPAP, NMO, mol. sieve 4A, 
DCM, rt (quant.); c) ethyl methacrylate, Pd(OAc)2, LiOAc, Cu(OAc)2.5H2O, 
DMF, 117 oC (52%); d) Br2, MeOH, NH3(g), -40 
oC; e) silica gel CC (55%). 
 
 
 
 The next steps were centered towards the extension of C6. One-carbon 
homologation using the Vielsmeier Haack reaction was unsuccessful. A number of 
studies recently reported direct intermolecular arylation of five-membered 
heteroarenes via C-H bond cleavage under the influence of palladium catalysts.  
These reactions are effective and straightforward tactics for making hetaryl-aryl 
platforms.32 Inspired by this concept, the direct vinylation of furans and thiophenes 
at the 2- and 5-position under palladium catalytic conditions have also been 
described (Scheme 18).33  
 
 
 
Scheme 18. Pd-catalyzed furan-acrylate coupling accdg. to Miura et al.  
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Adapting the procedure described by Miura and co-workers, a trial reaction 
was first performed between n-butyl acrylate and lactone 59. A moderate 
conversion (52%) to acrylate lactone 60 was observed (Scheme 18). Coupling of 
methacrylate ethyl ester with furan lactone 59 in the presence of 2 mol % 
Pd(OAc)2, LiOAc and CuOAc under aerobic conditions afforded acrylate lactone 
57 (55% isolated yield) (Scheme 17). Referring to the mechanism proposed for 
this reaction (Figure 18), a strong preference for -elimination at the least hindered 
carbon was observed (Figure 19).  This Csp2-Csp2 coupling protocol presents the 
first synthetic application of this carbon-carbon bond forming reaction in complex 
molecule setting. 
 
 
 
Scheme 19. Conditions: a) n-butyl acrylate, Pd(OAc)2, LiOAc, Cu(OAc)22H2O, DMF, 120 
oC, 12 h, 49%. 
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Figure 19. Mechanistic pathway for the Pd-catalyzed coupling of methacryl ester with 
lactone 59. 
 
The fascination of structural variations in furanocembranoid metabolites 
stems from the wide array of oxidative chemistry encompassed in the biosynthesis 
of the furan moiety. The new structural platforms afforded in these transformations 
triggers the creation of novel polycyclic derivatives which in turn lead to 
unprecedented biogenetic skeletons. This very behavior of furanocembranoids has 
sparked a number studies inspired from biogenetic hypotheses and has therefore, 
led to biomimetic total synthesis.17 For example, the Trauner (Germany)34 and 
Pattenden (United Kingdom)35 groups have explicitly studied bioinspired reaction 
pathways to install functionalities essential for the synthesis of highly oxidized 
furanocembranoid compounds.  
Thus, oxidative transformation of 57 was undertaken to study the installment 
of the exo-enol furan moiety. For this reaction, 2,5-methoxylation with Br2/MeOH 
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followed by a base work-up was employed. Under such oxidative chemistry, a 
regioselective methoxylation at carbons of furans is rather ensued instead of the 
usual electrophilic addition of bromine taking place using methanol as solvent 
(Scheme 20).36 With Na2CO3, the reaction proceeded very slow and an incomplete 
conversion was achieved. However in a separate experiment, when gaseous 
ammonia was bubbled into the solution after 30 minutes of stirring at 0 oC, a crude 
mixture of diastereomeric dimethoxylated products was afforded (Scheme 21). 
Interestingly, after purification of the products in a silica gel column, a less polar 
(major) spot was noted on TLC. Unambiguous NMR analysis of the isolated 
compound revealed a structure corroborative to a methyl protected Z-exo-
trienolfuran lactone 54 (along with its C3 epimer). The cyclic ketal motiffed product 
features a Z-olefinic geometry which was elucidated based on H5/H7 NOESY 
correlation. Other related coral natural products such as 61 and 62 also exhibit this 
oxidized moiety. Enol 54 was also found susceptible to decomposition when 
exposed to CDCl3 overnight. 
 
 
 
Scheme 20. Bromination of furan in methanol.    
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Scheme 21. Silica-assisted conversion of lactone diketal 63 to exo-enol furanlactone 54 
and structure of exo-enol ether diterpenoids 61and 62. 
 
The partial and regioselective deacetalization observed during the silica-
mediated reaction may have stemmed from the silica-induced elimination of the 
C6 methoxy group to give intermediate 64 followed by the formation of a 1,3-
furyldienium ion intermediate 65, which, after H7 eviction, is subsequently 
quenched through bond reorganization or resonance stabilization to finally furnish 
54. In relation to this interesting finding, we would also like to propose the 
possibility of a furanocembranoid with 2,5-dimethoxytetrahydrofuran moiety as 
plausible intermediate in the biosynthesis of furanocembranoids 1, 2, 61 and 
6234,35 in addition to previously published biogenetic speculations.10  The Z olefin 
thus observed should be amenable with the requisite double geometry for [2+2] 
photocycloaddition to install the cyclobutane core in accordance to Sulikowski’s 
study. 
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4.1.8 Conclusion 
In conclusion, we have developed a new diastereocontrolled strategy to 
approach the heterocycle-butyrolactone units of several complex natural product 
structures through vinylogous Mukaiyama addition of heterosiloxydienes to highly 
functionalized cyclopropane carbaldehyde 15 and lactonization sequences. In 
addition, the first synthesis of a Z-exo-trienolfuran lactone substructure 54 
representing the northeastern sector of bielschowskysin 1 was also accomplished.  
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4.2 Diastereocontrolled addition of organotitanium reagents to 
trifunctionalized cyclopropane 15 – synthesis of -arylbutyrolactones 
 
 Highly substituted -arylbutyrolactone motifs are profusely present in many 
synthetic intermediates and biologically active structures.37 In general, their 
enantiomeric purity and absolute configuration play a significant role on their 
purported pharmacologic properties.38 Thus, much effort has been invested in their 
asymmetric synthesis.39  Among the derivatives thus far reported, less attention 
has been devoted to the stereoselective synthesis of trans and especially, cis -
aryl- or heteroarylbutyrolactones.40 Construction of the two stereocenters in -
disubstituted--butyrolactone requires laborious, step-wise procedures. Thus, 
lactone-based synthons prepared in this respect may serve as intermediates for 
the synthesis of highly oxidized furanocembranoids (e.g. 1-3)6c,8,9 and lignan 
natural products (e.g. 66)41 (Figure 20). 
 
Figure 20. Representative -aryllactone-derived natural products. 
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In the previous section, a vinylogous Mukaiyama addition of siloxydienes to 
cyclopropyl aldehyde 15 which affords trans-lactones 33 with high 
diastereoselectivity following the Felkin-Ahn paradigm15,21 was described. As a 
useful alternative would appear is the addition of nucleophiles through a substrate-
controlled Cram chelate addition pathway that should lead to the corresponding 
cis- and trans-lactones. In this section, the addition of aryl- and heteroarylltitanium 
nucleophiles 67 to 15 giving rise to either cis- or trans-lactones 68, which appear 
to be useful building blocks towards the synthesis of 1-3 and 66 (Scheme 22) is 
discussed.42 
 
Scheme 22. Chelate-controlled addition of aryl nucleophiles to cyclopropane 15. 
Among all the possible means of introducing a heterocyclic entity (ex. furan) 
into a more complex organic structure is the straightforward use of metaloorganic 
reagent prepared by metalation of a heterocycle.43 The installation of a furan 
moiety into a system has a particular impact, not only due to its reactivity, but also 
because of a wide range of functional groups that can be harnessed through a 
one- or two-step sequence from the heterocycle. Inspired by the successful 
installation of butenolide units to cyclopropane carbaldehyde (see previous 
section), the addition of a furyl nucleophile was also envisaged as an alternative 
strategy. The furyl nucleophile in this concept is proposed to be in the form of 
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metalofuran 69 (Figure 21). Such straightforward introduction of furan in the 
lactone (obtained after the usual retro-aldol/lactonization sequences), should 
streamline the steps en route to intermediate 70 skipping reduction and 
reoxidation steps (see Scheme 17 for reference). Furanlactone 70 should be a 
convenient synthon for 71 and 72. 
 
 
Figure 21. Retrosynthesis based on metalofuran addition to 15.
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4.2.1 Synthesis of Metalofurans 
 Over the past years, several metaloorganics have been prepared. Their 
reactivity is enhanced with the iconicity of the carbon-metal bond, thus giving a 
difference in electronegativity between the metal component and carbon.  
 One of the most important procedures considered towards metalated 
heterocycles is dehydrometalation (Scheme 23). This reaction works if the acidity 
of the generated R-H from R-M is lower than that of the Het-H. Hydrogen-metal 
exchange reactions are highly direct methods being used mainly (but not 
exclusively) for the synthesis of hetaryllithiums using lithium alkyls.44  
 
Scheme 23. Dehydrometalation of heterocycles. 
 Hetaryllithiums are one of the most useful metalated heterocycles. They are 
usually obtained by direct deprotonotation of acidic hydrogens using strong bases 
or, by halogen exchange at the less acidic sites of aromatic rings. Thus, the 
preparation of 2-lithiofuran 73 serves as a convenient gateway towards the 
synthesis of various transition metal-bearing furan reagents via transmetalation 
reactions.44 
The preparation of 2-lithiofuran 73 was performed by dehydrolithiation of 
furan with n-BuLi in THF at -78 oC. Treatment of cyclopropane 15 with 73 resulted 
to substantial decomposition as expected. The highly labile methyloxallyloyx group 
and the two electrophilic carbonyl functionalities were not tolerated in this reaction 
because of the high basicity and poor selectivity conferred by hetaryllithium 73. 
The highly polarized carbon-metal bond and the high reactivity that is imparted by 
organolithium reagents preclude the presence of functional groups in an organic 
molecule. Nevertheless, a covalent bond formed between transition metals and 
carbon tolerates a variety of functional groups such as amide, ester, nitro 
functionalities, etc. Thus, screening of other transition metal-bearing furyl 
nucleophiles were undertaken considering the sensitive nature of the methyl oxa-
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late moiety in 15 under basic nucleophilic conditions. The metalofurans were 
prepared by transmetalation with CeCl3, CuCl2 and ZnCl2. Nevertheless, efforts to 
add several different 2-furyl metal reagents (ArCeCl2, ArCuCl, ArZnCl) (Scheme 
24) alone or in combination with BF3OEt2 to aldehyde 16 were also unsuccessful. 
Either decomposition or no reaction of the starting material was observed. 
 
Scheme 24. Dehydrolithiation and transmetalation of furan. Conditions: a) n-BuLi, 
THF, 2 h, -78 oC; b) ZnCl2, THF, 2 h, -78 
oC; c) CeCl3, THF, 2h, -78 
oC; d) TiCl(OPri)3, THF, 2 h, -78 
oC. 
 
We next turned our attention to a titanofuryl nucleophile (furyltris(2-
propoxo)titanium) 67a. Organotitanium reagents display high chemo- and 
diastereoselectivity towards aldehydes in comparison to other carbonyl 
functionalities and are considered as “well-behaved reagents” because of their 
ability to mitigate chemical reactivity and basicity.45 Despite studies describing 
additions of organotitanium reagents, direct asymmetric additions to carbonyls 
have been demonstrated in only a few investigations.46  
Reaction of the 2-furyltitanium reagent 67a with 15 was also unsuccessful, 
however, when BF3OEt2 was additionally employed, the desired furyl transfer was 
finally achieved to give rise to 74a (>90% conversion) (Scheme 25). It is well-
established that coordination of carbonyl groups to Lewis acids exerts a dramatic 
effect on the rates and selectivities of reactions at the carbonyl centers.47  
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Scheme 25. Addition of titanium furan 67a to 15. Conditions: a) 67a (4 equiv), BF3OEt2, 
THF, 16 h, -78 oC. 
 
4.2.2 Synthesis of -arylated and -alkylated lactones 
While 74a can be isolated, due to its sensitive nature, we opted to directly 
convert it to the corresponding lactone 68a through a retro-aldol and lactonization 
sequence upon saponifying the oxalylic ester, making use of 1,2-donor-acceptor 
relationship in the cyclopropane ring15,21,48 (see also section 1.4.1.4). Treatment of 
74a with Ba(OH)28H2O and triethylamine however, failed to give the expected 
furyllactone carbaldehyde (Scheme 26). Lactonization experiments with several 
stannoxanes were carried out next. Stannoxane catalysts 75 and 76 were 
prepared according to Scheme 27.49 After screening, catalyst 47 proved to be the 
most effective catalyst with an overall yield of the two-step sequence from 15 to 
68a to 40% (Table 2, entry 1).  
 
 
 50 
 
      MAIN PART Macabeo  2011 
 
Scheme 26. Base-catalyzed lactonization of 74a/Products detected from MS analysis. 
Conditions: a) Ba(OH)28H2O (0.55 equiv), MeOH, 2 h, 0 oC; b) TEA (2 
equiv), MeOH, 2 h, 0 oC. 
 
Scheme 27. Preparation of Otera catalysts 75 and 76. Conditions: a) benzene, 12 h, 
reflux (77%); b) dibutyltin oxide (1 equiv), PhMe, 12 h, reflux (90%); c) 
dibutyltin oxide (3 equiv), PhMe, 12 h, reflux (83%). 
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Table 2. -Aryl and alkyl lactone synthesis from cyclopropane aldehyde, 15. 
 
 
Entry Titanium Nucleophile 
67 
Lactone Structure 
68b 
Isolated 
Yieldc 
cis:trans 
ratiof 
1 
 
 
 
 
40 
23d 
29e 
14:86 
2 
 
 
38 54:46 
3a 
 
 
45 >99:1 
4a 
 
 
38 82:18 
5a 
 
 
33 76:24 
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Table 2 continuation.......... 
6 
 
 
37 6:94 
7 
 
- - - 
8 
 
- - - 
9 
  
29g 6:94 
10 
 
- - - 
11 
  
Tracesg - 
a Ent-15 was used. bMajor diastereomer shown. cUnless otherwise stated, 47 was used as 
catalyst. Overall yield in two steps. d 75 was used. e 76 was used. f Based on relative 
integrals in the 1H NMR spectrum. g Lactonization was carried out with Ba(OH)2•8H2O. 
 
A representative number of other aryltitanium reagents, being readily 
prepared by dehydrolithiation or dehalolithiation of aryl derivatives followed by 
titanation with ClTi(OPri)3, were tested for the synthesis of lactones of the type 68 
(Scheme 28).50 Besides 2-thienyl (entry 2) and phenyl  (entry 3), alkoxy substituted 
aryl groups (entries 4-6) being especially relevant towards naturally occuring 
compounds such as 66 were successfully introduced. However, aryltitanium 
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nucleophiles bearing substitutions at the ortho position, e.g those derived from 2-
bromoanisole 67g and 2-bromotoluene 67h (entries 7 and 8), were not amenable 
with this reaction sequence due to sterical hindrance.51 On the other hand, a 
number of unidentified products were observed with vinyltitanium 67j. 
 
 
Scheme 28. Pathways en route to cis- and trans--aryllactones.  
 
Interestingly, when the reaction was subjected to 10 mL per 100 mg dilution, 
the formation of a different rearrangement product was observed (Scheme 29). 
The structure was identified as a -methoxy--carbinolfuranelactone 77a after 
extensive NMR spectroscopic analysis in 65% yield. The elucidated structure was 
further evidenced by characteristic fragment ions from the EIMS spectrum (Figure 
22). The product can be converted to furanlactone 68a almost quantitatively after 
stirring in methanolic PTSA. The reaction also works with thienyl cyclopropyl 
carbinol to provide the corresponding -methoxylactone 77b albeit, in 19% overall 
yield. The mechanism of this rearrangement can be traced plausibly by the initial 
formation of the retro-aldol intermediate 78 (Scheme 30). Following the formation 
of -arylatedlactone aldehyde 79, a concomitant yielding of hemiacetal 80 followed 
by intramolecular transesterification reaction leads to the hetaryllactone adducts 
77a and 77b.  
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Scheme 29. Unusual rearrangement product of 74a. Conditions: a) 47 (10 mol %), MeOH 
(10 mL/ 100 mg), 12 h, reflux. 
 
 
Figure 22. Spectroscopic analysis of lactone 77a. 
 
Scheme 30. Plausible formation of rearrangement product 77. 
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The hetarylcarbinol lactones 77 could be useful synthons for the facile formal 
synthesis of cytotoxic heterolignanolides 81 and 8252 as outlined in Scheme 31. 
 
 
Scheme 31. Proposed synthesis of heterolignanolides 81 and 82. 
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4.2.3 Determination of stereochemistry 
The stereochemistry of 68a-f was confirmed through 2D-NOESY correlation 
experiments and X-ray analysis of 68c (Figure 23). Thus, it was revealed that the 
diastereoselectivity of this reaction sequence was greatly influenced by the type of 
aryl nucleophile being used. While the 2-furyltitanium 67a gave rise predominantly 
to the trans-lactone 68a (dr 86:14), the aryl substituted lactones 68c-68f were 
obtained with moderate to excellent cis-selectivity (dr 3:1 to >99:1), demonstrating 
for the first time that addition of nucleophiles to 15 can ultimately lead to cis-
lactone of type 68 as the major products. 
 
Figure 23. Single crystal X-ray structure of cis-lactone 68c. 
 
4.2.4 Proposed mechanism of metaloorganic nucleophile addition to 
cyclopropane aldehyde 15 
 
In a previous related study, Shuto and co-workers53 discovered that 
nucleophilic addition of Grignard reagents on a cyclopropane carbaldehyde 
derivative 83 proceeds with high stereoselectivity to give anti-product 84 in 
excellent yield and selectivity (Scheme 32). Initially, the proposed pathway was 
ascribed to a bisected-conformational transition state stabilized by the 
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characteristic electron donating effect of the cyclopropane moiety. In the end, they 
found that the anti-selectivity of the Grignard addition to cis-substituted 
cyclopropane carbaldehydes occurred through an unusual 7-membered 1,4-
chelation controlled pathway which agreed well with the proposed mechanism of 
Reiser for such Cram chelate-controlled addition reactions.54    
 
Scheme 32. Addition of methyl Grignard reagent to cyclopropyl aldehyde 83. 
In agreement to this mechanistic hypothesis, the cis-selectivity observed in 
the formation of 68c-68f with aryltitanium/BF3OEt2 reagents, contrasting the high 
trans-selectivity achieved in the corresponding transformations with allyl-
silanes/BF3OEt2 and the excellent oxygen-chelating capabilities of titanium 
reagents led to the proposal of a cyclic Cram chelate-type featuring a rather 
unusual 8-membered titanium complex under 1,5-stereocontrol . 
The aryl nucleophile is delivered externally from the sterically less hindered 
face of the carbonyl group, giving rise to 74c-g as the major diastereomer 
(Scheme 33, pathway I).55 In contrast, the syn-selectivity observed with furan 
titanate 67a results through the formation of an incipient bond between the furyl 
nucleophile and the electrophilic aldehyde carbon while the oxygen atom in the 
furan ring is coordinated with titanium, favoring the formation of syn addition 
product 74a (Scheme 33, pathway II). 
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Scheme 33. Chelate-controlled addition of organotitanium 67a-67f to cyclopropyl 
aldehyde 15. 
 
The poor diastereoselectivity achieved with the thienyl nucleophile 67b could 
be explained by the weaker coordination ability of sulfur to titanium, thus resulting 
in no preference either for pathway I or II. The lower diastereoselectivity for 
oxygenated aryltitanium reagents leading to 68d-68f compared to 68c might 
reflect different degrees of internal delivery of the nucleophile via coordination of 
titanium to the oxygen substituents in the aryl rings. In agreement with this 
proposal is the highly selective addition of allyltitanium 67i to 15 (Table 2, entry 9), 
leading to 68i by directed delivery of the allyl nucleophile via a Zimmerman-
Traxler-like transition state (Scheme 34, pathway III). 
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Scheme 34. Chelate-controlled addition of organotitanium 67i to cyclopropyl 
aldehyde 15. 
 
 
4.2.5 Synthesis of model fragment for the northeastern segment of 
furanolactonecembranoids 1 and 2 
 
Lactone 68a seemed to be a suitable precursor to study the synthesis of the 
northeastern segments of diterpenoids 1 and 2. Initial attempts to perform 
oxidative transformations on the furane ring using a number of methods known for 
that moiety, i.e. singlet oxygen oxidation, mCPBA or Jones oxidation56 to furnish a 
-hydroxybutenolide 85 were unsuccessful (Scheme 35). Using bromine57 in 
methanol, however, afforded the 2,5-dimethoxy-2,5-dihydrofuran 86 in 75% yield, 
albeit as a mixture of three diastereomers in a 1:1:2 ratio, from which 86c could be 
separated by chromatography (Scheme 36). From the mixture of 86a and 86b the 
former was obtained in pure form by crystallization and its structure could be 
assigned unambiguoulsy by X-ray structural analysis (Figure 24). The major 
diastereomer 86c was heated with  Bredereck’s reagent58 to install the -
dimethylaminomethylene handle, furnishing 87 in good yield (81%). The model 
precursor product thus obtained satisfies the needed 1S,2S,3S (and 6S) 
stereochemistries required in furanocembranoids 1 and 2. 
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Scheme 35. Attempted oxidative transformations of lactone 68a. 
                       Reagents/Conditions: a) NaClO2, KH2PO4, 
tBuOH, H2O; b) MMPP; 
c) mCPBA; d) 1O2, rose Bengal, h (254 nm). 
 
 
 
 
Scheme 36. Methoxylation of lactone 68a. Conditions: a) Br2, MeOH, NH3(g) (pH 
8), 30 min., 0 oC (75%). b) Bredereck’s rgt. ((Me2N)3CH), PhMe, 24 
h, 70 oC, 81%. 
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Figure 24. Single X-ray crystal structure of 86a. 
 
Attempts to deprotect the O-methyl acetal protecting group in 68a proved to 
be a very challenging task. A number of known deprotecting methods (including 
oxidative deprotection conditions, see Table 3) were tried but only pyridinium p-
toluene sulfonate (PPTS) in aqueous acetone showed considerable conversion 
(ca. >60%) to furyllactone -carbaldehyde 88a. 
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Table 3. Deprotection of lactone 68a. 
 
Entry Deprotection Condition Conversion 
 
1 
 
TFA-CHCl3-H2O (3:3:1) 
 
NR 
2 TFA-THF-H2O (3:3:1) NR 
3 1M HCl/THF NR 
4 HCO2H (150 equiv.), 0 
oC NR 
5 PPTS/H2O-Acetone (8:2), 
reflux 
>60% conversion 
6 SnCl2, C10H8, PhMe NR 
7 ZnBr2, DCM NR 
8 BBr3, DCM NR 
9 Otera catalyst 75, 
acetone, PhMe, reflux 
NR 
10 Jones rgt., acetone, 0 oC NR 
11 FeCl3, HCl, H2O2 NR 
NR = no reaction. 
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4.2.6 Conclusion 
In conclusion, a new diasteroselective approach was developed towards -
aryl lactones utilizing aryltitanium reagents in combination with the readily 
available cyclopropanecarbaldehyde 15. This methodology extends the previously 
reported functionalization of 15 with allylsilanes in substrate scope, but also offers 
for the first time a reversal of stereochemistry. Thus, cis-disubstituted -aryl--
methyl acetal lactones with good diastereoselectivity in enantiomerically pure form 
can be obtained, which compares well with previously reported methods.39,40 
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4.3 Synthetic approach employing diastereoselective reduction of furylated 
-keto esters 
 
Chiral paraconic acids or 5-oxo-tetrahydro-3-furancarboxylic acid derivatives 
are a small class of highly substituted -butyrolactones are commonly found 
metabolites in mosses, lichens and fungi.59 The non-natural paraconic acid 89, 5-
oxo-tetrahydro-3-furancarboxylic acid, is a first member of the series and 
considered as an important precursor in the synthesis of A-factor60, an inducer of 
the biosynthesis of streptomycin in non-active mutants of Streptomyces griseus. 
Paraconic acid esters have many industrial applications particularly in the perfume 
and solvent industries.61 Aside from the presence of a carboxylic group at the -
carbon atom, naturally occurring paraconic acid derivatives also contain an alkyl 
side chain at the -carbon atom and a methyl or exo-methylene group at the -
position.62 Several examples of natural paraconic acid metabolites are rocellaric 
acid 90, phaseolinic acid 91 and methylenolactocin 92 (Figure 25).63,64 
 
 
Figure 25. Structure of several paraconic acids. 
To address the challenge in their enantioselective synthesis, the 
development of different methods towards 89 and its analogues using chiral 
auxiliaries, enzymatic methods, and asymmetric catalysis by transition metal 
complexes has gathered interests.65 Its chiral derivatives have been demonstrated 
to be useful building blocks for the synthesis of compounds which may exhibit a 
different pharmacological activity pattern.66 Acids of type 89 bearing two 
stereocenters are difficult to synthesize according to known procedures, which 
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usually include several steps with the involvement of organometallic or difficult to 
handle reagents.65 The asymmetric reduction of acylsuccinates offers a promising 
route to chiral 2-alkylparaconic acids.  
Within the frame of this study to provide strategies towards the 
stereocontrolled synthesis of the furan lactone backbone of furanocembranoids 1-
36c,8,9 from furan derivatives, attention was further envisioned to synthesize a -
furyllactone -carboxy ester 93 by way of diastereoselective reduction of -keto 
furoylsuccinic diester 94 (Scheme 37). Lactone 93 was envisaged as a suitable 
derivative to further study homologation reactions leading to aldehyde 95 and 
subsequently provides opportunities for coupling with -alkylbutenolides as 
illustrated in Scheme 37.  
 
 
Scheme 37. Proposed synthesis of furanocembranoids 1-3 from furanlactone 93. 
 
4.3.1Synthesis of furylsuccinyl diester 94 
The synthesis of diester 94 started from furfural 96.67 Thus, treatment of 96 
with TBSCl, KCN and ZnI2 (catalyst) furnished siloxynitrile derivative 97 in 
excellent yield (96%). Umpolung manipulation of 97 via LDA assisted 
deprotonation at -78 oC provided the nucleophile intermediate 98 which 
subsequently undergone Michael addition to dimethylmaleate to provide diester 
nitrile 99 (Scheme 38).68 TBAF accelerated removal of the TBS group followed 
with concurrent eviction of the nitrile group furnished 94 in moderate yield (61%). 
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Scheme 38. Synthesis of furan diester 94. Conditions: a) TBSCl, KCN, ZnI2, MeCN, 12 h, 
rt (96%); b) (i) LDA, THF, 1 h, -78 oC; (ii) TBAF, HAc, THF, rt, 4h (61%). 
 
 
4.3.2 Diastereoselective lactone synthesis by Hydride Reduction of 94 
The hydride reduction of arylsuccinyl diesters has been previously reported. 
Treatment of furylsuccinyl diester with NaBH4 and Zn(BH4)2 followed by exposure 
in TFA afforded cis and trans, respectively, with different degrees of selectivity. A 
high preference to form the cis- and trans-lactones was observed with NaBH4 and 
Zn(BH4)2, respectively (Scheme 39).
68 This partiality can be explained on the basis 
of the Felkin-Ahn and Cram Chelate principles as shown in Figure 26. 
 
 
Scheme 39. Conditions: a) (i) NaBH4, MeOH, 2h, 0 
oC; (ii) PTSA (79%); b) (i) Zn(BH4)2, 
THF, 2 h, 0 oC; (ii) HAc (52%). 
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Figure 26. Addition of hydride in Felkin-Ahn and Chelate controlled conditions. 
 
Under the Felkin-Ahn control, the hydride (H-) is delivered at the least 
congested site to give anti-100 while the 1,3-stereocontrolled Zn(BH4)2 addition 
drives the hydride addition at the other side to furnish syn-100. Subsequently, the 
cis- and trans- lactones were generated from anti and syn intermediates 
respectively, under acidic conditions. 
 
4.3.3 Enantioselective reduction of 94 by dynamic kinetic resolution (DKR) 
 
As shown in Figure 27, substrate enantiomers SR and SS react at different 
rates, kR and kS, affording products PR and PS under certain chiral conditions. This 
dichotomy allows chemical and biological kinetic resolution of racemic mixtures. 
Chirally sensitive stereocenters that racemize during reaction can, in principle, be 
transformed in 100% yield to enantiomerically pure products regardless of the 
extent of substrate conversion.69 
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Figure 27. Pathways in DKR controlled reactions. 
 
The reduction of -substituted -keto esters is among the most common 
DKR reaction. The chiral substrates that undergo ready racemization passing 
through the enol form are converted to a series of important -hydroxy esters. 
Although four stereoisomers are furnished in this reaction, the selection of 
appropriate conditions may result in a single product with high stereoselectivity. 
 
4.3.3.1 Ruthenium-catalyzed asymmetric hydrogenation 
Established after the pioneering studies of Noyori and co-workers, 
asymmetric hydrogenation of -keto esters with chiral ruthenium catalysts has 
emerged as a powerful approach which can be often combined with dynamic 
kinetic resolution (DKR) methods to synthesize -substituted -hydroxy esters and 
related compounds (Scheme 40).70 
 
 
Scheme 40. Ruthenium catalyzed enantioselective carbonyl reduction. 
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Asymmetric hydrogenation of 94 with RuBr2[(R)-BINAP]] in methanol and 
asymmetric transfer hydrogenation with the Noyori/Ikariya’s [(R,R)-
RuCl(TsDPEN)(p-cymene)] and 5:2 HCO2H/Et3N as solvent and hydrogen source 
proved to be futile and challenging (Scheme 41 and 42). Recently, Vinogradov and 
co-workers described the asymmetric hydrogenation of acylsuccinates in the 
presence of a RuCl3–BINAP catalyst system.
71 This study has allowed the 
synthesis of chiral 2-alkylparaconic acid esters in preparative yields and excellent 
enantioselectivities (Scheme 43). Nevertheless, subjection of furylsuccinate 94 
with RuCl3/R-BINAP in absolute MeOH and 40 bar of H2 at 50 
oC did not promote 
conversion to the desired -hydroxy product 100 (Scheme 43). 
 
Scheme 41. Conditions: a) HBr, acetone, rt; b) Ru cat., MeOH, H2 (75 atm), 50 
oC. 
 
 
Scheme 42. Conditions: a) KOH (98%); b) Ru cat., HCO2H-Et3N (5:2), 4 days, rt. 
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Scheme 43. Conditions: a) RuCl3 (1 equiv), (R)-BINAP, H2 (40 atm), MeOH, 12 h, 60 
oC. 
 
4.3.3.2 Biocatalytic reduction using yeast 
 
A number of microorganisms and enzymes are also known to catalyze the 
stereoselective reduction of -keto esters to -hydroxy esters. The use of a 
baker’s yeast is probably one of the most convenient biological methods to carry 
out this protocol.69,72 
Bioreduction of furylsuccinate 94 with Saccharomyces cerevisiae (Baker’s 
yeast) biomass furnished a 25% combined yield of 3:1 cis- and trans-93 lactones 
(Scheme 44). Plagued with difficulty on their separation in silica, the -
hydroxysuccinate intermediates were directly treated with PTSA to afford the 
lactones. The low yield can be attributed to complications brought about by the 
high hydrolytic activity of S. cerevisiae enzymes and concomitant decarboxylation 
reactions occurring on many intermediates. Multifunctional substrates are 
particularly labile to decompositions owing to various membrane and/or 
cytoplasmic enzymes present in microbial whole cell systems. Figure 28 
summarizes the possible pathways of the transformations involved. Pathway a, is 
the most common for all yeast strains. It involves the hydrolysis of the secondary 
ester group of 94 to give the corresponding hemiester 101, whose subsequent fate 
is decarboxylation and hydrolysis en route to -hydroxyoacids 102. Pathway b 
involves the hydrolysis of the primary ester group and reduction of the carbonyl 
group of the ketodiester to give 100. Pathway c involves a retro Claisen reaction 
driving the formation of heteroaromatic acid 103.73 
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Scheme 44. Conditions: a) (i) Dr. Oetcker’s Yeast, H2O, 12 h; (ii) PTSA, THF, 4 h, 0 
oC 
(25%). 
 
 
Figure 28. Degradative pathways in yeast reductions. 
 
The absolute stereochemistry of cis-lactone 93 was established from its 
single X-ray structure (Figure 29). Thus, the C4 and C5 stereocenters were 
assigned the 4S,5R configuration. The trans-lactone 93 on the other hand was 
given the 4R,5R stereochemistry based on its negative Cotton effects around 210 
nm which readily corroborated for n-* transition of (R) -arylated--
carboxylactones (Figure 30).73  
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Figure 29. Single X-ray crystal of cis-lactone (-)-93. 
 
 
Figure 30. CD spectrum of cis-93 and trans-93. 
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4.3.4 Conclusion 
 
Enantioselective reduction of a furylated -keto succinate ester 94 was 
successfully carried out using yeast to furnish cis- and trans- lactones albeit in 
small yield. Thus, further investigations and optimizations on this aspect are still 
needed. Although the afforded trans stereochemistry was opposite to what is 
originally required, it can be a useful template for the synthesis en route the 
enantiomer of 1-3. 
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4.4 A Simplified Approach Towards the Total Synthesis of Bielschowskysin 
 
4.4.1 Synthetic Efforts towards Bielschowskysin (1) 
Although there are no reported total syntheses of bielschowskysin, there 
have been two reported syntheses of the cyclobutane core found in the natural 
product. 
As the key step towards bielschowskysin (1) (Figure 31) the Sulikowski74 and 
Lear75 groups envisaged along the lines of the proposed biosynthetic pathway a 
photostimulated [2+2] cycloaddition by constructing the C6/C12 and C7/C11 
junctions in building up the cyclobutane core, aiming at intermediates 104 and 
105, respectively. 
 
Figure 31. Retrosynthetic strategies for the synthesis of 1. 
 
Both synthetic routes towards the photocyclization precursors 106 and 107 
started from (L)-malic acid (108), going to the common intermediate 109 (Scheme 
44). The alkynyl group was manipulated in a different way by both groups:  
Elongation was carried out by Doroh and Sulikowski via a palladium-catalyzed 
cross coupling reaction, followed by oxidation of the alcohol and ultimately acid 
catalyzed 5-exo-dig cyclization of the carboxylic acid onto the acetylene moiety. 
Lear and coworkers converted the acetylene to an allene utilizing a copper-
catalyzed addition of formaldehyde followed by dehydration. 
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Scheme 44. Synthesis of furanones 106 and 107. 
 
[2+2] Photoaddition. According to the study done by Doroh and Sulikowski, 
photoirradiation of 106 was first done in chloroform using a 275 W sun lamp, 
however double bond isomerization in the alkylidene moiety of the forming 
furanone 110 was observed to a considerable extent. Further irradiation of the 
solution provided a complex mixture of products. Switching the solvent to acetone 
showed a dramatic effect (Scheme 45). A similar isomerization phenomenon 
occurred but this time prolonged exposure of the solution using a daylight lamp 
afforded a 5:1 mixture of two compounds (50%) with 104 being the major and 111 
as the minor [2+2] photoadduct. Sulikowski and Doroh postulated that the 
formation of 104 adheres with the norm of the ‘rule of five76 vis-à-vis [2+2] 
photoinduced addition of alkene derivatives to furanones.77 According to this rule, 
intramolecular 1,5-photocyclization events occur and are preferentially geared 
towards the formation of  a five-membered ring. High regioselectivity is usually 
achieved when two reacting olefins are separated by two to four atoms.78 Hence, 
in accordance with this rule, a plausible formation of a 1,4-biradical79 112 and 113 
intermediates rather than a concerted reaction mechanism may be operating in 
this photoaddition. It was envisaged that a photochemical equilibriation effected  
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a) cis-trans isomerization of 106 to 110 and vice versa;  
b) rotation of the C6 - C7 bond which triggered the interconversion of 112 to 
106 and 113 to 110; and 
 c) stereochemical mutation of triplet radicals, i.e. rotation around C6 and C12 
interconverts 112 to 113.  
The path favoring the formation of photoadduct 104 from these series of 
photoinduced equilibriation processes were ascribed by the authors to a more 
preferable dipole interaction in 113 during radical combination. 
 
Scheme 45. Photochemical phenomena leading to photoadduct 2. 
On a separate study, subjection of the dichloromethane/hexane solution of 
furanone 107 under UV-irradiation (254 nm) afforded 105 (70%) exclusively 
(Scheme 46). They suggest that the regiocontrolled [2+2] addition of the internal 
double bond of the allenyl moiety is attributed to the presence of a tertiary alcohol 
center at C8. Such favors the creation of a five-membered ring and averts the 
formation of a six-membered cyclic structure, hence, illustrating a photochemical 
system that is governed solely by the ‘rule of five’ as applied to [2+2] 
photoadditions of tethered allenes to enones.80 It has been reported that some 
allene photosubstrates possessing an oxygenated C3 substituent (in this case C7) 
have the propensity to form both straight photoadduct (as in 105) and bridgehead 
olefinic (as in 114).81 Therefore, Lear and co-workers ascribed the regioselectivity 
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and high stereocontrol of the photoreaction on the presence of a chiral quaternary 
center connected to C7 and on the conformation of the 1,3-allene moiety. 
 
Scheme 46. Photochemical cycloaddition en route to photoadduct 3. 
4.4.2 Retrosynthetic analysis 
Although the three previously discussed strategies present viable 
approaches to construct the northeastern sector of furanocembranoids 1-3, some 
unforeseen challenges might arise along the way especially when the synthesis 
will approach to its completion, noteworthy for 1. For example, a number of steps 
to build up the lower sector may be required which invokes refunctionalization and 
protection-deprotection sequences. To address this potential problem, the 
synthetic approach has been simplified for 1 through a convergent approach. The 
interest to pursue bielschowskysin (1) is mainly related to its structural complexity 
and pharmacological activity (antimalarial and anti-cancer).6c 
The retrosynthetic analysis (Figure 32) starts through a lateral scission of the 
middle portion of 1 affording retron 115 and 116. It was envisioned that 
connections between C3/C6, C4/C5 and C12/C13 can be installed via 
acetalization, RCM and aldol addition, respectively. The synthesis of 115 can be 
achieved from methallyl lactone aldehyde 117. The latter can be obtained from 
chiral cyclopropane 15 and methallyl TMS 118 through an established protocol for 
-allyl lactone synthesis. On the other hand, cyclobutane 116 was envisaged to be 
made from cyclopentenol maleate 119 through a [2+2] photocycloaddition as key 
step. The synthesis of 119 can be accomplished by way of Mitsunobo reaction of 
the known cyclopentene diol 120 with methylmaleate 121. The commonality 
among the starting materials can be traced on the fact that most of them are 
readily made from furan compounds. 
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Figure 32. Retrosynthesis of bielschowskysin (1). 
 
4.4.3 Synthesis towards ketolactol synthon 115 
Allylsilanes are convenient nucleophilic equivalents for Hosumi-Sakurai 
allylation reactions. In this sequence, a methallyl TMS 118 was used as a building 
block for the C3/C4/C18 segment.15 Thus, allylation of cyclopropane 
carboxaldehyde 15 with 115 under BF3OEt2 catalysis provided cyclopropane 
carbinol 122 in 97% (Scheme 47). One-pot retro-aldol and lactonization of 122 
under basic conditions (methanolic Ba(OH)28H2O) delivered trans-
methallyllactone 117 in moderate yield. Lactone 117 is now a suitable platform for 
further functionalizations. Moreover, it features the trans-1S,2S configuration 
required in furanocembranoid 1. 
 
Scheme 47. Synthesis of lactone 117. Conditions: a) BF3OEt2, DCM, 16 h, 78 oC (97%); 
b) Ba(OH)28H2O, MeOH, 0 
oC (44%). 
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The next planned sequence was the one-carbon homologation of the -
carbaldehyde functionality. Originally, an Arndt-Eistert reaction was proposed as 
the homologation strategy. However, this reaction requires toxic transformations 
and work-ups. Therefore, a less elegant incorporation of a nitrile group was 
proposed as alternative strategy. The nitrile group on the latter stage can be easily 
converted directly to an aldehyde functionality by DIBALH reduction. Thus, to carry 
out such chain extension chemistry, the -carbaldehyde was reduced first to an 
alcohol. Treatment of lactone 117 with NaBH4 in MeOH yielded methallyl lactone 
methanol 123 (Scheme 48). Tosylation of the resulting alcohol 123 with tosyl 
chloride in the presence of triethylamine and catalytic amounts of DMAP furnished 
the tosylated derivative 124 in a moderate yield. The tosylate group now opens an 
opportunity for SN2 reaction with nitrile as the nucleophilic component. Thus, 
treatment of tosylated lactone 124 with KCN in refluxing DMF afforded 
methallylated acetonitrile lactone 125 in good yield.  
 
Scheme 48. Synthesis of lactone 125. Conditions: a) NaBH4, MeOH, 1 h, 0 
oC 56%; b) 
TsCl, Et3N, DMAP, DCM, 12 h, 0 
oC 44%. (c) KCN, DMF, 48 h, reflux, 85%. 
 
The next critical step was the incorporation of a hydroxyl or keto group at the 
saturated methylene carbon in the methallyl arm of the lactone by way of allylic 
oxidation. Reaction of nitrile 125 with SeO2 in a biphasic solution (H2O-dioxane) 
resulted in the formation of three compounds with the keto derivative 126 as the 
main product in moderate yield (Scheme 49). The drawback in this reaction is the 
possibility of undergoing over and non-regioselective oxidation thus the co-
formation of products 127 and 128.  
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Scheme 49. Allylic oxidation of lactone 125. Conditions: a) SeO2, dioxane-H2O (1:1), 12 h, 
reflux (31% for 126; 22% 127 and 10% for 128). 
 
Installation of the exo-olefinic component by heating nitrile lactone 126 with 
Bredereck’s reagent to yield 129 and reduction with excess DIBALH should lead to 
the desired lactol 115 (Scheme 50).  
 
Scheme 50. Synthesis of lactol methyl ether 115. 
 
4.4.4 Synthesis towards cyclobutane synthon 116 
The asymmetric preparation of cyclopentene diol 120 has been already 
described in the literature. The synthesis was carried out following the well-
established procedure of Curran and co-workers for the macroscale preparation of 
optically active cis-2-cyclopenten-1,4-diols.82 The synthesis started with the acid-
catalyzed rearrangement of furfuryl alcohol 130 to racemic 4-hydroxy cyclopent-2-
enone 131 with improved modifications from Reiser and co-workers.83 This 
rearrangement presents an interesting mechanism that is well-reported in several 
studies.82 The introduction of a bulky protecting group in the free hydroxyl group in 
131 (ex. TBS group) drives the subsequent LAH reduction of 132 to occur in a 
highly diastereoselective fashion yielding the cis-substituted product 133 in a good 
yield (Scheme 51). 
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Scheme 51. Synthesis of alcohol 133. Conditions: a) TBDMSCl, NEt3, DMAP (5 mol %), 
THF, 0 °C - rt, 83%; b) LiAlH4 (0.70 eq.), LiI (0.50 eq.), toluene/TBME, -30 
°C, 3 h, 79%. 
 
The next step was delved on the kinetic enzymatic resolution of racemate 
133 using a porcine pancreas lipase (PPLE).84 The interest TBS-protected 
acetoxycyclopentene 134 was readily separated from the unreacted cyclopentenol 
(Scheme 52). Through a series of protection-deprotection transformations 
involving saponification and oxidation sequences known for this chiral 
cyclopentenol, a smooth conversion towards cyclopentenone 135 was achieved. 
Addition of the methyl nucleophile at the less hindered face of the cyclopentenone 
delivered tertiary alcohol 136 with good diastereoselectivity (92% dr). TBS removal 
under non-nucleophilic basic conditions using TBAF furnished chiral 
methylcyclopentendiol 120. 
 
 
Scheme 52. Enzymatic resolution: a) porcine pancreas lipase PPLE, vinylacetate, Et3N 
(0.68 eq.), TBME, rt, 48 h, 78%; b) (i) LiOH, THF:MeOH:H2O (3:1:1), rt, 2 h, 
93%; (ii) PCC, DCM, 2 h, 0 oC, 85%. c) MeLi, THF, 3 h, -78 oC, 63%; d) 
TBAF, NEt3, THF, rt, 24 h, 79%. 
 
Since the required stereoconfiguration at C10 is S, a Mitsunobo inversion 
was the next sensible step to perform. To further simply and accelerate the 
synthesis of the requisite diene, methylmaleate 121 was chosen as the 
nucleophilic component in the reaction. Thus, treatment of cyclopentendiol with 
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methylmaleate in the presence of DIAD and PPh3 provided diene ester 119 in 94% 
yield (Scheme 53). The maleate moiety and the olefin in the cyclopentene handle 
now constitute the electron-poor and electron-rich alkenes suitable for a 
photodriven [2+2] cycloaddition. Thus, a trial photoirradiation of 119 in acetone74 
afforded a crude mixture of diasteromeric cyclobutane products 137 as evidenced 
from the 1H and 13C NMR spectra (Figure 33). Due to the observation of many 
diastereomeric adducts, further optimization on this reaction is recommended. 
Further manipulations on cyclobutane 137 (e.g. conversion of carbomethoxy ester 
to aldehyde, Wittig olefination and allylic oxidation) should lead to intermediate 
cyclobutane 116. Alternatively, transformation of the Lear cyclobutane 105 to 116 
should also be investigated (Scheme 54). 
 
 
Scheme 53. Conditions: a) 121, PPh3, DIAD, MeCN, 4 h, 0 
oC, 85%; b) acetone, h (254 
nm), 24 h, >80% conversion. 
 
 
 
Scheme 54. .Synthesis of 116 from 137or 105. 
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Figure 33. 1H and 13C NMR spectra of cyclobutane 137. 
 
Once the eastern segment 115 and western segment 116 have been 
successfully synthesized, coupling of these two intermediates followed by 
deprotection should lead to bielschowskysin (1) (Scheme 55).  
 
 
Scheme 55. Proposed completion of 1. 
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4.4.5 Conclusion 
Starting from furan derivatives as starting materials, two intermediates 119 
and 126 relevant for constructing the two key building blocks 115 and 116 were 
successfully prepared. Further synthetic transformations of these compounds may 
potentially lead to the completion of bielschowskysin (1). 
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C. MAIN PART - DISCOVERY OF ANTIMICROBIAL AND ANTI-CANCER 
BENZYLOXYLATED KETOARYL ALDEHYDES AND 2-
ARYLIMIDAZOLINES 
One aspect of modern drug discovery involves the evaluation of small 
molecular weight compounds for their ability to modulate a biological pathway in 
cells or organisms. This approach is likely to benefit in the future from an evolving 
forward analysis of synthetic pathways used in diversity-oriented synthesis that 
leads to structurally complex and diverse small molecules. One of the aims of 
diversity-oriented syntheses is to synthesize efficiently a collection of small 
molecules capable of perturbing any disease-related biological pathway, leading 
eventually to the identification of therapeutic protein targets capable of being 
modulated by small molecules.1 
Nowadays, the driving force to contribute to the library of these compounds is 
to produce certain derivatives which may either contain a pharmacophore, a 
certain functional group or a substituent which enhances bioactivity. More often 
than not, some of these compounds may not be active to the target disease but 
rather to another type of disease. 
1. Antimicrobial drug discovery 
The discovery of antimicrobial agents to treat infectious diseases has been 
one of the most notable achievements of the past century.2 However, the rise of 
infective diseases caused by bacteria resistant to multiple antibacterial drug 
classes represents a serious world-wide health problem.3 The methicillin-resistant 
Staphylococcus aureus (MRSA) is considered as one of the most resistant 
bacterial strain and is now the causative agent for the majority of staphylococcal 
infections in hospitals, as well as a leading cause of serious infections in the 
community. Other problematic resistant Gram-positive bacteria include 
vancomycin-resistant enterococci (VRE) and penicillin resistant Streptococcus 
pneumoniae (PRSP). The stimulated use of antimicrobial agents available in the 
market has resulted in the emergence of resistance to the commonly used drugs 
with important implications for morbidity, mortality and health care costs.4,5 Inspite 
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of a large number of antibiotics and chemotherapeutics available for medical use, 
the antimicrobial resistance has created a substantial need for design of new class 
of antimicrobials and this area will always remain of immense significance. 
1.1 Discovery of antituberculosis agents 
Chronic pulmonary tuberculosis is a disease which continues to spread scare 
particularly to people in developing countries. It stays as a major global concern in 
the health sector despite the accessibility of efficient treatment regimens. 
According to the 2010/2011global fact sheet of the World Health Organization 
(WHO), TB causes a mortality rate of about 1.7 million deaths although the rate 
has decreased to 35% since 1990.6-8 This escalated condition has been 
aggravated by the emergence of multi-drug resistant (MDR) and extensively drug-
resistant (XDR) strains of Mycobacterium tuberculosis.9,10 With much 
consideration to the seriousness of this pandemic health problem, the need to 
explore and develop new compounds that may exhibit novel inhibitory mechanism 
is timely and significant in TB drug discovery research. 
Ideal TB drug targets should have three characteristics: they should be 
required for bacterial growth and persistence; it should be possible to inhibit their 
activity using small molecules; and they should be accessible to these modulatory 
compounds. Theoretically, the simplest way to locate targets that have these ideal 
characteristics is to discover an active compound and then define its target.11 
2. Anti-cancer drug discovery 
Cancer is a disease that is characterized by uncontrolled growth and spread 
of abnormal cells. It accounts for nearly 8 million deaths each year, and this is 
estimated to reach 12 million deaths by 2030. Current trend of the disease 
accounts that one out of every four males will die of cancer in the same manner as 
one out of every five females.12,13  
Traditional anticancer drug discovery follows the main dichotomy of current 
drug discovery in general, which is largely molecular-target-based. Global genomic 
and proteomic approaches that are being employed in conjunction with 
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bioinformatic tools to elucidate novel drug discovery targets and to probe 
mechanisms of action and toxicity of potential drug molecules have been reviewed 
recently. Combinatorial chemistry and high-throughput screening against pure 
molecular targets and cancer cells are established methods for primary anti-
cancer drug discovery. Most of the potential novel molecular targets for anti-
cancer drug discovery can be grouped into the following categories: growth factor 
receptor tyrosine kinases (RTKs) and serine/threonine kinase signal transduction 
pathway targets; cell cycle targets; apoptosis-related targets; extracellular matrix 
targets, tumor angiogenesis and metastasis targets; and cell life-span targets.14 
3. Biological activity of benzyloxy aldehyde derivatives 
Despite the simplicity and thus, lack of complexity in their structure, 
benzyloxybenzaldehyde and a number of its substituted derivatives have shown 
biological effects in a number of screening assays. They have been observed to 
exhibit significant inhibitory activity toward neutrophil superoxide formation and 
were also evaluated for cAMP-elevating capability equivalent to forskolin.15 In a 
cytotoxicity assay against Hela cells, several benzyloxy benzaldehyde derivatives 
were observed to arrest the cell cycle progression at G2/M phase and thus, 
induced cell apoptosis.16 In addition, they have been evaluated to possess 
superoxide dismutase-1 activity linked to familial amyotropic lateral sclerosis.17 
4. Biological activity of 2-imidazolines 
2-Imidazolines are found in the structures of various natural products and 
bioactive compounds. For example, the marine alkaloid 4,5-dihydro-6’-
deoxybromotopsentin was isolated from a Spongosorites sp. marine sponge with 
high cytotoxicity.18 Since the discovery of the imidazoline receptor (imidazoline 
binding site, IBS) in 1984,19 many bioactive 2-imidazoline-containing molecules 
have been synthesized and used as ligands. In addition, 2-imidazolines have also 
been investigated to exhibit antihyperglycemic, anti-inflammatory, 
antihypertensive, antihypercholesterolemic, and antidepressant reagents.20 
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5. Aim of this work 
 
 It was previously described in a Chinese patent that -benzylidene--
carboxyl--heptyl derivativeTM (1)21 exhibits potent antimycobacterial activity. 
Based on previous investigations where compounds with shikimate kinase activity 
display antimicrobial properties22-24 and that several derivatives of benzyloxylated 
benzaldehydes demonstrate promising inhibitory effect against Helicobacter pylori 
kinases,25 further explorations on the antituberculosis activity of the benzylidene 
substructure, in the form of benzaldehyde derivative 2a was carried out.  The 
study was engaged to prepare several derivatives of 2a in an intention to discover 
more biologically potent derivative(s) based on the modification of rings A (2 
series) and B (3 series) and aldehyde group C (4 series) (Figure 1, structure 2). To 
compare the activity of 2a with the other substructure, lactone acid 5 was also 
prepared to examine if the purported inhibitory activity will be sustained. Several 
highly substituted -lactone derivatives26-29 have been reported to exhibit 
antimycobacterial properties.  
 
 
Figure 1. a) Antimycobacterial benzylidene 1TM. b) Ring modifications leading to series  
                                                                                  2-4.  
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6. Synthesis and antituberculosis activity of -heptyl paraconic acid and 
benzyloxy benzaldehyde derivatives 
 
  
6.1 Synthesis of -heptyl paraconic acid 5 
 The synthesis of paraconic acid 5 started from cyclopropanealdehyde 6 
(prepared from furan ester 7) following previous methods reported for rocellaric 
acid and other paraconic acids (Scheme 1).30-32 Allylation with ally TMS in the 
presence of BF3OEt2 provided cyclopropyl carbinol 8 which underwent 
immediately retro-aldol and lactonization (using Ba(OH)2.8H2O) to give -allyl-
lactone -aldehyde  9 in 45%.  The allyl moiety of 9 was transformed to a heptyl 
group to furnish lactone aldehyde 10 in two steps by employing ruthenium-
catalyzed crossed-metathesis (CM) with 1-hexene and hydrogenation reactions. 
Finally, Jones oxidation of 10 afforded paraconic acid 5. 
 
 
 
Scheme 1.  Synthesis of -heptyl paraconic acid 3. Conditions: (a) 1-hexene, Grubbs I 
catalyst (20 mol %), DCM, reflux, 8 h, 61% b) H2, Pd/C (10%), THF, rt, 12 h, 
quant. c) Jones reagent, DCM, 0 oC, 30 mins, 95%. 
 
6.2 Synthesis of benzyloxy benzaldehyde derivatives 2a-2k and 3a-3e 
 4-(2’, 5’-Dichlorobenzyloxy)benzaldehyde 2a and other derivatives (2b-2k) 
and 3a-e) based on the modification of rings A and B were prepared through 
Williamson ether synthesis between several benzylic halides (11 or 12) and 
aromatic hydroxyaldehydes (13 or 14) (Scheme 2 and 3).15  
 
 94 
 
      MAIN PART Macabeo  2011 
Table 1. Synthesis of ring A modified derivatives. 
 
Scheme 2. Conditions: a). Reagents and conditions: K2CO3, acetone, 18 h, rt. 
Entry ArCH2X 11 Product 2 
Isolated 
Yield 
 
1 
 
 
 
 
 
97 
2 
 
 
86 
3 
 
 
56 
4 
 
 
23 
5 
 
 
77 
6 
 
 
75 
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7 
 
 
74 
8 
 
 
98 
9 
  
43 
10 
 
 
75 
11 
 
 
98 
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Table 2. Synthesis of B modified derivatives. 
 
Scheme 3. Conditions: a) Reagents and conditions: K2CO3, acetone, 18 h, rt. 
Entry ArCHO 14 Product 3 
Isolated 
Yield 
 
1 
 
 
 
 
 
19 
2 
 
 
13 
3 
 
 
7 
4 
 
 
20 
5 
 
 
9 
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6.3 Antituberculosis activity 
The compounds were screened in assays to quantify their antitubercular 
activity under both aerobic and anaerobic conditions. Briefly, the 8 day microplate-
based assay using Alamar blue reagent (added on day 7) for determination of 
growth (MABA)33 gave an assessment of activity against replicating M. tb, while 
the 11 day high-throughput, luminescence-based low-oxygen-recovery assay 
(LORA)34 measured activity against bacteria in a non-replicating state that models 
clinical persistence. Minimum inhibitory concentrations (MICs) are defined as the 
lowest compound concentration effecting >90% growth inhibition, and the values 
recorded in the Tables represent the mean of at least two independent 
determinations. For comparison purposes, several anti-TB drugs were used as 
standards ex. rifampin (RMP), isoniazid (INH) and streptomycin (SM). 
Based on the MABA and LORA MIC data (Table 3), benzaldehyde 2a 
showed the lowest MIC value while 2b, 2c, 2f, 2i, 2j, and 3c gave considerable 
MIC data. The presence of halogenic substituents in 2a-c and 3c was observed to 
conjure antitubercular activity. The presence of a 2,6-dichloro substitution was 
found critical for a more potent activity along the compound 2 series. The insertion 
of chlorine atom in an aromatic system has been reported to be essential for 
antitubercular activity.35,36 The substitution pattern in ring B was also significant for 
inhibitory activity. Compared to the 1,4-substituted 2 series, the 1,2-substitution 
featured in 3 series seemed to have diminishing effects as observed in 3a-3c and 
3e. The presence of a methoxy group in ring B  (e.g. 3d) also caused inactivity 
although a 1,4-substitution is exemplified. The poor inhibitory activity observed for 
paraconic acid 5 suggest that the bioactive segment in 1 may lie in the 
benzyloxyarylidene fragment. 
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Table 3. MABA and LORA MIC of 2 and 3 series, and acid 5 against M. tb. H37Rv 
Compound MABA MIC (g/mL) (% inh) LORA MIC (g/mL) (% inh) 
2aa 18.5 >20 (39%) 
2b 49.3 >100 (84%) 
2c 48.4 99.7 
2d >100 (80%) nd 
2e >100 (39%) nd 
2f >100 (2%) nd 
2g 81.2 >100(81%) 
2h 96.4 >100 (65%) 
2i 47.2 >100(86%) 
2j >100 (15%) nd 
2k >100 (80%) nd 
5a >20% (0%) nd 
3a >100 (32%) nd 
3b >100 (32%) nd 
3c >100 (33%) nd 
3d >100 (88%) nd 
3eb >50 (9%) nd 
RMP 0.15 0.84 
INH 0.68 >128 
SM 0.83 33.2 
ainitially screened at 20 g/mL; binitially screened at 50 mg/mL. nd = not determined. 
RMP = rifampin; INH = isoniazid; SM = streptomycin sulfate. 
 
 
7. Synthesis, antimicrobial and anticancer activity of benzyloxylated 2-
arylimidazolines 
7.1 Synthesis of benzyloxylated 2-arylimidazolines and benzophenone 18 
 Taking into account the inhibition values of 2a in the first series which 
present a 2,6-dichlorobenzyl group in ring A and a 1,4 structural pattern in Ring B, 
further efforts were aimed at modifying the aldehyde warhead. Modifications were 
done by changing the carbaldehyde moiety to 2-imidazolines and to a ketone. 
Thus, oxidative conversion of 2a was done with diamines 15-17 in the presence of 
molecular iodine and potassium carbonate under warming conditions to prepare 
the 4 series (Scheme 4).37 Compound 18 was synthesized from 4-
hydroxybenzophenone and 2,6-dichlorobenzyl bromide using reaction conditions 
stated for the 2 and 3 series (Scheme 5).15 
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Table 4. Synthesis of 2-arylimidazoline 4 and benzyoxylated acetophenone 20. 
 
Scheme 4. a) I2, K2CO3, 
tBuOH, 70 oC. 
Entry ArCHO Diamine Product Isolated 
Yield 
 
1 
 
2a 
 
15 
 
 
 
33 
2 2a 16 
 
20 
3 2a 17 
 
58 
4 2b 17 
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5 2c 17 
 
84 
6 2g 17 
 
70 
7 2h 17 
 
75 
8 2i 17 
 
66 
 
 
 
 
Scheme 5. Conditions: a) Reagents and conditions: K2CO3, acetone, 18 h, rt, 61%. 
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7.2 Antimicrobial and anticancer activity of benzyloxylated 2-
arylimidazolines 
According to Table 5, an improved activity was observed in the 4 series when 
the aldehyde functionality was transformed into a 2-imidazoline platform. 
Noteworthy, 4c, which features a trans-diphenyl configuration and 2,6-dichloro 
substitution showed the lowest MIC value. When other bioactive 2 derivatives 
were transformed to this 1,3-diazacyclopentene moiety, significant improvement of 
inhibition was also observed in 4d, 4e, 4g and 4h. It seemed that halogenated and 
hydrophobic characters in A ring are relevant for activity against M. tb. In addition, 
MIC values against slow-replicating M. tb. based on the LORA assay suggested 
high activity for chlorinated 4c and 4d and the highly hydrophobic 4h. 
 
Table 5. Antimicrobial activity of imidazoline 4 series and ketone 18. 
Compound MABA MIC 
(g/mL) 
LORA MIC 
[g/mL] 
M. smeg Staph. 
aureus 
Escherichia 
coli 
Candida 
albicans 
4a 39.1 - - - - - 
4b 11.1 12.9 11.4 50.0 >50 (21) >50 
4c 3.0 2.9 2.5 >50 (76%) >50 >50 
4d 6.1 2.8 2.3 2.9 >50 (22) >50 
4e 5.8 12.3 2.6 2.9 >50 (9) >50 
4f 10.7 11.0 2.6 5.9 >50 (8) >50 
4g 7.9 11.1 4.9 - >50 >50 
4h 6.1 3.1 4.5 4.6 >50 (11) >50 
20 >100 (82%) - - - - - 
RMP 0.15 0.84 18.08    
INH 0.68 >128 89.03    
MOX   0.11    
SM 0.83 33.2 0.12    
TMC   <0.008    
MET   >512    
Amp    2.37 18.96  
Genta    0.57 1.10  
Amphotericin 
B 
     0.36 
Ketoconazole      0.03 
MOX = moxifloxacin.; AMP = ampicillin; GENTA = gentamycin; MET = methicillin. 
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 Owing to the continual emergence of multi-drug resistance to clinically 
available antibiotics against bacterial and fungal pathogens,38,39 the bioactive 
congeners were also tested for antimicrobial activity against Mycobacterium 
smegmatis, Staphylococcus aureus (Gram-positive bacteria), Escherichia coli 
(Gram-negative bacteria) and Candida albicans (a fungus). The well-established 
antibiotics cited in Table 5 were used as positive controls. Against M. smegmatis, 
all trans-diphenyl derivatives showed good inhibition rates with the halogenated 
compounds 4c-4e and the methylenedioxyphenyl bearing 4f exhibiting the most 
potent activity. Versus S. aureus, the monosubstituted halogenic 4d and 4e 
displayed the highest selectivity. No activity was observed for all compounds 
against E. coli and C. albicans which suggested non-selectivity to Gram-negative 
bacteria and fungi. 
To investigate the cytotoxic activity of the imidazoline compounds against 
Hela cell line (cervic cancer cells), an MTT cell proliferation assay was performed. 
Xanthohumol (19) was used as a positive control for cytotoxicity assay since it has 
been demonstrated to inhibit the growth of Hela cells.40,41 The approximate IC50 
value for 19 was 9.4 M (Table 6). The most non-polar derivative 4h showed the 
best anticancer activity with 4.5 M IC50 value followed by 4c-4e and 4g. The 
presence of the trans-diphenyl in the imidazoline moiety seemed to be an 
important factor for cytotoxic activity. The electron-donating methylenedioxy 
substituent in 4f effected decreased activity along the trans-arylated congeners.  
 
Table 6. Cytotoxicity data for 4 (HeLa cells, 150.000 cells/mL, 
72 h incubation,IC50 values in lM ± SD, n = 8). 
 
Compound IC50 (M) 
4a 54.2 ± 12.5 
4b 31.5 ± 5.6 
4c 5.12 ± 1.3 
4d 7.4 ± 0.4 
4e 7.6 ± 1.0 
4f 13.6 ± 4.8 
4g 7.9 ± 0.7 
4h 4.5 ± 0.6 
Xanthohumol 9.4 ± 1.4 
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8. Conclusion 
A series of benzyloxylated ketoaryl aldehydes and 2-arylimidazoline 
analogues based on the benzylidene fragment of the known antimicrobial lactone 
acid (1) have been synthesized and evaluated for antimicrobial and anti-cancer 
activity. Results evidenced that inhibition against Mycobacteria and Gram-positive 
bacteria (S. aureus) is dependent on the presence of halogens in ring A and 
substitution pattern in ring B, whereas conversion of the aldehyde functionality to 
2-imidazoline with trans-diphenyl moiety dramatically effects enhanced activity. In 
the course of anti-cancer investigation against Hela cells, the cytotoxic activity of 
the bioactive imidazoline congeners was attributed to the presence of electron-
withdrawing groups and non-polar substituents in ring A, and trans-diphenyl 
imidazoline. 
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D. SUMMARY 
 Within the framework of the study’s interest on bioactive structure synthesis 
and discovery, chemical explorations have been undertaken to develop methods 
to synthesize complex, highly oxidized furanolactone cembranoids and 
antiproliferative benzyloxylated derivatives. Bulk of the study has been centered 
on synthetic strategies en route to the furanocembranoids bielschowskysin (1), 
verrillin (2) and bipinnatin K (3) starting from furan derivatives (Figure 1). Three 
approaches have been developed for their northeastern segments and in addition, 
a simplified approach for the total synthesis of 1 was also investigated. 
 
 
Figure 1. Furanolactone cembranoids 1-3. 
 
The first approach led to the development of a new diastereocontrolled 
strategy towards heterocycle-butyrolactone scaffolds 6 of several complex natural 
product structures in particular 1-3 through vinylogous Mukaiyama addition of 
heterosiloxydienes 5 to furan ester-derived highly functionalized cyclopropane 
carbaldehyde 6 and lactonization sequences. In addition, the first synthesis of a Z-
exo-trienolfuran lactone substructure 7 representing the northeastern sector of 
bielschowskysin 1 was also accomplished.  
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Scheme 1. Studies based on siloxydiene addition to cyclopropane 6. 
 
 
In the second approach, a new diasteroselective methodology was 
developed towards -aryl lactones utilizing aryltitanium reagents in combination 
with the readily available cyclopropanecarbaldehyde 6. This methodology extends 
the previously reported functionalization of 6 with allylsilanes in substrate scope, 
but also offers for the first time a reversal of stereochemistry. Thus, cis-
disubstituted -aryl--methyl acetal lactones 8 with good diastereoselectivity in 
enantiomerically pure form can be obtained, which compares well with previously 
reported methods. In addition, a two-step transformation of the trans-furan lactone 
derivative furnished a model compound 9 reminiscent of the oxidized northeastern 
sector of 1 and 2. 
 
 
 
Scheme 2. Studies based on organotitanium addition to cyclopropane 6. 
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The third approach was about the enantioselective reduction of a furylated -
keto succinate ester 10 using yeast to furnish cis- and trans- lactones 11. Further 
investigations and optimizations on this aspect are still needed. Although the 
afforded trans stereochemistry was opposite to what is originally required, it can be 
a useful platform for the synthesis of the enantiomer of 1-3. 
 
 
 
Scheme 3. Yeast reduction of diester 10. 
 
 
In an attempt to synthesize bielschowskysin (1), two intermediates 12 and 13 
relevant for constructing the two key building blocks 14 and 15 were successfully 
prepared starting from furan derivatives. Further synthetic transformations of these 
compounds may potentially lead to the completion of 1. 
 
 
Scheme 4. A simplified approach towards bielschowskysin 1. 
 
Finally, a series of benzyloxylated ketoaryl aldehydes (16 and 17 series) 
and 2-arylimidazoline (18 series) analogues based on the benzylidene fragment of 
the known antimicrobial lactone acid (19) were synthesized and biologically 
evaluated. Results indicated that inhibition against Mycobacteria and Gram-
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positive bacteria (S. aureus) is dependent on the presence of halogenic moieties 
in ring A and 1,4 substitution in ring B, whereas conversion of the aldehyde 
functionality to 2-imidazoline with trans-diphenyl moiety dramatically leads to 
increased activity. In the course of anti-cancer investigation, the cytotoxic activity 
of the bioactive imidazoline congeners against Hela cells was attributed to the 
presence of electron-withdrawing groups and non-polar substituents in ring A, and 
trans-diphenyl imidazoline. 
 
 
Figure 2. Synthesis and biological activity of benzyloxylated derivatives. 
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E. EXPERIMENTAL PART 
1. General 
1.1 Materials and methods 
Unless otherwise stated, reactions were performed at ambient temperature 
(typically 20–22 ºC) in flame-dried glassware under a nitrogen atmosphere using 
dry solvents. Abs. solvents were prepared according to usual lab procedures or 
taken from the MB-SPS solvent purification system. Ethyl acetate, hexanes (bp 
40-60 °C) and dichloromethane were purified by distillation before use. Further 
solvents and reagents were of pure, analytical quality. All other commercially 
available reagents were used as purchased from the supplier. Reactions 
performed at above room temperature were controlled by a Heidolph EKT 3001 
temperature modulator. For reactions which require cooling to temperatures < -40 
°C, a cryostat Haake EK 90 or dry ice/iso-propanol (or acetone) mixture was used. 
For carrying out ozonalysis, ozone was generated using a Fischer process 
technology ozone generator OZ 500 MM and oxygen was supplied from a gas 
tank. 
1.2 Analytics 
 
Optical rotations were measured with a 241 MC Perkin-Elmer polarimeter at 
a wavelength of 589 nm (Na-D) in a 1 dm. The concentration is given in [g/100 ml]. 
CD spectra were measured on a JASCO model J-710/720 at the Institut für 
Bioanalytic und Sensorik of the University of Regensburg (AK Prof. Dr. O. 
Wolfbeis) at 21° C between 300 and 200-180 nm in the specified solvent, the 
number of scans ranging between 10 and 50. The length of the cylindrical cuvettes 
was 1 cm, the resolution was 0.2 nm, the band width 1.0 nm, the sensitivity 20 
mdeg, the response 0.25 s, the speed 20 nm/min. The background was subtracted 
to each spectrum. The absorption value is measured as Molar Ellipticity per 
Residue (deg cm2 dmol-1). 
1H and 13C NMR spectra were recorded on a Bruker Avance 300, Bruker Avance 
400, Bruker Avance 600 and Bruker Avance 600 Kryo and are reported relative to 
residual solvent for 1H NMR (CHCl3 = 7.27 ppm) and 
13C NMR (CDCl3 = 77.0 
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ppm). Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) 
(multiplicitiy, coupling constant (Hz), integration). Multiplicities are reported as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, dt = doublet of triplets, td = 
triplet of doublets, dd = doublet of doublets, m = multiplet, bs = broad singlet. 
IR spectra were recorded on a Bio-Rad Excalibur FTS 300 spectrometer, 
equipped with a Specac Golden Gate Diamond Single Reflection ATR-System and 
are reported in frequency of absorption (cm-1).  
Mass spectrometric measurements were performed on Varian MAT 311A, 
Finnigan MAT 95 and Thermoquest Finnigan TSQ 7000..  
Single crystal X-ray crystallographic analyses were carried out on Stoe Imaging 
Plate Diffraction System (IPDS) (Stoe & Cie GmbH, Darmstadt). 
Measurements of extremely small crystals (esp. for compound 33c) were 
performed using Bruker AXS FR591 equipped with Montel focusing mirrors and a 
four circle Mach3 goniometer supporting a Pt135 CCD-detector at the Chemical 
Crystallography and Electron Microscopy Department, Max-Planck-Institut für 
Kohlenforschung, Mülheim an der Ruhr c/o Prof. Dr. Christian W. Lehmann.  
Melting points were measured on a Büchi SMP 20 in a silicon oil bath. The melting 
points are uncorrected. 
Elemental analysis was prepared by the Microanalytical Department of the 
University of Regensburg using a Vario EL III or Mikro-Rapid CHN (Heraeus). 
1.3 Chromatography 
 
Thin-layer chromatography (TLC) was performed using Merck silica gel 60 F254 
precoated plates (0.25 mm) and visualized by UV fluorescence quenching (short 
and long ), staining with I2, mostain, molybdatophosphoric-acid (5% in ethanol), 
KMnO4 solution or vanillin-sulfuric acid.  
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Column chromatography was performed in glass columns (wet or dry packing). As 
a stationary phase silica gel Merck 60 (0.063-0.200 mm) or flash silica gel Merck 
60 (0.040-0.063 mm) was used. 
Preparative HPLC was performed at the Analytical Department for HPLC and GC 
of the University of Regensburg (AK König, c/o Fr. S. Strauss) on a Autosampler 
Agilent 1100 Series (Diode array detector, 61361A Prep pump,  = 254 nm, 
Phenomenex Luna 10 mM C18 (2) 100A (250x21.2 mm, 10 µm, flow rate: 21 
mL/min, 25 °C, @ 0 min, 5% MeCN/H2O (0.006% TFA w/w); @ 17 min, 84% 
MeCN/H2O (0.006% TFA w/w); @ 18 min, 98% MeCN/H2O (0.006% TFAw/w); @ 
28 min, 98% MeCN/H2O (0.006% w/w)). 
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2. List of abbreviations 
abs absolute 
BOX                bisoxazoline 
BINAP            2,2'-bis(diphenylphosphino)- 
1,1'-binaphthyl 
Bu n-butyl 
BuLi n-butyl lithium 
cat catalytic 
CD                   circular dichroism 
dr                    diastereomeric ratio 
DCM               dichloromethane 
DIAD              diisopropylazodicarboxylate 
DIBALH           diisobutyl aluminum 
hydride 
DMAP N,N-dimethylamino 
pyridine 
DMF dimethyl formamide 
DMS dimethyl sulfide 
ee enantiomeric excess 
equiv equivalents 
EI electronic ionization 
Et ethyl 
h hour 
HPLC high pressure liquid  
 chromatography 
HRMS high resolution mass  
 Spectrometry 
HTS                  high-throughput screening 
iPr iso-propyl 
IR infra red 
LAH lithium aluminium hydride 
LDA                 lithium diisopropylamide 
LORA              low-oxygen recovery assay 
M metal 
MABA             microplate Alamar blue 
assay 
mCPBA m-chloroperbenzoic acid 
MDR                multi-drug resistant 
Me methyl 
MeCN acetonitrile 
MIC                 minum inhibitory 
concentration 
min minute 
MS molecular sieve 
NMR nuclear magnetic resonance 
NMO N-methylmorpholin-N-oxide 
NOESY            Nuclear Overhauser Effect 
Spectroscopy 
Nu nucleophile 
PCC pyridinium chlorochromate 
Pg protecting group 
Ph phenyl 
PMB p-methoxy-benzyl 
PPLE porcine pancreas lipase   
                         Enzyme 
PPTS                pyridinium –p-toluene 
sulfonate 
PRSP                penicillin-resistant 
Streptococcus pneumoniae 
PTSA               p-toluene sulfonic acid 
pyr pyridine 
quant quantitative 
RCM ring closing metathesis 
rt room temperature 
SAR structure-activity 
 relationship 
TBAF tetrabutylammonium 
fluoride 
TBME tert-butyl-methyl-ether 
TBS tert-butyldimethylsilyl 
TEA                  triethylamine 
TES triethylsilyl 
tBu tert-butyl 
TFA                  trifluoroacetic acid 
THF tetrahydrofuran 
TLC                  thin-layer chromatography 
TMS                trimethylsilane 
TMSCN           trimethylsilyl cyanide 
TPAP tetrapropylammonium 
 perruthenate 
Tf trifluormethanesulfonate 
Ts tosyl 
TsDPEN           tosyldiphenylamine 
TS                    transition-state 
VMAR             vinylogous Mukaiyama 
aldol reaction 
VRE                 vancomycin-resistant 
enterocci
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3. Synthetic preparation of literature-known compounds 
The compounds used in Chapter B (see list below) were prepared according to 
literature/theses procedure/s: 
 
Cpd number Compound Name Reference 
 
15 
 
(1S,2S,3S)-(-)-oxalic acid 2-
ethoxycarbonyl-3-formyl-cyclopropyl 
ester methyl ester 
 
Geyer, G. Ph.D. 
Dissertation. Universität 
Regensburg. 2008. 
38a 2(5H)-furanone 
 
Nasman, Jan H.    
Organic Syntheses  
(1990),  68  162. 
38c 2(5H)-Furanone, 4-methyl-  
 
 
 
Sharma, Vasudha; Kelly, 
Gilbert T.; Watanabe, 
Coran M. H.    Organic 
Letters  (2008),  10(21),  
4815-4818. 
38d 2(5H)-Furanone, 3,4-diphenyl-  
 
 
 
Zhang, Ji; Blazecka, 
Peter G.; Belmont, 
Daniel; Davidson, 
James G.    Organic 
Letters  (2002),  4(25),  
4559-4561. 
38f 1H-Pyrrole-1-carboxylic acid, 2,5-
dihydro-2-oxo-, 1,1-dimethylethyl 
ester 
  
 
 
 
Curti, Claudio; Sartori, 
Andrea; Battistini, Lucia; 
Rassu, Gloria; Burreddu, 
Paola; Zanardi, Franca; 
Casiraghi, Giovanni.    
Journal of Organic 
Chemistry  (2008),  
73(14),  5446 
41 (1S,2S,3S)-(-)-Oxalic acid 2-
ethoxycarbonyl-3-
formylcyclopropylester methyl 
Geyer, G. Ph.D. 
Dissertation. Universität 
Regensburg. 2008 (with 
slight modification e.g. 
using R,R-iPrBox 
Ligand) 
97 2-Furanacetonitrile, -[[(1,1-
dimethylethyl)dimethylsilyl]oxy]- 
 
 
 
Rawal, Viresh H.; Rao, 
J. Appa; Cava, Michael 
P.    Tetrahedron Letters  
(1985),  26(36),  4275-8. 
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115 Silane, trimethyl(2-methyl-2-propen-1-
yl)-  
 
 
 
Hagen, Gisela; Mayr, 
Herbert.    Journal of the 
American Chemical 
Society  (1991),  
113(13),  4954-61. 
121 2-Butenedioic acid (2Z)-, 1-methyl 
ester  
Pospisil, Jiri; Potacek, 
Milan.    Tetrahedron  
(2006),  Volume Date 
2007,  63(2),  337-346. 
134 4-Cyclopentene-1,3-diol, 1-acetate, 
(1R,3S)-  
Schall, A. Ph.D. 
Dissertation. Universität 
Regensburg. 2008 
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4. Syntheses and spectral data of relevant compounds 
4.1 Diastereocontrolled vinylogous Mukaiyama aldol addition of 
heterosiloxydienes to trifunctionalized cyclopropane 15 
 
Synthesis of aromatic furanone 38e 
3,4-Bis-(4-tert-butyl-phenyl)-5H-furan-2-one 
 
3,4-Dibromofuranone (500 mg, 2.07 mmol, 1 equiv) was combined with 4-tert-
butylphenylboronic acid (3.0 equiv), cesium fluoride (4.0 equiv.), PdCl2(PPh3)2 (5  
mol%), BnEt3NCl (5 mol %) and 10 mL each of degassed toluene and water. The 
reaction mixture was refluxed for 18 h. The reaction mixture was partitioned 
between 10 mL 1.5N hydrochloric acid and 100 mL toluene. The toluene extract 
was concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography with 8:1 hexanes-EtOAc to afford furanone 38e as a 
crystalline solid. 
Yield 532.8 mg,74%.1H NMR (300 MHz, CDCl3)  7.45 (m, 8H), 5.16 (s, 2H),1.37 
(s, 9H), 1.34 (s, 9H). 13C NMR (75 MHz, CDCl3)  174.1, 155.4, 154.2, 151.7, 
128.9, 127.2, 125.9, 125.7, 70.6, 34.9, 34.8, 31.4, 31.1. EI-HRMS: m/z calcd for 
C24H28O2 348.2089 [M]
+; found: 348.2091. IR (neat)  ̃ 1750, 1657, 1601, 1483, 
1438, 1341, 1157, 1119, 1029, 959, 784 cm-1. 
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Preparation of heterosiloxydienes 
 
TMSO-Furan. A mixture of triethylamine (1.7 mL, 12.32 mmol, 2 equiv) and 
trimethylchlorosilane (0.82 g, 6.47 mmol,1.05 equiv) was added to a pre-cooled (0 
oC) 2(5H)-furanone (517.5 mg, 6.16 mmol, 1 equiv) under nitrogen. The reaction 
mixture was allowed to stay at room temperature for 24 h. The mixture was filtered 
and the residue was washed three times with n-pentane. The filtrate was 
concentrated and the remaining liquid was fractionally distilled under reduced 
pressure to afford TMSO-furan (32a.1) with a small amount of triethylammonium 
chloride, which was removed by redistillation (595.3 mg, 62%), b.p. 44-46 oC/15 
mmHg (lit. 34.35 oC/ mmHg).  
 
General Procedure: Preparation of TBS-Heterocycles (32a.2-32g) 
As a representative procedure, to a stirring solution of 2(5H)-furanone (258.3 mg, 
3.08 mmol, 1 equiv) in anhydrous CH2Cl2 (5 mL), cooled to 0 °C, were sequentially 
added Et3N (0.64 mL, 4.62 mmol, 1.5 equiv) and TBSOTf (0.78 mL, 3.38 mmol, 
1.1 equiv) under argon atmosphere. After ambient temperature was reached, the 
reaction mixture was stirred for 2 h and the solvent was removed under vacuum. 
The oily residue was shaken with pentane (3x10 mL), the top organic layer 
pipetted off, washed with water (pH 7) and concentrated. The resulting light yellow 
oil was adjudged to be >95% pure in 1H NMR and was used without further 
purification. Typical yield of the semi-pure TBS-protected product is 70-75% which 
is sufficient for the next step. 
 
General procedure: Addition of heterosiloxydienes to cyclopropane 
aldehyde 15 – VMAR 
Under a nitrogen atmosphere, a solution of cyclopropylcarbaldehyde (+)-15 
(500 mg, 2.05 mmol, 1 equiv) in anhydrous DCM (20 ml) was added via canula to 
a flame-dried three-necked flask and was cooled to -78 °C. BF3OEt2 (0.28 mL, 
2.25 mmol, 1.1 equiv) was added via syringe and after stirring for 30 min, tert-
butyldimethylsiloxyfuran solution in DCM (2.15 mmol, 1.05 equiv) was added 
slowly resulting to an orange-colored solution. After stirring for 16 h at -78 °C, 
 119 
 
EXPERIMENTAL Macabeo  2011 
saturated NaHCO3 (45 mL) was added and the mixture was allowed to warm to 
room temperature. The layers were separated and the aqueous layer was 
extracted three times with DCM (45x2 mL). The combined organic layers were 
washed with brine (45 mL), H2O (45 mL), dried (Na2SO4) and concentrated in 
vacuo to give the carbinol cyclopropane 37 which was used for the next step 
without further purification. 
General procedure: Synthesis of butenolide lactone 
A round–bottomed flask, equipped with Dean–Stark trap was charged with 
cyclopropyl carbinol 37 (1 equiv) followed by ethylene glycol (224 L, 4.02 mmol, 2 
equiv), Sn–catalyst 47 (5 mol %) and 15 mL toluene. The mixture was gently 
refluxed for 12 h. Afterwhich, the crude mixture was evaporated and purified by 
chromatography on silica gel (ethyl acetate-hexanes 3:1) to yield -heterocyclic 
lactone -dioxolane, 33. 
 
(2S,3S,2'S)-3-Dimethoxymethyl-3,4-dihydro-2H,2'H-[2,2']bifuranyl-5,5'-dione 
(33a.1) 
 
Yield 188.1 mg, 38%. 1H NMR (300 MHz, CDCl3)  7.41 (m, 1H), 6.13 (m, 1H), 
5.13 (dd, J = 3.8, 1.9 Hz, 1H), 4.68 (m, 1H), 4.33 (t, J = 7.1 Hz, 1H), 3.39 (s, 3H), 
3.35 (s, 3H), 2.95 (m, 1H), 2.68 (m, 1H), 2.38 (m, 1H). 13C NMR (75 MHz, CDCl3) 
 175.1, 172.2, 152.3, 122.4, 105.1, 83.2, 77.1, 56.2, 54.5, 39.4, 29.8. EI-HRMS: 
m/z calcd for C11H15O6 243.0869 [M+H]
+; found: 243.0869. IR (neat)  ̃ 2945, 2837, 
1783, 1745, 1603, 1451, 1361, 1159, 1112, 1054, 827 cm-1. 
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(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-3,4-dihydro-2H,2'H-[2,2']bifuranyl-5,5'-dione 
(33a.2) 
 
 
Yield 196.3 mg, 40%. 1H NMR (600 MHz, CDCl3)  7.46 (m, 1H), 6.19 (dt, J = 
13.3, 6.6 Hz, 1H), 5.18 (m, 1H), 4.93 (m, 1H), 4.70 (m, 1H), 4.01 (m, 2H), 3.92 (m, 
2H), 2.99 (m, 1H), 2.76 (dt, J = 15.2, 7.6 Hz, 1H), 2.50 (m, 1H). 13C NMR (151 
MHz, CDCl3)  174.8, 171.8, 152.1, 123.3, 103.3, 83.1, 76.3, 65.5, 65.3, 39.9, 
29.2. LSI-HRMS: m/z calcd for C11H12O6 241.0712 [M+H]
+; found: 241.0711. IR 
(neat)  ̃ 2945, 2837, 1754, 1603, 1159, 1113, 1066, 896, 826 cm-1. 
 
(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-4'-methyl-3,4-dihydro-2H,2'H-[2,2']bifuranyl-
5,5'-dione (33b) 
 
Yield 103.5 mg, 40% (based on 1.02 mmol 15). 1H NMR (600 MHz, CDCl3)  7.01 
(m, 1H), 5.04 (m, 1H), 4.97 (m, 1H), 4.94 (m, 1H), 4.71 (m, 1H), 4.67 (m, 1H), 4.04 
(m, 1H), 3.94 (m, 1H), 2.94 (m, 1H), 2.78 (s, 3H), 2.52 (m, 1H), 1.97 (m, 1H). 13C 
NMR (151 MHz, CDCl3)  174.8, 173.1, 143.9, 132.2, 103.3, 80.8, 76.8, 65.5, 65.4, 
39.9, 29.3, 10.8. LSI-HRMS: m/z calcd for C12H15O6 255.0869 [M+H]
+; found: 
255.0870. IR (neat)  ̃ 2957, 2890, 1754, 1660, 1576, 1174, 1062, 1024, 943, 632 
cm-1. 
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(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-3'-methyl-3,4-dihydro-2H,2'H-[2,2']bifuranyl-
5,5'-dione ((33c) 
 
 
 
Yield 338.4 mg, 65%. []D
25 +3.6 (c 0.3, MeOH). 1H NMR (300 MHz, CDCl3)  5.87 
(m, 1H), 4.94 (d, J = 4.1 Hz, 2H), 4.69 (dt, J = 11.7, 5.8 Hz, 1H), 3.98 (m, 4H), 3.03 
(td, J = 9.9, 4.4 Hz, 1H), 2.79 (m, 1H), 2.49 (dd, J = 18.0, 5.4 Hz, 1H), 2.16 (dd, J = 
12.3, 1.0 Hz, 3H). 13C NMR (75 MHz, CDCl3)  175.1, 172.2, 164.3, 118.3, 103.3, 
84.5, 75.7, 65.8, 40.1, 29.4, 14.0. EI-HRMS: m/z calcd for C12H13O6 253.0712 [M-
H]+; found: 253.0710. IR (neat)  ̃ 2932, 2902, 2864, 1779, 1730, 1646, 1402, 
1266, 1188, 1147, 1089, 1019, 975, 899 cm-1. EI-HRMS: m/z calcd for C12H13O6 
253.0712 [M-H]+; found: 253.0710. IR (neat)  ̃ 2932, 2902, 2864, 1779, 1730, 
1646, 1402, 1266, 1188, 1147, 1089, 1019, 975, 899 cm-1. 
(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-3',4'-diphenyl-3,4-dihydro-2H,2'H-
[2,2']bifuranyl-5,5'-dione (33d) 
 
 
Yield 337.2 mg, 42%.1H NMR (300 MHz, CDCl3)  7.41 (m, 10H), 5.57 (d, J = 1.4 
Hz, 1H), 4.94 (m, 1H), 4.53 (dt, J = 8.2, 4.1 Hz, 1H), 3.96 (m, 4H), 3.16 (m, 1H), 
2.86 (m, 1H), 2.50 (dd, J = 18.0, 6.4 Hz, 1H). 13C NMR (151 MHz, CDCl3)  174.8, 
173.1, 143.9, 132.2, 103.3, 80.9, 76.8, 65.5, 65.4, 39.9, 29.3, 10.8. LSI-HRMS: 
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m/z calcd for C23H21O6 393.1338 [M+H]
+; found: 393.1328. IR (neat)  ̃ 2960, 2893, 
1789, 1750, 1643, 1446, 1355, 1156, 1027, 981, 910 cm-1. 
(2S,3S,2'S)-3',4'-Bis-(4-tert-butyl-phenyl)-3-[1,3]dioxolan-2-yl-3,4-dihydro-
2H,2'H-[2,2']bifuranyl-5,5'-dione (33e) 
 
 
Yield 458.1 mg, 49%.1H NMR (300 MHz, CDCl3)  7.38 (m, 6H), 7.25 (m, 2H), 
5.55 (d, J = 1.4 Hz, 1H), 4.94 (d, J = 4.4 Hz, 1H), 4.57 (dd, J = 5.4, 1.4 Hz, 1H), 
3.94 (m, 4H), 3.14 (m, 1H), 2.84 (m, 1H), 2.50 (m, 1H), 1.31 (s, 9H), 1.29 (s, 9H). 
13C NMR (75 MHz, CDCl3)  174.9, 172.2, 153.8, 151.8, 128.9, 127.8, 127.6, 
126.5, 126.1, 125.4, 103.7, 81.4, 76.2, 65.6, 65.4, 40.4, 34.9, 34.7, 31.2, 31.2, 
29.8. EI-HRMS: m/z calcd for C31H36O6 504.2512 [M]
+; found: 504.2501. IR (neat) 
 ̃ 2962, 2868, 1791, 1756, 1608, 1363, 1160, 1027, 982, 837 cm-1. 
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(E)-3-[1,3]Dioxolan-2-yl-4-((S)-5-oxo-2,5-dihydro-thiophen-2-yl)-but-3-enoic 
acid ethyl ester (48) 
 
 
 
Yield 25.8 mg, 9% (based on 1.02 mmol 15). 1H NMR (600 MHz, CDCl3)  7.54 
(m, 1H), 6.39 (m, 1H), 6.21 (m, 1H), 4.99 (m, 1H), 4.11 (m, 2H), 3.97 (m, 2H), 3.88 
(m, 2H), 2.74 (m, 1H), 2.51 (m, 1H), 1.22  (m, 1H), 0.89 (m, 3H). 13C NMR (151 
MHz, CDCl3)  171.2, 149.5, 141.0, 133.6, 130.5, 103.9, 65.4, 65.4, 60.8, 43.4, 
34.0, 25.8, 14.1. EI-HRMS: m/z calcd for C13H16SO6 284.0718 [M]
+; found: 
284.0724. IR (neat)  ̃ 2926, 2850, 2322, 1733, 1685, 1259, 1182, 1038, 895 cm-1. 
 
Synthesis of pyrrolidenone lactone -aldehyde 
(S)-2-((S)-3-Formyl-5-oxo-tetrahydro-furan-2-yl)-5-oxo-pyrrolidine-1-
carboxylic acid tert-butyl ester (33f) 
 
 
 
Palladium on carbon (10%, 74 mg) was added to a solution of ,-
unsaturated lactam cyclopropyl carbinol 37g (854 mg, 2 mmol) in anhydrous THF 
(10 mL) in the presence of a small amount of NaOAc (31 mg) at room 
temperature. The reaction vessel was evacuated by aspirator and thoroughly 
purged with hydrogen (three times), and the resulting heterogeneous mixture was 
stirred under a balloon of hydrogen. After 24 h, the hydrogen was evacuated, the 
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catalyst filtered off, and the filtrate was concentrated under vacuum to give a crude 
residue which was used for the next step without further purification. 
The crude alcohol (1.0 equiv) was dissolved in MeOH (10 mL/mmol) and 
cooled to 0 °C. Ba(OH)2⋅8H2O (0.55 equiv) was added in small portions over 1 h. 
After 1 h stirring at 0 °C, DCM (10 ml/mmol) and H2O (10 mL/mmol) were added 
and the layers were separated. The aqueous layer was again extracted with DCM 
(3x10 ml/mmol). The combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo. Chromatography on silica gel (hexanes:ethylacetate 1:4) 
afforded the corresponding lactam lactone aldehyde 37f as colorless syrup. 
 
 
Yield 130.2 mg, 43% (based on 1.02 mmol 15).1H NMR (600 MHz, CDCl3)  9.75 
(d, J = 1.4 Hz, 1H), 5.01 (ddd, J = 28.6, 14.3, 4.3 Hz, 1H), 4.38 (m, 1H), 3.47 (m, 
1H), 3.30 (m, 1H), 3.01 (m, 1H), 2.86 (m, 1H), 2.72 (m, 1H), 2.47 (m, 1H), 1.59 (m, 
1H), 1.54 (s, 9H). 13C NMR (151 MHz, CDCl3)  195.9, 172.8, 150.2, 84.3, 78.4, 
59.4, 49.2, 31.5, 28.9, 28.0, 28.0, 18.4. Anal. calcd for C14H19NO6: C, 56.56; H, 
6.44; N, 4.71 Found: C, 55.68; H, 6.72; N, 4.71. IR (neat)  ̃ 2974, 2934, 1781, 
1253, 1712, 1462, 1369, 1291, 1147, 1021, 971, 844, 797, 775 cm-1. 
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Synthesis of lactolfuran dioxolane 58 
 
(2S,3S,5S)-3-[1,3]Dioxolan-2-yl-2,3,4,5-tetrahydro-[2,2']bifuranyl-5-ol 
 
 
 
To a solution of 33c (1.25 g, 4.92 mmol,1 equiv) in CH2Cl2 (75 mL) at −78 °C, 
DIBAL-H (11.8 mL of 1 M solution in DCM, 11.80 mmol, 2.4 equiv) was added 
under nitrogen. After 30 min the mixture was warmed to 0 °C, quenched with wet 
Et2O and at room temperature, Et2O, Na2SO4 (1.0 g) and NaHCO3 (1.0 g) were 
added and the solution was stirred for 1 h, filtered through silica gel eluting with 
Et2O and EtOAc, and concentrated to afford a crude oil which was purified with 1:1 
hexanes-EtOAc to afford lactol 58. 
 
Yield 743.5 mg, 63% (dr 75:25, 16S/16R). 1H NMR (300 MHz, CDCl3)  7.27 (m, 
1H), 6.16 (m, 1H), 5.54 (m, 1H), 5.16 (dd, J = 5.7, 3.5 Hz, 1H), 4.98 (t, J = 3.4 Hz, 
1H), 4.52 (m, 1H), 4.06 (m, 1H), 3.94 (m, 1H), 2.91 (dddd, J = 11.0, 8.3, 5.5, 2.8 
Hz, 1H), 2.48 (m, 1H), 2.03 (s, 3H), 1.97 (d, J = 1.5 Hz, 2H, 1.61 (m, 1H)). 13C 
NMR (75 MHz, CDCl3)  148.0, 141.6, 117.8, 113.0, 103.9, 98.6, 71.3, 65.5, 65.3, 
44.4, 35.0, 9.7. EI-HRMS: m/z calcd for C12H16O5 240.0098 [M]
+; found: 240.0098. 
IR (neat)  ̃ 3430, 2959, 2886, 1738, 1556, 1454, 1405, 1152, 1091, 942, 783 cm-1. 
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Synthesis of lactonefuran dioxolane 59 
 
(2S,3S)-3-[1,3]Dioxolan-2-yl-3,4-dihydro-2H-[2,2']bifuranyl-5-one 
 
 
 
To a mixture of furanlactol 58 (79 mg, 0.335 mmol, 1 equiv), N-
methylmorpholine N-oxide (NMO) (58.2 mg, 0.497 mmol, 1.5 equiv), 1.5 equiv and 
MS (4 ̇) (170 mg) in dry CH2Cl2 (10 mL) was added TPAP (17.4 mg, 0.05 mmol, 
0.15 equiv). The reaction mixture was stirred at room temperature for 3 h under 
nitrogen and then was filtered through silica gel and Celite® eluting with EtOAc. 
The solvent was evaporated to give a crude oil, which was chromatographed on 
silica gel with 1:1 hexanes-EtOAc to afford furanlactone 59. 
 
Yield 83 mg, 98%. 1H NMR (300 MHz, CDCl3)  7.32 (m, 1H), 6.24 (m, 1H), 5.48 
(m, 1H), 4.92 (m, 1H), 4.02 (m, 2H), 3.92 (m, 2H), 3.15 (m, 1H), 2.92 (ddd, J = 
17.7, 7.7, 5.2 Hz, 1H), 2.66 (m, 1H), 2.08 (m, 3H). 13C NMR (75 MHz, CDCl3)  
175.7, 145.5, 142.4, 120.1, 113.3, 102.9, 72.6, 65.6, 65.4, 42.3, 29.6, 9.6. EI-
HRMS: m/z 238.0841 calcd for C12H14O5 [M]
+; found: 238.0843. IR (neat)  ̃ 2900, 
1775, 1348, 1175, 1136, 1031, 945, 767 cm-1. 
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Synthesis of furanlactone methacrylate ethyl ester 57 
 
2-((2'S,3'S)-3'-[1,3]-Dioxolan-2-yl-3-methyl-5'-oxo-2',3',4',5'-tetrahydro-
[2,2']bifuranyl-5-ylmethyl)-acrylic acid ethyl ester 
 
 
 
 
 
A mixture of 59 (50 mg, 0.21 mmol, 1 equiv), ethyl methacrylate (105 L, 
0.84 mmol, 4 equiv), Pd(OAc)2 (2.4 mg, 0.011 mmol, 0.05 equiv), Cu(OAc)2.H2O 
(84 mg, 0.42 mmol, 2 equiv) and LiOAc (55 mg, 0.84 mmol, 4 equiv) was stirred in 
DMF (1 mL) at 117 oC under air. After cooling, the reaction mixture was extracted 
with ethyl acetate and dried with anhydrous sodium sulfate. Compound 57 was 
purified by preparative reversed-phase HPLC using a gradient elution method with 
increasing amounts of acetonitrile in water. 
 
Yield 38 mg, 52%. []D
25 +54.4 (c 0.4, DCM). 1H NMR (300 MHz, CDCl3)  6.24 (t, 
J = 3.3 Hz, 1H), 5.91 (s, 1H), 5.52 (t, J = 4.2 Hz, 1H), 5.41 (m, 1H), 4.92 (t, J = 3.9 
Hz, 1H), 4.22 (m, 2H), 3.96 (m, 4H), 3.57 (d, 2H), 3.13 (m, 1H), 2.87 (m, 1H), 2.63 
(m, 1H), 2.03 (t, 3H), 1.30 (t, 3H). 13C NMR (75 MHz, CDCl3)  174.9, 165.8, 
152.1, 143.0, 135.9, 125.5, 119.8, 109.5, 101.6, 72.2, 64.3, 59.4, 41.2, 29.6, 28.3, 
13.0, 8.9. EI-HRMS: m/z calcd for C18H22O7 [M]
+: 350.1366; found: 350.1364. IR 
(neat): 2962, 2904, 1779, 1714, 1634, 1406, 1260, 1196, 1024, 947, 795 cm-1. 
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Synthesis of trienol methyl ketal 54 
 
2-[(2S,2'S,3'S)-3'-[1,3]Dioxolan-2-yl-2-methoxy-3-methyl-5'-oxo-2',3',4',5'-
tetrahydro-2H-[2,2']bifuranyl-(5Z)-ylidenemethyl]-acrylic acid ethyl ester 
 
 
A solution of 57 (15 mg, 0.042 mmol, 1 equiv) in a mixture of MeOH (50 L) 
and diethyl ether (35 L) was stirred and cooled to -40oC. Liquid bromine (7.1 L, 
0.044 mmol, 1.03 equiv) in dry MeOH (0.1 mL) was added dropwise over 5 min. 
After addition, stirring was continued for an additional 10 min. The mixture was 
saturated with ammonia gas to pH 8, allowed to warm to room temperature, 
diluted with ether and evaporated. The residue was purified by flash 
chromatography (silica, 1:1 EtOAc–hexanes) to afford a mixture of 1:1 54 and 3-
epi-54. 
 
Yield 8.8 mg, 55% (dr 50:50, 3S/3R). 1H NMR (300 MHz, CDCl3)  6.34 (s, 1H), 
6.18 (q, J = 1.4 Hz, 1H), 5.41 (d, J = 5.1 Hz, 1H), 4.85 (d, J = 3.5 Hz, 1H), 4.50 (d, 
J = 2.1 Hz, 1H), 4.23 (m, 2H), 3.92 (m, 4H), 3.47 (s, 2H), 3.14 (s, 2H), 2.84 (m, 
1H), 2.68 (m, 1H), 2.42 (m, 1H), 1.95 (s, 3H), 1.31 (t, J = 3.2 Hz, 3H). 13C NMR (75 
MHz, CDCl3)  176.7, 166.9, 157.6, 141.2, 133.7, 127.1, 124.1, 115.0, 103.9, 94.0, 
81.1, 65.8, 61.3, 50.9, 50.4, 38.4, 28.9, 14.1, 12.4. EI-HRMS: m/z calcd for 
C19H24O8 [M]
+: 380.1471; found: 380.1478. IR (neat): 2904, 1782, 1710, 1636, 
1447, 1366, 1244, 1130, 1021, 957, 942, 852 cm-1. 
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Synthesis of bislactone 52 
(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-tetrahydro-[2,2']bifuranyl-5,5'-dione 
 
 
A solution of lactone 33a.1 (177 mg, 0.731 mmol, 1 equiv) in 7 mL of 
absolute MeOH was cooled to 0 °C and treated with NiCl
2
·6H
2
O (0.91 g, 3.8 mmol, 
0.25 equiv). The resulting mixture was stirred at the same temperature for 15 min 
before the addition of NaBH
4 
(0.29 g, 7.6 mmol, 1 equiv). After 30 min, further 
portion of NaBH
4 
(0.14 g, 3.8 mmol, 0.5 equiv) was added, and the reaction was 
allowed to stir for additional 10 min. The reaction was quenched with saturated 
NH
4
Cl solution and extracted with 3x10 mL CH
2
Cl
2
. The combined extracts were 
dried (Na2SO4) and concentrated under vacuum. Silica gel flash chromatographic 
purification (1:1 hexanes-EtOAc) afforded saturated compound 52 as a colorless 
oil. 
Yield 149.6 mg, 84% (dr 76:24, 3S/3R). 1H NMR (300 MHz, CDCl3)  4.58 (m, 1H), 
4.44 (m, 1H), 4.27 (m, 1H), 3.37 (s, 3H), 3.32 (s, 3H), 2.85 (dt, J = 10.1, 4.5 Hz, 
1H), 2.47 (m, 6H). 13C NMR (75 MHz, CDCl3)  176.4, 175.3, 105.2, 80.6, 79.9, 
55.9, 54.2, 39.7, 30.2, 27.9, 23.8. EI-HRMS: m/z calcd for C11H16O6 [M-H]
+: 
243.0689; found: 243.0866. IR (neat): 2947, 2838, 1768, 1457, 1367, 1152, 1121, 
1052, 981, 876 cm-1. 
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4.2 Diastereocontrolled addition of organotitanium reagents to 
trifunctionalized cyclopropane 15 – synthesis of -arylbutyrolactones  
General Procedure A: Preparation of Aryltitanium Nucleophiles 
From five-membered heterocyles. As representative procedure, to a THF (26 
mL) solution of furan (1.5 mL, 8.04 mmol) at –78 °C, n-BuLi (5.27 mL, 8.44 mmol) 
was added slowly. The mixture was stirred for 2 h at this temperature, and the 
resulting solution was treated with a solution of chlorotriisopropoxytitanium in 
hexane (8.84 mL, mmol, 1.1 eq) dropwise over 5 min and stirred further for 30 min. 
 
From bromophenyl derivatives. As representative procedure, to a solution of 4- 
methoxyphenyllithium was prepared by slow addition of n-butyllithium in hexane 
(1.6 M, 5.27 mL, 8.44 mmol, 1.05 eq) to 4-bromoanisole (1.0 mL, 8.04 mmol, 1 eq) 
in THF (mL) under a nitrogen atmosphere and was stirred for 2h at –78 °C. 
Chlorotriisopropoxytitanium in hexane (1 M, 8.84 mL, 8.84 mmol, 1.1 eq) was 
added dropwise over 5 min at –78 °C under nitrogen. After completion of the 
addition, the mixture was stirred further for 30 min. 
 
General Procedure B: Addition of Aryltitanium Nucleophiles to 
Cyclopropanecarbaldehyde, 15 
 
Under a nitrogen atmosphere, a solution of cyclopropylcarbaldehyde (+)-15 
(500 mg, 2.01 mmol, 1 equiv) in anhydrous THF (20 mL) was added via canula to 
a flame-dried three-necked flask and was cooled to -78 °C. BF3OEt2 (0.28 mL, 
2.21 mmol, 1.1 equiv) was added via syringe and after stirring for 30 min., the 
aryltitanium nucleophile solution (8.04 mmol, 4 equiv) was added slowly resulting 
to a color change (typically yellow-orange to reddish-orange). 
After stirring for 16 h at -78 °C, saturated NaHCO3 (45 mL) was added and 
the mixture was allowed to warm to room temperature. The layers were separated 
and the aqueous layer was extracted three times with ethyl acetate (45x2 mL). 
The combined organic layers were washed with brine (45 mL), H2O (45 mL), dried 
(Na2SO4) and concentrated in vacuo to give the arylcarbinol cyclopropane 10 
which was used for the next step without further purification. 
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General Procedure C: Synthesis of -Aryllactone Methyl Acetals 68a-68f 
A round–bottomed flask, equipped with Dean–Stark trap was charged with 
arylcyclopropyl carbinol 74 (1 equiv) followed by methanol (2 mL per mmol) and 
Sn–catalyst 47 (10 mol%). The mixture was gently refluxed for 12 h. Afterwhich, 
the crude mixture was evaporated and purified by chromatography on silica gel 
(ethyl acetate-hexanes 1:2) to yield the protected aryllactone aldehyde, 68. 
 
(2S,3S)-3-Dimethoxymethyl-3,4-dihydro-2H-[2,2']bifuranyl-5-one (68a) 
 
 According to general procedure B, 181 mg (40%, 86:14 trans-cis ratio). 1H NMR 
(300 MHz, CDCl3)  7.42 (dd, J = 1.8, 0.8 Hz, 1H), 6.25 (m, 2H), 5.40 (d, J = 4.6 
Hz, 1H), 4.35 (d, J = 5.7 Hz, 1H), 3.38 (s, 3H), 3.34 (s, 3H), 3.10 (m, 1H), 2.83 (dd, 
J = 17.9, 9.4 Hz, 1H), 2.61 (dd, J = 17.9, 5.4 Hz, 1H). 13C NMR (75 MHz, CDCl3)  
175.9, 151.0, 143.6, 110.5, 109.2, 104.3, 74.9, 55.4, 54.5, 42.2, 30.1. HR-EIMS: 
calcd for C11H14O5 [M]
 +: 226.0841, found: 226.08422. IR:   ̃= 2937, 1738, 1734, 
1591, 1445, 1372, 1253, 1172, 1067, 748, 632, 537, 497 cm-1. 
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(4S,5R)-4-Dimethoxymethyl-5-thiophen-2-yl-dihydro-furan-2-one (68b) 
 
According to general procedure B, 184 mg (38%, 55:45 cis-trans ratio)1H NMR 
(300 MHz, CDCl3)  7.34 (d, J = 2.5 Hz, 1H), 7.03 (m, 2H), 5.84 (d, J = 7.7 Hz, 
2H), 3.93 (d, J = 7.3 Hz, 2H), 3.59 (m, 1H), 3.25 (s, 3H), 3.21 (s, 3H), 2.73 (dd, J = 
23.5, 13.4 Hz, 1H), 2.56 (dd, J = 17.6, 8.8 Hz, 1H). 13C NMR (75 MHz, CDCl3)  
175.4, 141.9, 126.9, 126.2, 125.9, 104.3, 78.3, 54.9, 54.8, 52.7, 43.2, 29.1. HR-
EIMS: calcd for C11H14O4S [M]
+: 242.0613, found: 242.06144 IR:   ̃= 2940, 2834, 
1782, 1732, 1441, 1169, 1062, 953, 712, 632, 540, 495 cm-1. 
(4S,5S)-4-Dimethoxymethyl-5-thiophen-2-yl-dihydro-furan-2-one (minor 
trans-68b) 
 
1H NMR (300 MHz, CDCl3)  7.32 (d, J = 2.5 Hz, 1H), 7 (m, 2H), 5.65 (d, J = 5.1 
Hz, 1H), 4.39 (d, J = 5.4 Hz, 1H), 3.41 (s, 3H), 3.37 (s, 3H), 3.14 (m, 2H), 2.91 (dd, 
J = 11.1, 5.8 Hz, 1H), 2.77 (dd, J = 19.3, 7.7 Hz, 2H). 13C NMR (75 MHz, CDCl3)  
172.6, 138.2, 127.0, 126.1, 125.8, 105.1, 78.0, 55.2, 54.9, 46.6, 29.9. 
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(4R,5S)-4-Dimethoxymethyl-5-phenyl-dihydro-furan-2-one (68c). 
 
 
 
According to general procedure B, 214 mg (45%, >99% cis). Mp 86-89oC, [α]20
D -
17 (c 0.12, MeOH). 1H NMR (300 MHz, CDCl3)  7.40 (m, 5H), 5.60 (d, J = 7.7 Hz, 
1H), 3.63 (d, J = 6.1 Hz, 1H), 3.35 (m, 1H), 3.12 (s, 3H), 3.10 (s, 3H), 2.71 (dd, J = 
17.7, 7.6 Hz, 1H), 2.58 (dd, J = 17.7, 9.0 Hz, 1H). 13C NMR (75 MHz, CDCl3)  
176.4, 135.7, 128.7, 125.8, 103.9, 81.9, 55.1, 52.9, 43.0, 29.7. HR-EIMS: calcd for 
C13H16O4 [M]
+: 236.104, found: 236.10469. IR:   ̃= 3008, 2936, 2879, 2836, 1747, 
1606, 1500, 1454, 1379, 1306, 1222, 1166, 1118, 1051, 972, 879, 737, 688, 562, 
510, 429 cm-1. 
 
(4R,5S)-4-Dimethoxymethyl-5-(4-methoxy-phenyl)-dihydro-furan-2-one (68d). 
 
According to general procedure B, 203 mg (38%, 82:18 cis-trans ratio).1H NMR 
(300 MHz, CDCl3)  7.18 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 8.9 Hz, 1H), 5.58 (d, J = 
7.7 Hz, 1H), 3.82 (s, 3H), 3.40 (d, J = 6.1 Hz, 1H), 3.17 (s, 3H), 3.13 (s, 3H), 3.08 
(m, 1H), 2.70 (dd, J = 16.8, 7.4 Hz, 1H), 2.57 (dd, J = 17.7, 9.0 Hz, 1H). 13C NMR 
(75 MHz, CDCl3)  176.4, 159.7, 127.6, 113.8, 103.8, 81.5, 55.5, 54.9, 52.9, 43.2, 
29.5. HR-EIMS: calcd for C14H18O5 [M]
+: 266.1154, found: 266. 11558. IR:   ̃= 
2962, 2836, 1779, 1613, 1515, 1462, 1254, 1176, 1020, 797, 632, 537, 497 cm-1. 
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(4R,5S)-5-Benzo[1,3]dioxol-5-yl-4-dimethoxymethyl-dihydro-furan-2-one 
(68e) 
  
According to general procedure B, 186 mg (33%, 76:24 cis-trans ratio). 1H NMR 
(300 MHz, CDCl3)  6.74 (m, 3H), 5.93 (s, 1H), 5.47 (d, J = 7.6 Hz, 1H), 3.67 (d, J 
= 6.1 Hz, 1H), 3.14 (s, 1H), 3.11 (s, 1H), 3.00 (m, 1H), 2.64 (dd, J = 18.1, 7.4 Hz, 
1H), 2.51 (dd, J = 16.8, 9.8 Hz, 1H). 13C NMR (75 MHz, CDCl3)  176.2, 148.0, 
147.6, 129.6, 119.6, 108.2, 106.7, 103.6, 101.3, 81.4, 54.9, 53.4, 43.3, 29.5. HR-
EIMS: calcd for C14H16O6 [M]
+: 280.0947, found: 280.09519. IR:   ̃= 2936, 1776, 
1612, 1492, 1445, 1243, 1177, 1036, 930, 632, 539, 495 cm-1. 
(4R,5R)-5-Benzo[1,3]dioxol-5-yl-4-dimethoxymethyl-dihydro-furan-2-one 
(minor trans-68e) 
 
 
 
1H NMR (300 MHz, CDCl3)  6.69 (m, 3H), 5.92 (s, 1H), 5.27 (d, J = 4.9 Hz, 1H), 
4.31 (d, J = 5.1 Hz, 1H), 3.34 (s, 3H), 3.28 (s, 3H), 2.98 (m, 1H), 2.63 (m, 1H), 
2.51 (m, 1H). 13C NMR (75 MHz, CDCl3)  176.0, 148.2, 147.7, 133.3, 119.3, 
108.3, 106.1, 104.8, 101.3, 81.8, 65.4, 54.7, 53.4, 46.4, 29.9.  
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(4S,5R)-4-Dimethoxymethyl-5-(6-methoxy-naphthalen-2-yl)-dihydro-furan-2-
one (68f) 
 
According to general procedure B, 235 mg (37%, 92:8 cis-trans ratio).1H NMR 
(300 MHz, CDCl3)  7.46 (m, 6H), 5.75 (d, J = 7.6 Hz, 1H), 3.93 (s, 3H), 3.66 (d, J 
= 6.1 Hz, 1H), 3.17 (m, 1H), 3.12 (s, 3H), 3.09 (s, 3H), 2.78 (dd, J = 17.7, 7.7 Hz, 
1H), 2.63 (dd, J = 17.6, 9.0 Hz, 1H). 13C NMR (75 MHz, CDCl3)  176.6, 158.2, 
134.3, 130.8, 129.5, 128.4, 127.0, 125.1, 124.3, 119.5, 105.7, 103.7, 81.6, 55.3, 
54.9, 53.4, 43.4, 29.7. HR-EIMS: calcd for C18H20O5 [M]
+: 316.1311, found: 
316.13092. IR:   ̃= 2999, 2929, 2837, 1772, 1609, 1487, 1458, 1384, 1302, 1265, 
1182, 1119, 1054, 983, 859, 783, 704, 474 cm-1. 
 
Synthesis of trans-allyllactone 68i. 
(2R,3S)-2-Allyl-5-oxo-tetrahydro-furan-3-carbaldehyde 
 
To a THF (26 mL) solution of allymagnesium bromide in THF (4.02 mL, 2M, 4.02 
mmol, 1 equiv) at –78 °C, chlorotriisopropoxytitanium in hexane  (8.84 mL, 1 M, 
8.84 mmol, 1.1 equiv) was added dropwise over 5 min under nitrogen atmosphere. 
After completion of the addition, the mixture was stirred further for 30 min. Under a 
nitrogen atmosphere, a solution of cyclopropylcarbaldehyde (-)-15 (500 mg, 2.01 
mmol, 1 equiv) in anhydrous THF (20 mL) was added via canula to a flame-dried 
three-necked flask and was cooled to -78 °C. BF3OEt2 (0.28 mL, 2.21 mmol, 1.1 
equiv) was added via syringe and after stirring for 30 min., the allyltitanium 
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nucleophile solution (8.04 mmol, 4 equiv) was added slowly resulting to a color 
change (orange-red). After stirring for 16 h at -78 °C, saturated NaHCO3 (45 mL) 
was added and the mixture was allowed to warm to room temperature. The layers 
were separated and the aqueous layer was extracted three times with ethyl 
acetate (45x2 mL). The combined organic layers were washed with brine (45 mL), 
H2O (45 mL), dried (Na2SO4) and concentrated in vacuo to give the allylcarbinol 
cyclopropane 74i which was used for the next step without further purification. 
Crude alcohol 74i (1.0 equiv) was dissolved in MeOH (10 mL/mmol) and cooled to 
0 °C. Ba(OH)2⋅8H2O (0.55 equiv) was added in small portions over 1 h. After 1 h 
stirring at 0 °C, DCM (10 mL/mmol) and H2O (10 mL/mmol) were added and the 
layers were separated. The aqueous layer was again extracted with DCM (3x10 
mL/mmol). The combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo. Chromatography on silica gel (hexanes:ethylacetate 1:1) 
afforded the corresponding lactone aldehyde 68i as a very light yellow oil. 
 
Yield 90 mg (29%, 94:6 trans-cis ratio).1H NMR (300 MHz, CDCl3):  7.89 (dd, J = 
7.9 Hz, 1.1 Hz, 1H), 7.33 (td, J = 7.6 Hz, 1.3 Hz, 1H), 7.10 (dd, J = 7.7 Hz, 1.7 Hz, 
1H), 7.07- 6.97 (m, 1H), 5.60 (d, J = 4.7 Hz, 1H), 4.48 (d, J = 4.4 Hz, 1H), 2.45 (tt, 
J = 11.3 Hz, 3.5 Hz, 1H), 1.99 (m, 1H), 1.69 (m, 3H), 1.23 (m, 6H). 13C NMR (75.5 
MHz, CDCl3):  211.0, 139.4, 139.0, 129.3, 127.9, 127.6, 99.3, 80.1, 45.4, 28.9, 
26.6, 24.7, 24.5, 24.0.  
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Synthesis of lactone acetals 86a-86c from 68a. 
(2S,3S,2'R,5'S)-3-Dimethoxymethyl-2',5'-dimethoxy-3,4,2',5'-tetrahydro-2H-
[2,2']bifuranyl-5-one (14a) and (2S,3S,2'S,5'S)-3-Dimethoxymethyl-2',5'-
dimethoxy-3,4,2',5'-tetrahydro-2H-[2,2']bifuranyl-5-one (86b, relative 
stereochemistry assigned) 
 
A solution of 68a (40 mg, 0.388, 1 equiv) in a mixture of MeOH (0.1 mL) and 
diethyl ether (70 L) was stirred and cooled to -40 oC. Liquid bromine (7.1 L, 
0.1429 mmol, 1.03 equiv) in dry MeOH (0.1 mL) was added dropwise over 5 min. 
After addition, stirring was continued for an additional 10 min. The mixture was 
saturated with ammonia gas to pH 8, allowed to warm to room temperature, 
diluted with ether and evaporated. The residue (2:1:1 mixture of three 
stereoisomers) was purified by flash chromatography (silica, 1:1 EtOAc–hexanes) 
to afford a mixture of 86a and 86b (19 mg) and pure 86c (19 mg). 
 
1H NMR (600 MHz, CDCl3)  6.13 (d, J = 2.8 Hz, 1H), 6.09 (d, J = 0.9 Hz, 1H), 
6.07 (d, J = 0.8 Hz, 1H), 5.81 (s, 1H), 5.48 (s, 1H), 4.40 (d, J = 2.0 Hz, 1H), 4.26 
(d, J = 5.5 Hz, 1H), 4.23 (d, J = 1.5 Hz, 1H), 3.51 (s, 2H), 3.46 (s, 1H), 3.40 (s, 
3H), 3.38 (d, J = 1.0 Hz, 3H), 3.19 (s, 1H), 3.12 (s, 1H), 2.98 (m, 1H), 2.72 (ddd, J 
= 17.9, 10.0, 5.7 Hz, 1H), 2.40 (dt, J = 18.0, 2.2 Hz, 1H). 13C NMR (150 MHz, 
CDCl3)  177.6, 132.7, 132.4, 132.1, 130.9, 113.4, 112.4, 108.5, 107.4, 105.5, 
105.3, 83.7, 83.4, 56.5, 55.5, 55.3, 54.9, 54.6, 53.9, 50.7, 50.1, 37.9, 30.0. HR-
LSIMS: calcd for C13H21O7 [M+H]
+: 289.1287, found: 289.13011. IR:   ̃= 2944, 
2838, 1769, 1632, 1444, 1373, 1188, 1118, 1075, 1017, 972, 829, 697, 625 cm-1. 
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(2S,3S,2'S,5'R)-3-Dimethoxymethyl-2',5'-dimethoxy-3,4,2',5'-tetrahydro-2H-
[2,2']bifuranyl-5-one (86c) 
 
 
 
 
1H NMR (600 MHz, CDCl3)  6.18 (dd, J = 5.9, 0.9 Hz, 1H), 5.87 (dd, J = 5.9, 1.3 
Hz, 1H), 5.76 (s, 1H), 4.49 (d, J = 2.1 Hz, 1H), 4.27 (d, J = 5.6 Hz, 1H), 3.45 (s, 
3H), 3.39 (s, 6H), 3.16 (s, 3H), 3.00 (m, 1H), 2.67 (dd, J = 18.0, 10.0 Hz, 1H), 2.43 
(dd, J = 18.0, 2.8 Hz, 1H). 13C NMR (150 MHz, CDCl3)  176.7, 133.7, 129.9, 
114.2, 109.3, 104.6, 80.7, 56.5, 54.9, 54.4, 50.0, 38.0, 29.5. HR-LSIMS: calcd for 
C13H21O7 [M+H]
+: 289.1287, found: 289.13010. IR:   ̃= 2942, 2835, 1780, 1632, 
1450, 1374, 1247, 1193, 1117, 1076, 1016, 981, 834, 631, 536, 497 cm-1. 
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Synthesis of compound 87 
(2S,3S,2'S,5'R)-3-Dimethoxymethyl-4-dimethylaminomethylene-2',5'-
dimethoxy-3,4,2',5'-tetrahydro-2H-[2,2']bifuranyl-5-one 
 
 
 
A mixture of 7 mg 86c (0.0243 mmol, 1 equiv) and 5.9 L (0.0340 mmol, 1.4 
equiv) of tris-(dimethylamino)methane was heated under nitrogen with stirring at 
70 oC for 48 h. The crude product was dried under vacuum for 2 h and filtered on 
silica gel with 2:1 hexanes-ethyl acetate to give 7 mg (81%) of 87. 
 
1H NMR (600 MHz, CDCl3)  7.17 (d, J = 0.8 Hz, 1H), 6.07 (dd, J = 5.9,  0.8 Hz, 
1H), 5.88 (dd, J = 5.9, 1.2 Hz, 1H), 5.76 (s, 1H), 4.49 (s, 1H), 4.15 (d, J = 6.7 Hz, 
1H), 3.75 (d, J = 6.7 Hz, 1H), 3.44 (s, 3H), 3.41 (s, 3H), 3.41 (s, 3H), 3.15 (s, 3H), 
3.04 (s, 6H). 13C NMR (150 MHz, CDCl3)  175.0, 147.9, 132.5, 130.5, 114.8, 
109.1, 107.2, 88.1, 79.0, 57.2, 56.3, 53.9, 50.0, 41.9, 29.7. HR-EIMS: calcd for 
C16H25NO7 [M]
+: 343.1631, found: 343.16316. IR:   ̃= 2923, 2851, 1722, 1616, 
1444, 1375, 1193, 1119, 1015, 771, 697, 622, 575, 437 cm-1. 
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General Procedure D: Synthesis of Hetarylcarbinol lactone methyl acetals 
77a and 77b 
 
A round–bottomed flask, equipped with Dean–Stark trap was charged with 
arylcyclopropyl carbinol 74 (1 equiv) followed by methanol (10 mL per mmol) and 
Sn–catalyst 47 (10 mol%). The mixture was gently refluxed for 12 h. Afterwhich, 
the crude mixture was evaporated and purified by chromatography on silica gel 
(ethyl acetate-hexanes 1:2) to yield the hetarylcarbinols 77. 
 
(4S,5S)-4-((S)-Furan-2-yl-hydroxy-methyl)-5-methoxy-dihydro-furan-2-one 
(77a) 
 
 
Yield 140.1 mg, 65%. 1H NMR (300 MHz, CDCl3)  7.41 (dd, J = 5.0, 1.3 Hz, 1H), 
6.35 (m, 2H), 5.51 (d, J = 5.1 Hz, 2H), 4.64 (m, 1H), 3.452 (s, 3H), 2.76 (m, 1H), 
2.25 (m, 1H). 13C NMR (75 MHz, CDCl3)  175.8, 153.3, 142.9, 110.4, 107.9, 
106.4, 67.6, 56.8, 46.1, 30.4. LR-EIMS: m/z (%) 230.1 [M+NH4]
+, 212 [M]+, 198.1 
(94), 195 (41), 181 (5), 170 (21), 146 (5), 129 (2). IR:   ̃= 1756, 1448, 1359, 1112, 
1158, 1066, 896, 826 cm-1 
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(4S,5S)-4-((R)-Hydroxy-thiophen-2-yl-methyl)-5-methoxy-dihydro-furan-2-one 
(77b) 
 
 
 
Yield 22.0 mg, 19% (dr 60:40). 1H NMR (300 MHz, CDCl3)  7.25 (dd, J = 4.8, 1.5 
Hz, 1H), 6.93 (dt, J = 3.5, 1.2 Hz, 1H), 5.46 (t, J = 5.1 Hz, 1H), 4.77 (m, 1H), 3.42 
(s, 3H), 2.67 (m, 2H), 2.16 (m, 1H). 13C NMR (75 MHz, CDCl3)  175.9, 144.9, 
127.0, 125.9, 125.3, 106.6, 70.0, 56.9, 48.8, 30.7. LR-EIMS: m/z (%) 228.0 [M]+, 
196 (10), 168 (8), 123 (29), 113 (100), 85 (48), 71 (24). 
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5. Synthetic approach employing diastereoselective reduction of furylated -
keto esters 
2-(Furan-2-carbonyl)-succinic acid dimethyl ester 94 
 
To LDA (13.92 mmol, 1.1 equiv) in toluene (200 mL) were added dropwise 
successively the cyanohydrin 97 (3 g, 12.7 mmol, 1 equiv) in toluene (20 mL) and 
dimethyl maleate (1.91 g, 13.3 mmol, 1.05 equiv) in toluene (20 mL) at -78 °C 
under nitrogen atmosphere. The mixture was quenched by addition of aqueous 
AcOH (15%, 11 mL, 25.3 mmol). The organic layer was separated, and the 
aqueous layer was extracted with EtOAc (200 mL). The combined organic layer 
was washed with brine (100 mL) and dried (MgSO4). After evaporation of the 
solvent, the residue was dissolved in THF (100 mL), and then AcOH (1.2 mL, 19 
mmol) and TBAF (1.0 M in THF, 17 mL) were added to the solution at room 
temperature. After 30 min, the solution was washed with water (100 mL), 10% 
citric acid (100 mL), and brine (100 mL) and then dried (MgSO4). After evaporation 
of the solvent, the residue was purified by silica gel column chromatography using 
hexane/EtOAc (1:1) as an eluent to afford 94 as a brown syrup. 
 
Yield 1.86g, 61%.1H NMR (300 MHz, CDCl3)  7.58 (dd, J = 1.7, 0.7 Hz, 1H), 7.29 
(m, 1H), 6.52 (m, 1H), 4.53 (m, 1H), 3.60 (dd, J = 8.6, 3.5 Hz, 6H), 2.96 (m, 2H). 
13C NMR (75 MHz, CDCl3)  182.3, 171.4, 168.8, 151.5, 147.4, 119.2, 112.8, 52.8, 
52.0, 49.4, 32.4. HR-EIMS: calcd for C11H12O6 [M]
+: 240.0634, found: 240.0636. 
IR:   ̃= 1738, 1677, 1466, 1262, 1165, 1016, 890 cm-1. 
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Diastereoselective reduction of furan diester 94 
5-Oxo-2,3,4,5-tetrahydro-[2,2']bifuranyl-3-carboxylic acid methyl ester 
 
Zn(BH4)2 reduction of 94 
To a suspension of NaBH4 (190 mg, 5 mmol, 2 equiv) in diethyl ether (3 mL) 
was added ZnCl2 (1M in diethyl ether, 2.5 mL, 2.5 mmol, 1 equiv), at room 
temperature. The mixture was stirred for 5 h and the insoluble materials were 
filtered off. The filtrate was poured into a solution of 94 (2.45 mmol) in diethyl ether 
(50 mL) at -20 oC. The solution was allowed to warm to 0 oC and stirred for 2 h. 
The reaction was quenched by the addition of acetic acid (40 mmol). The mixture 
was washed with brine and dried and concentrated in vacuo. The residue was 
chromatographed on silica gel using hexane-EtOAc (2:1) to afford lactone 93 in 
52% yield (267.5 mg, 86:14 trans/cis). 
 
NaBH4 reduction of 94 
To a suspension of NaBH4 (190 mg, 5 mmol, 2 equiv) in methanol (20 mL) at 
0 oC, was added 94 (2.45 mmol) in methanol (10 mL). The solution was allowed to 
warm to 0 oC and stirred for 2 h. The reaction was quenched with water and 
concentrated. The aqueous layer was extracted with EtOAc (3x10 mL) and 
concentrated. The residue was dissolved in 25 mL THF and catalytic PTSA was 
added. The solution was stirred further for 3 h and water was added (25 mL). The 
solution was extracted with 20 mL EtOAc (3x). The combined organic layers were 
washed with saturated NaHCO3, brine and dried (Na2SO4). After concentration, 
the residue was chromatographed on silica gel using hexane-EtOAc (2:1) to afford 
lactone 93 in 79% yield (406 mg, 19:81 trans/cis). 
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Yeast reduction 
 
In a 1 L Erlenmeyer flask, 300 mg of furan succinate 94 in 5 mL ethanol and 
100 mL water were added. Eight packs of Dr. Oetcker’s yeast were added and the 
flask was shaken. Fermentation was signaled by the evolution of gas (CO2) and 
the flask was set aside for 3 days. The yeast mixture was mixed with Celite 535 
and filtered under vacuum and the residue was washed with some volumes of 
ethanol. The collected filtrate was concentrated in vacuo until ethanol was 
completely removed. The aqueous mixture was partitioned with diethyl ether 
(3x100 mL) and the combined organic layers were washed with brine (100 mL) 
and concentrated. The residue was chromatographed in silica using hexanes-
EtOAc (4:1) to furnish cis 93 and trans 93 (75:25) in 25 % combined yield. 
(2R,3R)-5-Oxo-2,3,4,5-tetrahydro-[2,2']bifuranyl-3-carboxylic acid methyl 
ester (trans-93) 
 
Yield 16.3 mg. 1H NMR (300 MHz, CDCl3)  7.35 (dd, J = 10.2, 9.2 Hz, 1H), 6.35 
(d, J = 3.3 Hz, 1H), 6.29 (dd, J = 3.3, 1.9 Hz, 1H), 5.67 (d, J = 8.5 Hz, 1H), 3.74 
(m, 1H), 3.49 (s, 3H), 3.26 (dd, J = 17.7, 9.9 Hz, 1H), 2.69 (m, 1H). 13C NMR (75 
MHz, CDCl3)  174.4, 169.1, 148.6, 143.6, 110.5, 110.1, 74.2, 52.4, 44.7, 30.2. 
HR-EIMS: calcd for C10H10O5 [M]
+: 210.0528, found: 210.0527. IR:   ̃= 1781, 1733, 
1437, 1260, 1189, 1154, 984, 923, 885, 751 cm-1. 
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 (2R,3S)-5-Oxo-2,3,4,5-tetrahydro-[2,2']bifuranyl-3-carboxylic acid methyl 
ester (cis-93) 
 
 
Yield 49.1 mg. 1H NMR (300 MHz, CDCl3)  7.39 (dd, J = 1.8, 0.8 Hz, 1H), 6.42 (d, 
J = 3.3 Hz, 1H), 6.32 (dd, J = 3.3, 1.9 Hz, 1H), 5.59 (d, J = 6.3 Hz, 1H), 3.70 (s, 
3H), 3.63 (m, 1H), 2.94 (m, 2H). 13C NMR (75 MHz, CDCl3)  173.98, 171.29, 
144.21, 110.99, 110.73, 75.65, 53.21, 44.52, 32.30.  HR-EIMS: calcd for C10H10O5 
[M]+: 210.0528, found: 210.0526. IR:   ̃= 2954, 1773, 1773, 1737, 1441, 1369, 
1211, 1166, 1099, 945, 737 cm-1 
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6. A Simplified Approach Towards the Total Synthesis of Bielschowskysin 
Synthesis of lactone tosylate 124 
Benzenesulfonic acid (2R,3R)-2-(2-methyl-allyl)-5-oxo-tetrahydro-furan-3-
ylmethyl ester 
 
 
To a solution of methallyllactone alcohol 123 (200 mg, 1.18 mmol) in dry 
DCM (6 mL) were added p-toluenesulfonyl chloride (336 mg, 1.74 mmol, 1.5 
equiv), Et3N (1.77 mL, 11.8 mmol, 10 equiv), and DMAP (20 mg, 0.84 mmol, 15 
mol %) at 0 °C. After 4 h at room temperature, the mixture was poured into ice-
water and extracted with DCM (30 mL). The combined organic layers were 
washed with saturated NaHCO3 solution, and brine, dried over anhydrous MgSO4, 
and concentrated at reduced pressure. The residue was purified by column 
chromatography on silica gel (EtOAc/hexane, 1:3) to give tosylate 124. 
 
Yield160.2.4 mg, 42%. 1H NMR (300 MHz, CDCl3)  7.74 (m, 2H), 7.34 (d, J = 8.0 
Hz, 2H), 5.67 (m, 1H), 5.13 (m, 1H), 5.09 (dt, J = 4.6, 1.5 Hz, 1H), 4.27 (dt, J = 9.2, 
4.1 Hz, 1H), 3.99 (dd, J = 4.4, 1.6 Hz, 2H), 2.63 (m, 1H), 2.54 (m, 1H), 2.42 (m, 
3H), 2.36 (ddd, J = 5.7, 3.8, 2.5 Hz, 2H), 2.28 (m, 2H). 13C NMR (75 MHz, CDCl3) 
 174.6, 145.5, 132.2, 131.3, 130.1, 127.9, 119.8, 80.5, 69.0, 38.9, 38.6, 31.1, 
21.7. HR-EIMS: calcd for C16H20SO5 [M]
+: 324.1031, found: 324.1030. IR:   ̃= 
2945, 2855, 232, 1778, 1734, 1444, 1376, 1179, 1022 cm-1 
 
 
 
 
 147 
 
EXPERIMENTAL Macabeo  2011 
Synthesis of lactone nitrile 125 
[(2R,3S)-2-(2-Methyl-allyl)-5-oxo-tetrahydro-furan-3-yl]-acetonitrile 
 
 
To a stirred solution of tosylate 124 (200 mg, 0.617 mmol) in DMF (10 mL) at room 
temperature was added potassium cyanide (80 mg, 1.23 mmol, 2 equiv). The 
resulting mixture was warmed to 90 °C and stirred for 30 h before it was cooled to 
room temperature, quenched with H2O (10 mL) and diluted with Et2O (10 mL). The 
layers were separated, and the aqueous layer was extracted with Et2O (3 × 10 
mL). The combined organic layers were dried (Na2SO4) and concentrated in 
vacuo. Flash column chromatography (silica gel, hexanes:EtOAc 2:1) afforded 
nitrile 125 as a colorless oil. 
 
Yield 93.7 mg, 85%.1H NMR (300 MHz, CDCl3)  4.96 (m, 1H), 4.88 (d, J = 7.6 Hz, 
1H), 4.42 (ddd, J = 11.8, 6.0, 2.6 Hz, 1H), 2.83 (m, 1H), 2.50 (m, 5H), 1.81 (s, 3H), 
1.78 (d, J = 7.8 Hz, 1H). 13C NMR (75 MHz, CDCl3)  173.7, 139.7, 116.6, 115.0, 
81.7, 42.4, 36.9, 33.8, 22.7, 20.6. LR-EIMS = m/z 179.1[M]+, 124.0(100), 97.0(78), 
68.1(47), 41.1(52). IR:   ̃= 2920, 2851, 2163, 1778, 1651, 1425, 1183, 896 cm-1 
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Synthesis of ketolactone nitrile 126 
[(2S,3S)-2-(2-Methyl-acryloyl)-5-oxo-tetrahydro-furan-3-yl]-acetonitrile 
 
The methallyllactone nitrile 125  (60 mg, 0.335 mmol, 1 equiv) was 
dissolved in dioxane (3 mL). Selenium dioxide (39 mg, 0.352 mmol, 1.05 equiv) 
was dissolved in dioxane (3 mL) and added to the other solution. Finally, 0.25 mL 
of water was added and the mixture was heated at 60 °C and stirred for 16 h 
under reflux. The solvent was evaporated, water was added and the product was 
extracted with ether (3x20 mL). Combined organic layers were dried by Na2SO4. 
The product was purified by flash chromatography (PE/EA 1:1) to give 126 as a 
yellowish oil.  
 
Yield 19.9 mg, 31%.1H NMR (300 MHz, CDCl3)  6.24 (d, J = 4.1 Hz, 1H), 6.13 (q, 
J = 1.4 Hz, 1H), 5.31 (d, J = 4.4 Hz, 1H), 5.30 (s, 1H), 2.86 (m, 1H), 2.65 (m, 1H), 
2.42 (m, 1H), 1.94 (m, 3H), 1.82 (m, 1H). 13C NMR (75 MHz, CDCl3)  194.5, 
172.9, 141.6, 129.6, 114.6, 79.8, 34.7, 31.8, 20.6, 17.4. LR-EIMS = m/z 193.1[M]+, 
124.0(20), 97.0(25), 69.1(100), 41.1(79). IR:   ̃= 2930, 2248, 1774, 1686, 1420, 
1372, 1157, 1011, 907 cm-1 
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Synthesis of cyclopentene diol 120 
 (1S,4R)-1-Methylcyclopent-2-ene-1,4-diol 
 
A solution of TBS-protected 136 (183 mg, 0.80 mmol) in anhydrous THF (5 
mL) and Bu4NF (1.0 M solution in THF, 1.5 mL, 1.5 mmol) was stirred at room 
temperature for 3 h. The solvent was evaporated under reduced pressure, and the 
residue was purified via column chromatography eluting with EtOAc/MeOH (49:1) 
to afford of 120 as a colorless syrup. 
 
Yield 54.8 mg, 55%. 1H NMR (300 MHz, CDCl3)   5.82 (m, 2H), 4.62 (d, J = 6.8 
Hz, 1H), 3.48 (d, J = 26.9 Hz, 1H), 2.32 (dd, J = 14.4, 7.1 Hz, 1H), 1.77 (m, 1H), 
1.29 (s, 3H). 13C NMR (75 MHz, CDCl3)  141.1, 134.2, 81.2, 75.4, 49.6, 27.5. 
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Synthesis of maleic ester 119 
(Z)-But-2-enedioic acid (1S,4S)-4-hydroxy-4-methyl-cyclopent-2-enyl ester 
methyl ester 
 
 
A solution of triphenyphosphine (88.5 mg, 0.338 mmol, 2 equiv) in toluene (3 
mL) and diisopropylazodicarboxylate (75 L, 0.338mmol, 2 equiv) was added over 
a period of 10 min. This mixture was stirred at rt for 20 min to yield a white 
precipitate of the triphenylphosphine-diisopropyl azodicarboxylate complex. To this 
latter complex as a suspension were added methylmaleate (28.5 mg, 0.219 mmol, 
1.3 equiv) and a solution of 120 (19 mg, 0.0.168 mmol, 1 equiv) in toluene (3 mL). 
The reaction mixture was stirred at room temperature for 16 h. The solvent was 
removed under reduced pressure, and the residue was purified via column 
chromatography eluting with hexanes/EtOAc (3:1) to afford of 119 as a yellowish 
oil. 
 
Yield 19.1 mg, 54%. 1H NMR (300 MHz, CDCl3)  6.17 (m, 2H), 5.96 (m, 1H), 5.83 
(m, 2H), 3.71 (s, 3H), 2.34 (m, 1H), 1.96 (m, 1H), 1.89 (d, J = 18.5 Hz, 1H), 1.40 
(s, 3H). 13C NMR (75 MHz, CDCl3)  165.6, 165.0, 144.1, 130.2, 130.0, 129.4, 
82.1, 79.9, 52.2, 46.2, 28.6. LR-EIMS = m/z 211.1 [M-CH3]
+, 131(18), 113(100), 
97.1(23), 81.0(44), 43.1(31). IR:   ̃= 3411, 2980, 1725, 1643, 1437, 1374, 1218, 
1163  cm-1 
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Photoinduced synthesis of cyclobutane  137 
 
(2S,3aS)-2-Hydroxy-2-methyl-5-oxo-octahydro-4-oxa-cyclobuta[cd]pentalene-
1-carboxylic acid methyl ester 
 
 
 
The maleic ester 119 (7 mg, 0.031 mmol) was dissolved in acetone (8 mL), and 
the resulting solution was bubbled with N2 for 15 min. This solution was then 
irradiated with a high pressure UV lamp (254 nm) in a quartz test tube with stirring 
for 72 h. After consumption of the starting material, as indicated by TLC, the 
solvent was removed and the residue was purified by chromatography (4:1 
hexane/ethyl acetate) to give photoadduct 137 as a yellowish oil and a mixture of 
diastereomers (>80% conversion). 
 
1H NMR (600 MHz, CDCl3)  3.74 (m), 2.26 (m), 1.32 (m). 
13C NMR (150 MHz, 
CDCl3)  177.8, 174.2, 170.4, 168.3, 84.5, 83.4, 81.7, 80.0, 59.7, 56.5, 52.3, 50.2, 
48.8, 47.1, 46.0, 44.0, 30.0, 29.0, 27.2, 23.7, 21.3, 19.8, 18.8. IR:   ̃= 3479, 2981, 
1715, 1623, 1436, 1373, 1227, 1165, 1045, 941 cm-1. 
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7. Discovery of antimicrobial and anti-cancer benzyloxylated  ketoaryl 
aldehydes and 2-arylimidazolines 
A. General procedure for the synthesis of benzyloxylated ketoaryl 
derivatives (2a-2k, 3a-3e, 20) 
 
Phenol carbaldehydes (13 or 14) (1 equiv) or 4-hydroxybenzophenone (16) 
were dissolved in acetone (8 mL per mmol). To the solution was added the 
substituted benzyl bromides (or chlorides) (11 or 12) (1 equiv), and K2CO3 (1.5 
equiv). The resulting mixture was stirred at room temperature for 12 h. In the case 
of reactions with benzyl chlorides, warming at 40oC was necessary. The reaction 
mixture was concentrated under reduced pressure and filtered on a 3 cm silica 
column eluting with hexanes/EtOAc to give the corresponding benzyloxylated 
ketoaryls derivatives (2a-2k, 3a-3e, 20). 
 
4-(2,6-Dichloro-benzyloxy)-benzaldehyde (2a) 
 
 97% from 2,6-dichlorobenzyl bromide (1 mmol) and 4-hydroxybenzaldehyde 13 
(1.01 mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  9.91 (s, 1H), 
7.86 (m, 2H), 7.38 (m, 2H), 7.28 (m, 1H), 7.12 (m, 2H), 5.36 (s, 2H). 13C NMR (75 
MHz, CDCl3)  190.8, 163.8, 137.0, 132.0, 131.3, 130.8, 130.4, 128.6, 115.1, 65.3. 
LRMS (EI, 75 eV): m/z 280.0 [M]+. 
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4-(3-Chloro-benzyloxy)-benzaldehyde (2b) 
 
86% from 3-chlorobenzyl bromide (0.97 mmol) and 4-hydroxybenzaldehyde 13 
(1.07 mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  9.83 (s, 1H), 
7.76 (m, 2H), 7.39 (d, J = 0.5 Hz, 1H), 7.26 (t, J = 1.9 Hz, 3H), 6.98 (m, 2H), 5.04 
(s, 2H). 13C NMR (75 MHz, CDCl3)  190.7, 163.3, 138.1, 134.6, 132.0, 130.3, 
130.1, 128.4, 127.4, 125.5, 115.1, 69.3. LRMS (EI, 75 eV): m/z 246.1 [M]+. 
 
4-(4-Trifluoromethoxy-benzyloxy)-benzaldehyde (2c) 
 
 56% from 4-trifluoromethoxybenzyl bromide (0.78 mmol) and 4-
hydroxybenzaldehyde 13 (0.86 mmol) according to procedure A. 1H NMR (300 
MHz, CDCl3)  9.85 (s, 1H), 7.81 (m, 2H), 7.37 (m, 3H), 7.16 (t, J = 10.3 Hz, 1H), 
7.00 (m, 2H), 5.12 (s, 2H). 13C NMR (75 MHz, CDCl3)  190.7, 163.3, 149.5, 149.5, 
138.4, 132.0, 130.4, 130.2, 125.6, 120.6, 119.8, 115.1, 69.2. LRMS (EI, 75 eV): 
m/z 296.1 [M]+. 
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4-(4-Bromo-benzyloxy)-benzaldehyde (2d). 
 
 23% from 4-bromobenzyl bromide (0.80 mmol) and 4-hydroxybenzaldehyde 13 
(0.88 mmol) according to procedure A.1H NMR (300 MHz, CDCl3)  9.85 (d, J = 
11.3 Hz, 1H), 7.84 (m, 2H), 7.52 (m, 2H), 7.32 (m, 2H), 7.05 (m, 2H), 5.08 (s, 2H). 
13C NMR (75 MHz, CDCl3)  190.8, 163.4, 135.0, 132.1, 131.9, 130.2, 129.1, 
122.3, 115.2, 69.4. LRMS (EI, 75 eV): m/z 290.0 [M]+. 
 
4-(4-Cyano-benzyloxy)-benzaldehyde (2e) 
 
 77% from 4-cyanobenzyl bromide (1.02 mmol) and 4-hydroxybenzaldehyde 13 
(1.12 mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  9.87 (s, 1H), 
7.86 (m, 2H), 7.67 (m, 2H), 7.55 (dd, J = 13.5, 5.5 Hz, 2H), 7.01 (m, 2H), 5.20 (s, 
2H). 13C NMR (75 MHz, CDCl3)  190.7, 163.0, 141.4, 132.5, 132.1, 130.5, 127.6, 
118.6, 115.1, 112.1, 69.1. LRMS (EI, 75 eV): m/z 296.1 [M]+. 
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4-(4-Nitro-benzyloxy)-benzaldehyde (2f).  
 
75% from 4-nitrobenzyl bromide (0.92 mmol) and 4-hydroxybenzaldehyde 13 (1.01 
mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  9.87 (s, 1H), 8.23 
(m, 2H), 7.83 (m, 2H), 7.60 (m, 2H), 7.06 (m, 2H), 5.25 (s, 2H). 13C NMR (75 MHz, 
CDCl3)  190.7, 163.5, 147.7, 144.1, 132.1, 130.8, 124.1, 115.1, 68.6. LRMS (EI, 
75 eV): m/z 257.1 [M]+. 
 
4-(Benzo[1,3]dioxol-5-ylmethoxy)-benzaldehyde (2g) 
 
 74% from 3,4-methylenedioxybenzyl bromide (0.93 mmol) and 4-
hydroxybenzaldehyde 13 (1.02 mmol) according to procedure A. 1H NMR (300 
MHz, CDCl3)  9.86 (s, 1H), 7.80 (m, 2H), 7.04 (m, 2H), 6.82 (m, 3H), 5.95 (s, 2H), 
5.01 (s, 2H). 13C NMR (75 MHz, CDCl3)  190.8, 163.7, 148.1, 147.7, 132.0, 130.1, 
129.6, 121.4, 115.2, 108.4, 108.3, 101.3, 70.2. LRMS (EI, 75 eV): m/z 256.0 [M]+. 
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4-benzyloxybenzaldehyde (2h) 
 
 98% from benzyl bromide (1.17 mmol) and 4-hydroxybenzaldehyde 13 (1.28 
mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  9.87 (s, 1H), 7.86 
(m, 2H), 7.42 (m, 5H), 7.06 (t, J = 5.6 Hz, 2H), 5.12 (s, 2H). 13C NMR (75 MHz, 
CDCl3)  190.8, 163.8, 136.0, 132.1, 130.2, 128.8, 128.4, 127.6, 115.20, 70.3. 
LRMS (EI, 75 eV): m/z 212.1 [M]+.  
 
4-(2,4,6-Trimethyl-benzyloxy)-benzaldehyde (2i) 
 
 43% from 2,4,6-triemethylbenzyl chloride (1.19 mmol) and 4-
hydroxybenzaldehyde 13 (1.30 mmol) according to procedure A. 1H NMR (300 
MHz, CDCl3)  9.93 (s, 1H), 7.92 (m, 2H), 7.16 (m, 2H), 6.98 (s, 2H), 5.14 (s, 2H), 
2.41 (s, 6H), 2.35 (s, 3H). 13C NMR (75 MHz, CDCl3)  189.3, 162.8, 137.0, 136.3, 
130.4, 128.2, 127.5, 127.2, 114.4, 113.2, 63.2, 19.3, 17.7. HRMS (EI, 50 eV) 
calculated for C17H18O2: 254.1307, found: 254.1313. IR (̃): 2191, 2051, 1612, 
1568, 1515, 1450, 1373, 1244, 1171, 1108, 990, 835, 758, 696 cm-1.  
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4-(Naphthalen-2-ylmethoxy)-benzaldehyde (2j) 
 
 75 % from bromomethylnapthalene (0.90 mmol) and 4-hydroxybenzaldehyde 13 
(0.99 mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  9.89 (s, 1H), 
7.91 (m, 6H), 7.54 (m, 3H), 7.12 (m, 2H), 5.27 (s, 2H). 13C NMR (75 MHz, CDCl3)  
190.9, 163.8, 133.5, 133.3, 133.2, 132.1, 130.2, 128.7, 128.0, 127.8, 126.6, 126.5, 
126.4, 125.2, 115.2, 70.4. LRMS (EI, 75 eV): m/z 262.1 [M]+. 
 
4-(Pyridin-2-ylmethoxy)-benzaldehyde (2k) 
 
 98 % from 2-pyridine chloromethane (1.57 mmol) and 4-hydroxybenzaldehyde 7 
(1.73 mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  9.82 (s, 1H), 
8.57 (m, 2H), 8.53 (m, 1H), 7.78 (m, 1H), 7.68 (m, 1H), 7.45 (t, J = 9.2 Hz, 1H), 
7.21 (m, 1H), 7.05 (m, 1H), 5.23 (s, 2H). 13C NMR (75 MHz, CDCl3)  190.8, 163.3, 
156.0, 149.3, 137.1, 132.0, 130.3, 123.1, 121.5, 115.2, 70.7. LRMS (EI, 75 eV): 
m/z 237.1 [M]+. 
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2-(2,6-Dichloro-benzyloxy)-benzaldehyde (3a) 
 
19% from 2,6-dichlorobenzyl bromide (1.55 mmol) and 2-hydroxybenzaldehyde 
(1.63 mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  10.42 (d, J = 
0.8 Hz, 1H), 7.89 (m, 1H), 7.59 (m, 1H), 7.39 (t, J = 2.1 Hz, 1H), 7.37 (s, 1H), 7.25 
(m, 2H), 7.06 (m, 1H), 5.41 (s, 2H). 13C NMR (75 MHz, CDCl3)  189.9, 161.2, 
136.9, 135.9, 131.4, 130.8, 128.6, 128.2, 121.5, 113.5, 65.9. HRMS (EI, 50 eV) 
calculated for C14H10Cl2O2: 280.0058, found: 280.0062. IR (̃): 2877, 1685, 1597, 
1581, 1564, 1483, 1456, 1433, 1377, 1281, 1100, 1001, 865, 784,754 cm-1. 
 
2-(2,6-Dichloro-benzyloxy)-3-methoxy-benzaldehyde (3b) 
 
13% from 2,6-dichlorobenzyl bromide (1.25 mmol) and 3-methoxy-2-
hydroxybenzaldehyde (1.31 mmol) according to procedure A. 1H NMR (300 MHz, 
CDCl3)  10.21 (s, 1H), 7.34 (m, 3H), 7.16 (m, 3H), 5.54 (s, 2H), 3.96 (s, 3H). 
13C 
NMR (75 MHz, CDCl3)  190.4, 153.2, 151.0, 137.2, 132.1, 130.7, 128.6, 128.6, 
124.5, 118.7, 117.9, 69.9, 56.2. HRMS (EI, 50 eV) calculated for C15H12Cl2O3: 
310.0164, found: 310.0162. IR (̃): 3008, 2869, 1690, 1582, 1435, 1369, 1266, 
1245, 1089, 969, 858, 779 cm-1. 
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5-Bromo-2-(2,6-dichloro-benzyloxy)-benzaldehyde (3c). 
 
 7% from 2,6-dichlorobenzyl bromide (0.94 mmol) and 5-bromo-2-
hydroxybenzaldehyde (0.99 mmol) according to procedure A. 1H NMR (300 MHz, 
CDCl3)  10.31 (s, 1H), 7.94 (t, J = 3.7 Hz, 1H), 7.66 (dt, J = 5.9, 2.9 Hz, 1H), 7.39 
(t, J = 2.9 Hz, 1H), 7.37 (s, 1H), 7.28 (t, J = 3.1 Hz, 1H), 7.12 (d, J = 8.9 Hz, 1H), 
5.39 (s, 2H). 13C NMR (75 MHz, CDCl3)  188.4, 160.1, 138.2, 136.9, 131.0, 130.9, 
130.9, 128.7, 126.8, 115.6, 114.4, 66.2. HRMS (EI, 50 eV) calculated for 
C14H9BrCl2O2: 357.9163, found: 357.9162. IR (̃): 2859, 1682, 1589, 1476, 1437, 
1267, 1122, 1004, 820, 766 cm-1. 
 
2-(2,6-Dichloro-benzyloxy)-naphthalene-1-carbaldehyde (3d) 
 
 9% from 2,6-dichlorobenzyl bromide (1.10 mmol) and 2-hydroxynapthalene 
carbaldehyde (1.16 mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  
10.81 (s, 1H), 9.28 (d, J = 8.3 Hz, 1H), 8.11 (t, J = 6.5 Hz, 1H), 7.81 (m, 1H), 7.64 
(m, 1H), 7.50 (d, J = 9.1 Hz, 1H), 7.44 (m, 2H), 7.38 (s, 1H), 7.31 (m, 1H), 5.55 (s, 
2H). 13C NMR (75 MHz, CDCl3)  192.4, 163.4, 137.4, 136.9, 131.3, 130.9, 129.9, 
129.1, 128.7, 128.3, 125.1, 117.9, 114.7, 67.1. HRMS (EI, 50 eV) calculated for 
C18H12Cl2O2: 330.0214, found: 330.0220. IR (̃): 2872, 1667, 1510, 1436, 1243, 
1051, 815, 759, 665 cm-1. 
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4-(2,6-Dichloro-benzyloxy)-3-methoxy-benzaldehyde (3e).  
 
20% from 2,6-dichlorobenzyl bromide (1.25 mmol) and vanillin (1.31 mmol) 
according to procedure A.1H NMR (300 MHz, CDCl3)  9.84 (s, 1H), 7.44 (dd, J = 
8.1, 1.9 Hz, 1H), 7.39 (d, J = 1.9 Hz, 1H), 7.31 (t, J = 2.3 Hz, 1H), 7.29 (s, 1H), 
7.20 (m, 1H), 7.14 (m, 1H), 5.34 (s, 2H), 3.83 (s, 3H). 13C NMR (75 MHz, CDCl3)  
190.9, 153.8, 150.3, 137.1, 131.3, 130.8, 130.7, 128.5, 126.5, 112.9, 109.8, 66.2, 
56.1. LRMS (EI, 75 eV): m/z 310.0 [M]+. 
 
[4-(2,6-Dichloro-benzyloxy)-phenyl]-phenyl-methanone (20)  
 
61% from 2,6-dichlorobenzyl bromide (0.95 mmol) and 4-hydroxybenzophenone 
(1.01 mmol) according to procedure A. 1H NMR (300 MHz, CDCl3)  7.86 (m, 2H), 
7.76 (m, 1H), 7.56 (m, 1H), 7.45 (m, 1H), 7.35 (m, 1H), 7.23 (m, 2H), 7.09 (m, 2H), 
5.35 (s, 2H). 13C NMR (75 MHz, CDCl3)  193.9, 160.8, 136.3, 135.1, 130.8, 130.2, 
129.6, 128.9, 128.7, 127.9, 126.7, 126.4, 112.7, 63.5. HRMS (EI, 50 eV) 
calculated for C20H14Cl2O2: 356.0371, found: 356.0377. IR (̃): 2898, 1650, 1595, 
1506, 1438, 1243, 1172, 1008, 847, 765, 696 cm-1. 
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Synthesis of heptyl--lactone acid 3 
 
 
(2R,3S)-2-Heptyl-5-oxo-tetrahydro-furan-3-carboxylic acid (5) 
 
 
The synthesis of 3 was carried out following the method for the preparation of 
paraconic acids previously reported by our group. Under a nitrogen atmosphere, a 
DCM solution of allyllactone aldehyde 4 (100 mg, 0.59 mmol) was canulated to a 
three-necked round bottom flask and was degassed three times using a freeze-
thaw method. 1-Hexene (1.05 equiv) was added and the solution was heated to 40 
oC. A solution (10 mL) of Grubbs I catalyst (20 mol %) contained in a syringe was 
slowly added to the reaction mixture via canula. After complete addition, the 
reaction mixture was further refluxed for 8 h. The solution was evaporated in 
vacuo and chromatographed on a silica gel using 3:1 hexanes-ethyl acetate to 
afford an oily compound which was directly dissolved in MeOH (10 mL). 
Hydrogenation was carried out next using 10% Pd/C under a hydrogen 
atmosphere (1 atm). After 24 h, the solution was filtered on Celite and the filtrate 
was evaporated to give an oily compound 5, which was directly oxidized with 
Jones reagent in acetone at 0 oC. After a conventional work-up, lactone acid 3 was 
afforded as a white solid 
. 
57% (in three steps). 1H NMR (300 MHz, CDCl3)  10.67 (s, 1H), 4.61 (m, 1H), 
3.11 (m, 1H), 2.87 (m, 2H), 1.76 (m, 2H), 1.39 (m, 10H), 0.87 (t, J = 6.6 Hz, 3H). 
13C NMR (75 MHz, CDCl3)  176.37, 174.63, 81.94, 45.45, 35.36, 31.91, 31.69, 
29.13, 29.05, 25.18, 22.60, 14.07. HRMS (EI, 50 eV) calculated for C12H21O4: 
229.1440 [M+H]+ found: 229.1445. IR (̃): 3083, 1692, 1610, 1578, 1508, 1249, 
1160, 1002, 874, 831, 767 cm-1. 
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B. General procedure for the synthesis of benzyloxylated 2-arylimidazolines 
(4a-4h) 
 
To a solution of the benzyloxybenzaldehydes 2a-2c, 2g-2i (1 equiv) in t-BuOH 
(8 mL per mmol) was added the diamines 15 or 16 or 17 (1.05 equiv). The 
obtained mixture was stirred at room temperature for 30 min. on a covered 
scintillation vial and K2CO3 (2.5 equiv) and I2 (1.1 equiv) were added next to the 
reaction mixture and magnetically stirred at 70 oC. After 3h, the mixture was 
quenched with aqueous Na2SO3 until the deep orange disappeared and was 
extracted with DCM. The organic layer was washed with saturated NaHCO3 and 
brine, and dried over Na2SO4. After filtration in a silica gel column (3 cm) eluting 
first with hexanes/EtOAc (to remove unreacted aldehydes) followed by 
DCM/MeOH (19:1), the second fraction was evaporated in vacuo to afford the 
benzyloxylated 2-arylimidazolines (4a-4h) in an almost pure state. 
 
2-[4-(2,6-Dichloro-benzyloxy)-phenyl]-4,5-dihydro-1H-imidazole (4a) 
 
33% from aryl aldehyde derivative 2a (1.51 mmol) and diamine 15 (1.66 mmol) 
according to procedure B. 1H NMR (300 MHz, CDCl3)  8.01 (dd, J = 13.5, 5.5 Hz, 
2H), 7.34 (t, J = 2.2 Hz, 1H), 7.31 (s, 1H), 7.23 (m, 2H), 7.01 (dd, J = 11.8, 5.5 Hz, 
2H), 5.28 (d, J = 10.8 Hz, 2H), 3.86 (s, 4H). 13C NMR (75 MHz, CDCl3)  162.8, 
136.9, 131.2, 130.8, 130.7, 128.5, 115.2, 65.4, 46.3. HRMS (EI, 50 eV) calculated 
for C16H14Cl2N2O: 320.0483 [M]
+, found: 320.0482. IR (̃): 3115, 2959, 1607, 1557, 
1507, 1437, 1257, 1186, 1090, 983, 835, 783, 766 cm-1. 
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(7S,7aS)-2-[4-(2,6-Dichloro-benzyloxy)-phenyl]-3a,4,5,6,7,7a-hexahydro-1H-
benzoimidazole (4b) 
 
20% from aryl aldehyde derivative 2a (0.88 mmol) and diamine 16 (0.97 mmol) 
according to procedure B. 1H NMR (300 MHz, CDCl3)  7.78 (m, 2H), 7.36 (m, 2H), 
7.26 (m, 2H), 7.02 (m, 2H), 5.30 (m, 2H), 3.12 (m, 2H), 2.32 (dd, J = 16.9, 10.7 Hz, 
2H), 1.82 (m, 2H), 1.46 (m, 4H). 13C NMR (75 MHz, CDCl3)  165.1, 160.9, 137.4, 
131.6, 130.8, 128.4, 114.6, 69.1, 65.4, 30.6, 24.8. HRMS (EI, 50 eV) calculated for 
C20H20Cl2N2O: 374.0953, found: 374.0949. IR (̃): 2933, 2858, 1610, 1564, 1510, 
1438, 1244, 1007, 779 cm-1. 
 
(S)-2-[4-(2,6-Dichloro-benzyloxy)-phenyl]-5-phenyl-4-(R)-phenyl-4,5-dihydro-
1H-imidazole (4c) 
 
58% from aryl aldehyde derivative 2a (0.214 mmol) and diamine 17 (0.23 mmol) 
according to procedure A. 1H NMR (300 MHz, CDCl3)  7.91 (m, 1H), 7.38 (m, 
15H), 7.07 (m, 2H), 5.35 (d, J = 9.5 Hz, 2H), 4.87 (d, J = 7.8 Hz, 2H). 13C NMR (75 
MHz, CDCl3)  162.9, 161.2, 143.6, 137.0, 131.8, 130.6, 129.2, 128.7, 128.5, 
127.5, 126.6, 122.8, 114.7, 65.4. HRMS (EI, 50 eV) calculated for C28H22Cl2N2O: 
472.1109, found: 472.1108. IR (̃): 3380, 2890, 1611, 1565, 1514, 1437, 1244, 
1172, 1009, 836, 762 cm-1. 
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(S)-2-[4-(3-Chloro-benzyloxy)-phenyl]-5-phenyl-4-(R)-phenyl-4,5-dihydro-1H-
imidazole (4d) 
 
99% from diamine 17 (0.12 mmol) and aryl aldehyde derivative 2b (0.11 mmol) 
according to procedure B. 1H NMR (300 MHz, CDCl3)  7.88 (m, 2H), 7.46 (ddd, J 
= 7.1, 4.2, 1.8 Hz, 2H), 7.32 (m, 13H), 7.01 (m, 2H), 5.07 (d, J = 7.6 Hz, 2H), 4.86 
(s, 1H). 13C NMR (75 MHz, CDCl3)  162.7, 160.6, 143.5, 138.6, 134.6, 131.1, 
130.1, 129.9, 129.2, 128.7, 128.6, 128.3, 127.5, 127.4, 126.6, 125.3, 122.8, 115.0, 
114.8, 69.2. HRMS (EI, 50 eV) calculated for C28H23ClN2O: 438.1499, found: 
438.1496. IR (̃): 2918, 2869, 1612, 1572, 1514, 1451, 1245, 1172, 837, 756, 697 
cm-1. 
 
(S)-5-Phenyl-4-(R)-phenyl-2-[4-(4-trifluoromethoxy-benzyloxy)-phenyl]-4,5-
dihydro-1H-imidazole (4e) 
 
84% from diamine 17 (0.13 mmol) and aryl aldehyde derivative 2c (0.12 mmol) 
according to procedure 3.3.  1H NMR (300 MHz, CDCl3)  7.90 (m, 2H), 7.34 (m, 
15H), 7.00 (m, 2H), 5.13 (s, 2H), 4.87 (s, 2H). 13C NMR (75 MHz, CDCl3)  162.7, 
160.8, 143.3, 138.8, 130.1, 129.2, 128.7, 127.6, 126.6, 125.6, 120.4, 119.9, 114.8, 
69.1. HRMS (EI, 50 eV) calculated for C29H23F3N2O: 488.1712, found: 488.1709. 
IR (̃): 3402, 2898, 1613, 1519, 1449, 1251, 1171, 1029, 835, 757, 696 cm-1. 
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(S)-2-[4-(Benzo[1,3]dioxol-5-ylmethoxy)-phenyl]-5-phenyl-4-(R)-phenyl-4,5-
dihydro-1H-imidazole (4f) 
 
70% from diamine 17 (0.19 mmol) and aryl aldehyde derivative 2g (0.18 mmol) 
according to procedure B. 1H NMR (300 MHz, CDCl3)  7.87 (m, 2H), 7.28 (m, 
11H), 6.89 (m, 5H), 5.97 (d, J = 4.3 Hz, 2H), 5.00 (s, 2H), 4.88 (d, J = 12.1 Hz, 
2H). 13C NMR (75 MHz, CDCl3)  162.8, 161.1, 148.0, 147.6, 143.2, 130.1, 129.3, 
128.8, 127.6, 126.6, 121.4, 114.8, 108.4, 101.2, 70.1. HRMS (EI, 50 eV) 
calculated for C29H24N2O3: 448.1787, found: 446.1795. IR (̃): 3185, 2873, 1606, 
1519, 1419, 1349, 1250, 1172, 1035, 924, 825, 758, 695 cm-1. 
 
 
(S)-2-(4-Benzyloxy-phenyl)-5-phenyl-4-(R)-phenyl-4,5-dihydro-1H-imidazole 
(4g) 
 
 75% from diamine 17 (0.11 mmol) and aryl aldehyde derivative 2h (0.10 mmol) 
according to procedure B. 1H NMR (300 MHz, CDCl3)  7.89 (m, 2H), 7.36 (s, 
16H), 6.98 (m, 2H), 5.13 (d, J = 5.6 Hz, 2H), 4.88 (d, J = 7.0 Hz, 2H). 13C NMR (75 
MHz, CDCl3)  162.6, 161.0, 143.2, 136.9, 129.2, 128.7, 128.7, 128.6, 128.2, 
127.5, 127.5, 126.6, 122.5, 114.6, 69.9. HRMS (EI, 50 eV) calculated for 
C28H24N2O: 404.1889, found: 404.1894. IR (̃): 3876, 2926, 1611, 1517, 1451, 
1260, 1172, 1027, 839, 735, 694 cm-1. 
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(S)-5-Phenyl-4-(R)-phenyl-2-[4-(2,4,6-trimethyl-benzyloxy)-phenyl]-4,5-
dihydro-1H-imidazole (4h) 
 
66% from diamine 17 (0.20 mmol) and aryl aldehyde derivative 2i (0.19 mmol) 
according to procedure B. 1H NMR (300 MHz, CDCl3)  7.96 (m, 2H), 7.34 (m, 
11H), 7.08 (m, 2H), 6.95 (m, 2H), 5.10 (m, 2H), 4.90 (d, J = 5.6 Hz, 2H), 2.39 (d, J 
= 4.8 Hz, 6H), 2.34 (d, J = 8.5 Hz, 3H). 13C NMR (75 MHz, CDCl3)  162.9, 161.8, 
143.6, 138.6, 138.1, 129.4, 129.2, 129.2, 128.8, 127.5, 126.6, 122.3, 114.6, 64.8, 
21.1, 19.5. HRMS (EI, 50 eV) calculated for C31H30N2O: 446.2358, found: 
446.2355. IR (̃):2957, 1690, 1602, 1575, 1508, 1244, 1160, 980, 837, 807, 648 
cm-1. 
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F. APPENDICES 
 
Appendix 1 - NMR Spectra 
 
1.1 Spectra of compounds from Chapter B 
 
 
General Note: 
 
 The upper image is the 1H NMR spectrum 
 
 
 The lower image is the 13C NMR spectrum 
 
 
 All compounds were measured in CDCl3 
 
 
 
 
 
 
 168 
 
APPENDICES Macabeo  2011 
3,4-Bis-(4-tert-butyl-phenyl)-5H-furan-2-one (38e)  
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(2S,3S,2'S)-3-Dimethoxymethyl-3,4-dihydro-2H,2'H-[2,2']bifuranyl-5,5'-dione 
(33a.1) 
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(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-3,4-dihydro-2H,2'H-[2,2']bifuranyl-5,5'-dione 
(33a.2) 
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(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-4'-methyl-3,4-dihydro-2H,2'H-[2,2']bifuranyl-
5,5'-dione (33b) 
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(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-3'-methyl-3,4-dihydro-2H,2'H-[2,2']bifuranyl-
5,5'-dione (33c)  
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(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-3',4'-diphenyl-3,4-dihydro-2H,2'H-
[2,2']bifuranyl-5,5'-dione (33d) 
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(2S,3S,2'S)-3',4'-Bis-(4-tert-butyl-phenyl)-3-[1,3]dioxolan-2-yl-3,4-dihydro-
2H,2'H-[2,2']bifuranyl-5,5'-dione (33e)  
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(E)-3-[1,3]Dioxolan-2-yl-4-((S)-5-oxo-2,5-dihydro-thiophen-2-yl)-but-3-enoic 
acid ethyl ester (48)  
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(S)-2-((S)-3-Formyl-5-oxo-tetrahydro-furan-2-yl)-5-oxo-pyrrolidine-1-
carboxylic acid tert-butyl ester (33f)  
 
 
 177 
 
APPENDICES Macabeo  2011 
(2S,3S,5S)-3-[1,3]Dioxolan-2-yl-2,3,4,5-tetrahydro-[2,2']bifuranyl-5-ol (58) 
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(2S,3S)-3-[1,3]Dioxolan-2-yl-3,4-dihydro-2H-[2,2']bifuranyl-5-one (59) 
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2-((2'S,3'S)-3'-[1,3]-Dioxolan-2-yl-3-methyl-5'-oxo-2',3',4',5'-tetrahydro-
[2,2']bifuranyl-5-ylmethyl)-acrylic acid ethyl ester (57) 
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2-[(2S,2'S,3'S)-3'-[1,3]Dioxolan-2-yl-2-methoxy-3-methyl-5'-oxo-2',3',4',5'-
tetrahydro-2H-[2,2']bifuranyl-(5Z)-ylidenemethyl]-acrylic acid ethyl ester (54) 
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2D NOESY spectrum of lactone 54 
 
  
 
 
 
 
 
Key NOESY correlations in 54 
 
 182 
 
APPENDICES Macabeo  2011 
(2S,3S,2'S)-3-[1,3]Dioxolan-2-yl-tetrahydro-[2,2']bifuranyl-5,5'-dione (52) 
 
 
 
 183 
 
APPENDICES Macabeo  2011 
(2S,3S)-3-Dimethoxymethyl-3,4-dihydro-2H-[2,2']bifuranyl-5-one (68a) 
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2D NOESY spectrum of lactone 68a 
 
  
Key NOESY correlations in 68a 
 
 185 
 
APPENDICES Macabeo  2011 
(4S,5R)-4-Dimethoxymethyl-5-thiophen-2-yl-dihydro-furan-2-one (68b) 
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(4R,5S)-4-Dimethoxymethyl-5-phenyl-dihydro-furan-2-one (68c) 
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(4R,5S)-4-Dimethoxymethyl-5-(4-methoxy-phenyl)-dihydro-furan-2-one (68d). 
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(4R,5S)-5-Benzo[1,3]dioxol-5-yl-4-dimethoxymethyl-dihydro-furan-2-one 
(68e) 
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(4S,5R)-4-Dimethoxymethyl-5-(6-methoxy-naphthalen-2-yl)-dihydro-furan-2-
one (68f) 
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(2S,3S,2'R,5'S)-3-Dimethoxymethyl-2',5'-dimethoxy-3,4,2',5'-tetrahydro-2H-
[2,2']bifuranyl-5-one (86a) and (2S,3S,2'S,5'S)-3-Dimethoxymethyl-2',5'-
dimethoxy-3,4,2',5'-tetrahydro-2H-[2,2']bifuranyl-5-one (86b, relative 
stereochemistry assigned) 
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2D NOESY spectrum of 86a and 86b 
 
 
  
 
Key NOESY correlations in 86a and 86b 
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(2S,3S,2'S,5'R)-3-Dimethoxymethyl-2',5'-dimethoxy-3,4,2',5'-tetrahydro-2H-
[2,2']bifuranyl-5-one (86c) 
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2D NOESY spectrum of 86c 
 
 
Key NOESY correlations in 86c 
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(2S,3S,2'S,5'R)-3-Dimethoxymethyl-4-dimethylaminomethylene-2',5'-
dimethoxy-3,4,2',5'-tetrahydro-2H-[2,2']bifuranyl-5-one (87) 
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2-(Furan-2-carbonyl)-succinic acid dimethyl ester (94) 
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(2R,3R)-5-Oxo-2,3,4,5-tetrahydro-[2,2']bifuranyl-3-carboxylic acid methyl 
ester (trans-93) 
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(2R,3S)-5-Oxo-2,3,4,5-tetrahydro-[2,2']bifuranyl-3-carboxylic acid methyl 
ester (cis-93) 
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Benzenesulfonic acid (2R,3R)-2-(2-methyl-allyl)-5-oxo-tetrahydro-furan-3-
ylmethyl ester (124) 
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[(2R,3S)-2-(2-Methyl-allyl)-5-oxo-tetrahydro-furan-3-yl]-acetonitrile (125) 
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[(2S,3S)-2-(2-Methyl-acryloyl)-5-oxo-tetrahydro-furan-3-yl]-acetonitrile (126) 
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(Z)-But-2-enedioic acid (1S,4S)-4-hydroxy-4-methyl-cyclopent-2-enyl ester 
methyl ester (119) 
 
 
 
 202 
 
APPENDICES Macabeo  2011 
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1.2 Spectra of compounds from Chapter C 
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4-(2,4,6-Trimethyl-benzyloxy)-benzaldehyde (2i)  
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2-(2,6-Dichloro-benzyloxy)-benzaldehyde (3a)  
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2-(2,6-Dichloro-benzyloxy)-3-methoxy-benzaldehyde (3b)  
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5-Bromo-2-(2,6-dichloro-benzyloxy)-benzaldehyde (3c)  
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2-(2,6-Dichloro-benzyloxy)-naphthalene-1-carbaldehyde (3d) 
  
 
 
 209 
 
APPENDICES Macabeo  2011 
[4-(2,6-Dichloro-benzyloxy)-phenyl]-phenyl-methanone (20)  
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(2R,3S)-2-Heptyl-5-oxo-tetrahydro-furan-3-carboxylic acid (5) 
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2-[4-(2,6-Dichloro-benzyloxy)-phenyl]-4,5-dihydro-1H-imidazole (4a)  
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(7S,7aS)-2-[4-(2,6-Dichloro-benzyloxy)-phenyl]-3a,4,5,6,7,7a-hexahydro-1H-
benzoimidazole (4b)  
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(S)-2-[4-(2,6-Dichloro-benzyloxy)-phenyl]-5-phenyl-4-(R)-phenyl-4,5-dihydro-
1H-imidazole (4c)  
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(S)-2-[4-(3-Chloro-benzyloxy)-phenyl]-5-phenyl-4-(R)-phenyl-4,5-dihydro-1H-
imidazole (4d) 
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(S)-5-Phenyl-4-(R)-phenyl-2-[4-(4-trifluoromethoxy-benzyloxy)-phenyl]-4,5-
dihydro-1H-imidazole (4e)  
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(S)-2-[4-(Benzo[1,3]dioxol-5-ylmethoxy)-phenyl]-5-phenyl-4-(R)-phenyl-4,5-
dihydro-1H-imidazole (4f) 
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(S)-2-(4-Benzyloxy-phenyl)-5-phenyl-4-(R)-phenyl-4,5-dihydro-1H-imidazole 
(4g)  
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(S)-5-Phenyl-4-(R)-phenyl-2-[4-(2,4,6-trimethyl-benzyloxy)-phenyl]-4,5-
dihydro-1H-imidazole (4h)  
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Appendix 2 – X-ray structure and data 
 
 
Crystal data and structure refinement for compound 33c. 
 
 
Identification code  7301 
Empirical formula  C12 H14 O6 
Color  colourless 
Formula weight  254.23  g · mol-1 
Temperature  100 K 
Wavelength  1.54184 Å 
Crystal system  ORTHORHOMBIC 
Space group  P21 21 21,  (no. 19) 
Unit cell dimensions a = 5.4669(6) Å = 90°. 
 b = 10.3228(11) Å = 90°. 
 c = 20.605(2) Å  = 90°. 
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Volume 1162.8(2) Å3 
Z 4 
Density (calculated) 1.452  Mg · m-3 
Absorption coefficient 1.002 mm-1 
F(000) 536 e 
Crystal size 0.25 x 0.05 x 0.03 mm3 
 range for data collection 4.29 to 54.43°. 
Index ranges -5  h  5, -10 k  10, -21  l  21 
Reflections collected 36878 
Independent reflections 1429 [Rint = 0.0827] 
Reflections with I>2(I) 1342 
Completeness to  = 54.43° 99.9 % 
Absorption correction Gaussian 
Max. and min. transmission 0.97 and 0.87 
 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1429 / 0 / 165 
Goodness-of-fit on F2 1.006 
Final R indices [I>2(I)] R1 = 0.0432 wR
2 = 0.1016 
R indices (all data) R1 = 0.0467 wR
2 = 0.1053 
Absolute structure parameter -0.1(3) 
Extinction coefficient 0.027(3) 
Largest diff. peak and hole 0.311 and -0.236 e · Å-3 
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Crystal data and structure refinement for lactone 68c.  
   
   
Empirical formula           C13H16O4  
Formula weight               236.26  
Crystal size                     0.467 x 0.148 x 0.050 mm  
Crystal description          needle  
Crystal colour                 colourless  
Crystal system                Orthorhombic  
Space group                   P 21 21 21  
Unit cell dimensions          a =  5.9224(2) A      alpha =    90 deg.  
                                           b = 11.4859(4) A    beta   =     90 deg.  
                                           c = 17.6998(5) A    gamma = 90 deg.  
    
Volume                                      1204.01(7) A^3  
Z, Calculated density                 4,  1.303 Mg/m^3  
Absorption coefficient                0.96 mm^-1  
F(000)                                        504  
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Measurement device type Goniometer Xcalibur, detector: Ruby (Gemini   
ultra Mo)  
Measuremnet method                w scans  
Temperature                              123 K  
Wavelength                               1.54184 A  
Monochromator                          graphite  
Theta range for data collection              4.59 to 66.57 deg.  
Index ranges                                         -6h7, -10k13, -20l20  
Reflections collected / unique               5996 / 2090 [R (int) = 0.0182]  
Reflections greater I>2\s(I)                    2043  
Absorption correction                            Semi-empirical from equivalents  
Max. and min. transmission                  0.962 and 0.784  
   
Refinement method                   Full-matrix least-squares on F^2  
Hydrogen treatment 
Data / restraints / parameters    2090 / 0 / 156  
Goodness-of-fit on F^2              1.074  
Final R indices [I> 2sigma (I)     R1 = 0.0292, wR2 = 0.0746  
R indices (all data)                     R1 = 0.0296, wR2 = 0.0749  
Absolute structure parameter    0.07(15)  
Largest diff. peak and hole        0.104 and -0.181 e.A^-3  
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Crystal data and structure refinement for compound 86a.  
 
 
Empirical formula                       C13H20O7  
Formula weight                          288.29  
Crystal size                                0.2359 x 0.1897 x 0.1102 mm  
Crystal description                     plate  
Crystal colour                             colourless  
Crystal system                           Monoclinic  
Space group                               P 21  
Unit cell dimensions             a = 7.8226(2) A       alpha = 90 deg.  
                                              b = 10.0497(2) A    beta = 102.925(2) deg.  
                                              c = 9.1628(2) A      gamma = 90 deg.  
   
Volume                              702.08(3) A^3  
Z, Calculated density         2, 1.364 Mg/m^3  
Absorption coefficient       0.943 mm^-1  
F(000)                               308 
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Measurement device type        Goniometer Xcalibur, detector: Ruby (Gemini 
ultra Mo)  
Measuremnet method                  w scans  
Temperature                                123 K  
Wavelength                                 1.54184 A  
Monochromator                           graphite  
Theta range for data collection  4.95 to 66.79 deg.  
Index ranges                               -9 h 8, -11 k 11, -10 l 10  
Reflections collected / unique    6700 / 2377 [R (int) = 0.0245]  
Reflections greater I>2\ s(I)         2308  
Absorption correction                  Analytical  
Max. and min. transmission       0.916 and 0.864  
   
 
Refinement method                     Full-matrix least-squares on F^2  
Hydrogen treatment 
Data / restraints / parameters     2377 / 1 / 181  
Goodness-of-fit on F^2               1.080  
Final R indices [I> 2sigma(I)]       R1 = 0.0282, wR2 = 0.0739  
R indices (all data)                      R1 = 0.0289, wR2 = 0.0742  
Absolute structure parameter     0.06(15)  
Largest diff. peak and hole          0.238 and -0.150 e.A^-3  
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Crystal data for compound cis-93  
 
Bond precision          C-C = 0.0023 A         Wavelength=1.54184 
Cell                           a=16.6289(13)     b=5.7810(4)     c=10.2054(9) 
                                  alpha=90          beta=98.362(8)           gamma=90 
Temperature            123 K 
Calculated Reported 
Volume                      970.63(13) 970.63(13) 
Space group             C 2 C 2 
Hall group                 C 2y C 2y 
Moiety formula         C10 H10 O5 C10 H10 O5 
Sum formula             C10 H10 O5 C10 H10 O5 
Mr                              210.18 210.18 
Dx,g cm                     -3 1.438 1.438 
Z 4 4 
Mu (mm-1)                 1.000 1.000 
F000 440.0 440.0 
F000’ 441.66 
h,k,l                             max 19,6,12 19,6,12 
Nref                             945[ 1705] 1396 
Tmin,Tmax                 0.919,0.961 0.928,1.000 
Tmin’                          0.803 
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Appendix 3 - Biological assays 
 
 
Alamar blue susceptibility test (MABA). Antimicrobial susceptibility testing was 
performed in black, clear-bottomed, 96-well microplates (black view plates; 
Packard Instrument Company, Meriden, Conn.) in order to minimize background 
fluorescence. Outer perimeter wells were filled with sterile water to prevent 
dehydration in experimental wells. Initial drug dilutions were prepared in either 
dimethyl sulfoxide or distilled deionized water, and subsequent twofold dilutions 
were performed in 0.1 ml of GAS (no Tween 80) in the microplates. 
 
BACTEC 12B-passaged inocula were initially diluted 1:2 in GAS, and 0.1 ml was 
added to wells. Subsequent determination of bacterial titers yielded 1 3 106, 
2.5 3 106, and 3.25 3 105 CFU/ml in plate wells for H37Rv, H37Ra, and M. avium, 
respectively. Frozen inocula were initially diluted 1:20 in BACTEC 12B medium 
followed by a 1:50 dilution in GAS. Addition of 1/10 ml to wells resulted in final 
bacterial titers of 2.0 3 105 and 5 3 104 CFU/ml for H37Rv and H37Ra, respectively. 
Wells containing drug only were used to detect auto fluorescence of compounds. 
Additional control wells consisted of bacteria only (B) and medium only (M). Plates 
were incubated at 37°C. Starting at day 4 of incubation, 20 ml of 103 alamar Blue 
solution (Alamar Biosciences/Accumed, 
 
Westlake, Ohio) and 12.5 ml of 20% Tween 80 were added to one B well and one 
M well, and plates were reincubated at 37°C. Wells were observed at 12 and 24 h 
for a color change from blue to pink and for a reading of $50,000 fluorescence 
units (FU). Fluorescence was measured in a Cytofluor II microplate fluorometer 
PerSeptive Biosystems, Framingham, Mass.) in bottom-reading mode with 
excitation at 530 nm and emission at 590 nm. If the B wells became pink by 24 h, 
reagent was added to the entire plate. If the well remained blue or #50,000 FU 
was measured, additional M and B wells were tested daily until a color change 
occurred, at which time reagents were added to all remaining wells. Plates were 
then incubated at 37°C, and results were recorded at 24 h post-reagent addition. 
Visual MICs were defined as the lowest concentration of drug that prevented a 
color change. For fluorometric MICs, a background subtraction was performed on 
all wells with a mean of triplicate M wells. Percent inhibition was defined as 1 2 
(test well FU/mean FU of triplicate B wells) 3 100. The lowest drug concentration 
effecting an inhibition of >90% was considered the MIC. 
 
Relevant literature: L. Collins and S.G. Franzblau, Microplate alamar blue assay versus 
BACTEC 460 system for high-throughput screening of compounds against Mycobacterium 
tuberculosis and Mycobacterium avium, Antimicrobial Agents and Chemotherapy 41 
(1997). 1004–1009. 
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Low-Oxygen Recovery Assay. The potential of samples to target the 
subpopulation of Mycobacterium tuberculosis in the non-replicating persistent 
(NRP) state was assessed using a low oxygen recovery assay (LORA). This 
employed Mycobacterium tuberculosis H37Rv (pFCA-luxAB) which synthesises 
luciferase when actively growing. The strain was cultured in 300mL of Dubos 
Tween–albumin broth (supplier) in a BioStatQ fermentor with a head space ratio of 
0.5 and agitated at 120rpm with no detectable perturbation of the medium surface. 
The dissolved oxygen concentration (DOC) was monitored with an Ingold oxygen 
sensor probe. Cells were harvested when the OD at 570 nm indicated 
achievement of the desired growth phase (i.e. late non-replicating persistence). 
Aliquots of bacterial culture (50 mL) were centrifuged at 2700×g for 30 min, 
washed once with phosphate buffered saline (PBS), suspended in PBS (1 mL), 
and stored at −80 oC. Prior to use, cultures were thawed, diluted in Middlebrook 
7H12 broth and sonicated for 15 s. Cultures were diluted to obtain an OD at 
570nm of 0.03–0.05 and 2000–5000 relative light units (RLU) per 100 L (i.e. 
5×105 to 2×106 CFU/mL). Twofold serial dilutions of compounds were prepared 
in 100 L in black 96-well plates, and 100 L of the cell suspension was 
subsequently added. The microplate cultures were placed under anaerobic 
conditions (oxygen < 0.16%) using an Anoxomat Model WS-8080, three cycles of 
evacuation and filling with amixture of 10% H2, 5% CO2, balance N2. Plates were 
incubated at 37 ◦C for 7 days and then transferred to an ambient gaseous 
condition (5% CO2-enriched air) incubator for a 24 h “recovery”. On day 7 and 8, 
100 L of culture were transferred to white opaque 96-well plates. A 10% solution 
of n-decanal in ethanol was freshly diluted 10-fold in PBS and 100 L added to 
each well with an auto-injector. Luminescence was measured in a Victor2 multi-
label reader (1 s reading time). Samples reducing viability under these non-growth 
conditions led to a decreased luciferase signal following aerobic recovery. Pure 
compounds were tested at 50 and 10 g/mL and MICs were determined. 
 
Relevant Literature: S.H. Cho, S. Warit, B. Wan, C.H. Hwang, G.F. Pauli and S.G. 
Franzblau, Low-oxygen-recovery assay for high-throughput screening of compounds 
against nonreplicating Mycobacterium tuberculosis, Antimicrobial Agents and 
Chemotherapy 51 (2007) 1380–1385. 
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Cytotoxicity study using HeLa cells. The cytotoxicity of the compounds was 
determined using the HeLa cells (ATCC CCL17). The test was carried out with 
some modifications according to the screening technique of Swanson and Pezzuto 
in 96-well plates (Falcon) with an inoculum of 2.5-104 cells/ mL. Test solutions 
were made as stocks in ethanol. Test concentrations were freshly prepared by 
diluting the stock solution with water to the required concentration. Final ethanol 
concentration was 1% (v/v) or less. Total assay volume was 150 L. STLs and 
GSH/l-cys were added simultaneously. For quantification of the cytotoxicity, 15 L 
of an aqueous solution of methylthiazolyltetrazolium chloride (MTT, Fluka, 5 
mg/mL in PBS) was added after 72 h. During incubation at 37 oC for 4 h, the 
surviving cells metabolized MTT into an insoluble formazan dye. The culture 
medium was drawn off and the formazan dye was dissolved using 150 L of 10% 
SDS (sodium dodecylsulfate) in water. After 24 h of incubation at room 
temperature, the optical density was measured at 540 nm using a microplate 
reader. For determination of the IC50 values, the optical density was plotted 
against the log concentration and six different concentrations have been tested. 
Every test was performed at least in duplicates and all experiments have been 
repeated at least twice. Maximal observed standard deviation was about 20% 
(absolute). Positive control measurements were performed with xanthohumol. 
 
Relevant literatures:  
 
J. Heilmann, M.R. Wasescha and T J. Schmidt. Bioorg. Med. Chem. 9 (2001) 2189–2194. 
 
S. M. Swanson and J. M. Pezzuto. In Drug Bioscreening.Drug Evaluation Techniques in 
Pharmacology; Thompson, E.B. Ed.; VCH:New York, Weinheim, Cambridge, 1990; pp 
273–297. 
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